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Alzheimer’s disease (AD) is the most frequently occurring form of dementia 
worldwide. Calcium (Ca2+) is important in maintaining cellular physiology with roles in gene 
expression, cell proliferation, differentiation and survival. One mechanism by which 
aggregated amyloid-b (Ab), a main protagonist in AD, can cause Ca2+ dysregulation and 
subsequent changes in cell activity is through changes in both the expression and activity of 
VGCCs. Carbon monoxide (CO) acting as a gasotransmitter has shown a range of 
cytoprotective roles potentially mediated by ion channel-dependant mechanisms. The aim 
of this study was to identify the effect of protofibrillar Ab1-42 on voltage-gated calcium 
channels (VGCCs) and to investigate how CO can modulate these channels and therefore 
interfere with Ab-mediated cytotoxicity. 
Chemical analysis and neuroblastoma activity assays revealed time-dependent 
(48hr) protofibril formation of Ab1-42 using NH4OH demonstrating protofibril formation that 
structurally and functionally resembles aggregated Ab1-42 cytotoxicity seen in vivo. 
Moreover, mimicking the microenvironment of cell membranes, SDS was shown to aid Ab1-
42 aggregation. Molecular approaches (qPCR) revealed that within retinoic acid (RTA) 
differentiated cells protofibril Ab1-42 changes Cav1 expression at gene level, proposed to be 
representative of Ca2+ dysregulation seen at early stages of AD. On the other hand, 
electrophysiology findings revealed that Ab1-42 is capable of inhibiting Cav2.2 currents of 
stably transfected HEK293 cells. Reduction in Cav2.2 dependent Ca2+ influx represents 
changes in Ca2+ homeostasis seen at late stages of AD where significant neurotransmitter 
depletion and synaptotoxicity is observed. CO, generated using the donor CORM2 
(tricarbonyldichlororuthenium(II) dimer), was shown to inhibit Cav2.2 channels through 
selective changes in channel kinetics. Further through electrophysiological investigation it 
was revealed that CO acts similarly to an oxidant, with the reducing agent DTT 
(dithiothreitol) reversing CO inhibitory effects on the channel. 
 Findings from the current study aid our understanding of AD by highlighting the 
different effects of Ab  on Ca2+ homeostasis dependent on early or late AD stage. Moreover, 
this study reveals that CO, might inhibit VGCCs, via an oxidant action, which may be 
beneficial in targeting Ca2+ dyshomeostasis seen at early stage of the disease where 
neuronal hyperactivity is observed. This study demonstrates the potential of CO, or the 




Ab – amyloid-b  
AChE – acetylcholinesterase 
AD – Alzheimer’s disease 
ADDLs – Ab-derived diffusible ligands 
ADP – adenosine diphosphate 
AICD – APP intracellular domain 
ALS – Amyotropic lateral sclerosis 
AMP – adenosine monophosphate 
AMPK – AMP-activated protein kinase 
APOE – apolipoprotein E 
APP – amyloid-precursor protein 
ATP – adenosine triphosphate 
Ba2+ – barium 
BACE1 – b-secretase gene 
BaCl2 – barium chloride 
BBB – blood-brain barrier 
BDNF – brain derived neurotrophic factor 
BPSD – behavioural and psychological symptoms of dementia 
Ca2+ – calcium 
CAMKII – Ca2+/calmodulin dependent protein kinase II 
CCB – calcium channel blocker 
CdCl2 – cadmium chloride   
cDNA – complementary DNA 
cGMP – cyclic guanosine monophosphate 
ChAT – choline acetyltransferase 
CHO cells – Chinese hamster ovary cells 
CNS – central nervous system 
CO – carbon monoxide 
CORM – carbon monoxide releasing molecule  
CORM-A1 – Sodium boranocarbonate 
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CORM1 – manganese decacarbonyl 
CORM2 – Tricarbonyldichlororuthenium(II) dimer 
CORM3 – Tricarbonylchloro(glycinato)ruthenium (II) 
COX – cyclooxygenase 
CREB – cAMP response element-binding protein 
CsCl – cesium chloride 
CSF – cerebrospinal fluid 
CVD – cardiovascular disease 
DMEM – Dulbecco’s Modified Eagle Medium  
DMSO – dimethyl sulfoxide  
DNA – deoxyribonucleic acid  
DTDP – dithiodipyridine 
DTT – dithiothreitol 
EGTA – egtazic acid 
ER – endoplasmic reticulum 
FBS – foetal bovine serum  
Fe3+ – ferrous ion 
G418 – geneticin  
HEK293 cells – human embryonic kidney 293 cells 
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFIP – hexafluorisopropanol  
His – histidine  
H2O2 – hydrogen peroxide 
HO – heme oxygenase  
HO-1 – heme-oxygenase-1 
HO-2 – heme-oxygenase-2 
HO-3 – heme-oxygenase-3 
HVA – high-voltage activated 
iCORM2 – inactive CORM2  
IDE – insulin degrading enzyme 
iPSCs – induced pluripotent stem cells 
LRP1 – low density lipoprotein receptor-related protein 1 
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LVA – low-voltage activated 
LXR-b – activating liver-X receptor-b 
MAPK – mitogen-activated protein kinase 
MCI – mild cognitive impairment 
MEM – Minimum Essential Medium  
MgCl2 – magnesium chloride 
MMSE – mini-mental state examination 
MRI – magnetic resonance imaging 
mRNA – messenger RNA 
mTOR – mammalian target of rapamycin 
MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
NaOH – sodium hydroxide  
NeuN – neuronal nuclear protein 
NF-kB – nuclear factor k-light-chain-enhancer of activated B cells  
NH4OH – ammonium hydroxide 
NMDA – N-methyl-D-aspartate 
NO – nitric oxide 
NOS – nitric oxide synthase  
NPCs – Neural Progenitor cells  
Nrf2 – nuclear factor erythroid 2–related factor 2 
NSAID – non-steroidal anti-inflammatory drugs 
NSCs – neural stem cells 
PBS – phosphate buffered saline  
PCR – polymerase chain reaction 
PD – Parkinson’s disease 
PET – positron emission tomography 
PiB – Pittsburgh compound B 
PKA – protein kinase A 
PMS – phenazine methosulfate 
ppm – parts per million 
PrP – prion protein 
PSEN 1 – presinilin 1  
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PSEN 2 – presinilin 2  
qPCR – quantitative PCR 
RBCs – red blood cells 
RNA – ribonucleic acid 
ROCs – receptor-operated calcium channels 
ROS – reactive oxygen species 
RTA – retinoic acid  
RT-PCR – Real time PCR 
Ru – ruthenium   
RyRs – ryanodine receptors 
SDS – sodium dodecyl sulfate 
sGC – soluble guanylyl cyclase 
SNAP25 – synaptosomal-associated protein 
SOCs – store-operated calcium channels 
SOD – superoxide dismutase 
TAE – Tris-acetate-EDTA  
TEA – triethylamine 
TEM – transmission electron microscopy 
ThT – Thioflavin 
TMO – Trimethadione  
Trx – thioredoxin 
VAMP-2 – vesicle-associated membrane protein-2 
VGCCs – voltage-gated calcium channels 
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1.1. Alzheimer’s disease 
 
1.1.1. Dementia Prevalence 
 
 Dementia is a neurodegenerative disease mainly characterised by cognitive 
impairment. Alzheimer’s disease (AD) is the most common form of dementia and it 
accounts for around 2/3 of dementia cases, with some individuals exhibiting 
comorbidities such as the presence of a mixture of dementias (Prince and Jackson, 2009; 
Qiu, Kivipelto and Strauss, 2009; DeTure and Dickson, 2019). For example, post-mortem 
studies have revealed that some individuals suffered from a combination of vascular 
dementia and AD (James et al., 2012; Chui and Ramirez-Gomez, 2015). Other symptoms 
of dementia include agitation, apathy and changes in the sleep pattern, and also 
psychological changes such as aggression, depression, stress and hallucinations (Prince 
and Jackson, 2009; Qiu, Kivipelto and Strauss, 2009; Ryan et al., 2010; Cerejeira, Lagarto 
and Mukaetova-Ladinska, 2012; Prince, Guerchet and Prina, 2015). These are grouped 
and collectively termed behavioural and psychological symptoms of dementia (BPSD) 
(Cerejeira, Lagarto and Mukaetova-Ladinska, 2012). Impairment in thinking, learning 
and memory process, and also language and orientation may contribute to these 
symptoms (Prince and Jackson, 2009; Qiu, Kivipelto and Strauss, 2009; Ryan et al., 
2010). Although dementia itself is a devastating symptom of the disease, BPSD 
significantly reduce the quality of life, with individuals exhibiting difficulties in carrying 
out daily tasks, therefore significantly increasing the burden on carers. 
In 2015 approximately 50 million people worldwide were living with dementia, 
and it is estimated that by 2030 the number of cases will be double (Prince, Guerchet 
and Prina, 2015). Epidemiological studies revealed that in 2010, around 6.5% of 
individuals above 65 years of age lived with dementia, with 4.4% of cases due to AD 
(Lobo et al., 2000; Qiu, Kivipelto and Strauss, 2009).  Worldwide, 1 new dementia case 
arises every ~4 seconds (Prince, Guerchet and Prina, 2015). Although epidemiological 
studies suggest that dementia cases will rapidly increase over the next decade, a recent 
study investigating the trend in incidence of dementia in Europe and North America 
over the last 3 decades has revealed an approximate 13% decrease in dementia 
incidence per decade (Wolters et al., 2020). The expected increase in dementia cases 
also has an economic impact, with more carers needed and an increase in demand for 
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medication requirement for symptomatic relief (Prince, Guerchet and Prina, 2015). In 
2015 alone, an approximate £670 billion was spent on dementia worldwide (Prince, 
Wimo, Guerchet, 2015). In recent years, there has been increased focus in promoting 
AD awareness, to enhance the public’s understanding of the disease, with the aim to 
help individuals, their families and carers in managing and living with dementia (Prince 







































1.1.2. Alzheimer’s disease epidemiology 
 
AD was first characterized in a female patient (Auguste D.) who presented signs 
of cognitive impairment and BPSD by a German physician Alois Alzheimer’s in 1901 
(Hippius and Neundörfer, 2003; Finder and Glockshuber, 2007; Qiu, Kivipelto and 
Strauss, 2009). Following the death of the patient in 1906, post-mortem histological and 
morphological observations revealed the two main AD hallmarks now known as amyloid 
plaques and neurofibrillary tangles (Hippius and Neundörfer, 2003). 
 AD is split into two forms dependent on the age that symptoms start developing. 
Early-onset AD or Familial AD, which accounts for 10% of cases, has been linked to 
mutations in presenilin 1 and 2 genes (PSEN 1 & 2). The majority of these mutations are 
autosomal missense, found on chromosome 14 and 1 respectively, which encode the 
PSEN1 and PSEN2 catalytic domains of g-secretase, an enzyme which leads to amyloid-
b (Ab) peptide production (Levy-Lahad et al., 1995; Rogaev et al., 1995; Qiu, Kivipelto 
and Strauss, 2009; Sadigh-Eteghad et al., 2015; DeTure and Dickson, 2019). Post-
mortem and isolated-Ab from serum CSF have revealed that Ab can be present in 
various lengths in the brain, with Ab1-42 considered the most toxic form, as it’s the most 
prone to aggregation (Pachahara et al., 2012; Podlisny et al., 1995; Finder and 
Glockshuber, 2007; Nichols et al., 2015). More than 150 mutations have been identified 
in PSEN1 which lead to partial loss of function and a subsequent gain in toxic activity 
resulting in an increase in both Ab production and changes in the Ab1-40/Ab1-42 ratio (De 
Strooper, 2007; Heilig et al., 2010, 2013; Sun et al., 2016). In contrast fewer mutations 
have been identified in PSEN2 (Cai, An and Kim, 2015). Although the role of PSEN1 and 
PSEN2 mutations in AD are not fully understood, toxic function might involve changes 
in Ab1-42 production or by making the brain more susceptible to AD-mediated 
cytotoxicity, for example through impairment in Notch signalling responsible for 
synaptic plasticity (Citron et al., 1997; Marjaux, Hartmann and De Strooper, 2004; Wang 
et al., 2004; De Strooper, 2007; Heilig et al., 2013). Other mutations which have also 
been linked to Familial AD, include missense mutations and duplications found on the 
amyloid-precursor protein (APP) gene which encodes the APP peptide that can be 
cleaved into Ab (Carter, Desmarais and Bellis, 1992; Rovelet-Lecrux et al., 2006; Qiu, 
Kivipelto and Strauss, 2009; DeTure and Dickson, 2019). Evidence of the role of APP in 
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AD originally came from individuals with Trisomy 21 (Down Syndrome) that exhibit 
amyloid pathology, as the APP gene is found within chromosome 21 (DeTure and 
Dickson, 2019).  
 Late-onset AD, also known as Sporadic AD, accounts for the majority of AD cases 
with no direct known genetic causes linked to its development (Prince and Jackson, 
2009; Qiu, Kivipelto and Strauss, 2009; DeTure and Dickson, 2019). Ageing (>65 years) 
constitutes the main risk factor for developing late-onset AD. Epidemiological studies 
revealed that individuals over 65 years of age have a 10% chance of developing 
dementia, with risk doubling every ~5 years (Prince and Jackson, 2009; Qiu, Kivipelto 
and Strauss, 2009; DeTure and Dickson, 2019). The ageing population is expected to 
increase to 1 billion by 2030, this will inevitably lead to an increase in dementia cases as 
well (Qiu, Kivipelto and Strauss, 2009). The Framingham Heart study, a cohort study 
conducted over 30 years, revealed that although ageing is the main AD risk factor, 
incidence in individuals educated at higher degree level, and with lower vascular disease 
risk due to early prognosis and diagnosis, report a decline in AD cases over time 
(Satizabal et al., 2016). Moreover, a recent Lancet report has also linked traumatic brain 
injury (TBI), smoking, high alcohol consumption, obesity, lack of physical activity, 
depression and low social contact as additional risk factors accounting for some 
dementia cases (Livingston et al., 2020). As all these risk factors are considered 
modifiable, it is believed that the incident of dementia can also be changed if measures 
are taken against these risk factors.  
 Several molecules have been found to have a role in Ab clearance from the brain. 
Although no genetic causes have been linked to Sporadic AD, the presence of the APOE4 
(APOE; apolipoprotein E) allele has shown to increase risk of developing late-onset AD 
(Qiu, Kivipelto and Strauss, 2009; DeTure and Dickson, 2019).  APOE, an apolipoprotein 
produced by both neurons and glial cells responsible for cholesterol and lipid transport 
to neurons, has been linked to Ab processing and specifically, clearance from the brain 
(Buttini et al., 2010; Liu et al., 2017). In transgenic animal models that overexpress APP 
(V717F mutation) and that lack the rodent APOE which shares 70% homology with 
human APOE, show no significant brain Ab deposition in contrast to animals expressing 
rodent APOE (Bales et al., 1999). This suggests that APOE can interfere with Ab 
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clearance, therefore aiding its accumulation in the brain. APOE has also been shown to 
have a role in peptide aggregation (Wisniewski et al., 1994; Mouchard et al., 2019). For 
example Wisniewski and colleagues revealed that in vitro APOE, and especially APOE4, 
accelerates Ab aggregation into fibrils by direct interaction with the peptide 
(Wisniewski et al., 1994). In support of this, a study conducted on post-mortem tissue 
revealed the presence of cleaved-APOE/Ab small heteroligomer ‘complexes’ in AD 
individuals, preventing peptide clearance from the brain (Mouchard et al., 2019). A 
meta-analysis study revealed that the presence of APOE e4 allele in Caucasian 
individuals increases the risk of developing AD by ~3 (one copy) and ~15 (both copies of 
the alleles are present), compared to the presence of the e3, and the e2 isoform which 
is believed to be protective (Farrer et al., 1997; Liu et al., 2013). The presence of APOE4 
allele has also been linked to individuals with Familial AD (Qiu, Kivipelto and Strauss, 
2009). In support of this, Bales et al. revealed that an increase in Ab accumulation in the 
brain was seen at a higher degree when both rodent APOE alleles where present, and 
this was also shown to be age-dependent (Bales et al., 1999). In contrast to APOE, LRP1 
(low density lipoprotein receptor-related protein 1) dependent Ab clearance through 
the BBB (blood-brain barrier) via transcytosis occurs in a faster manner (Li et al., 2001; 
Deane et al., 2008). Deane et al. (2008) revealed that APOE4 can interfere with this 
pathway, by creating a complex with Ab, and therefore preventing LRP1 from binding. 
APOE4 dependent Ab clearance from the brain occurs through a VLDL (very-low density 
lipoprotein) receptor-dependent mechanism which is slower than the one observed by 
LRP1, leading to significant Ab accumulation in the brain (Deane et al., 2008).   
Diet has also been identified as a factor that can influence the risk of AD 
(Scarmeas et al., 2006; Qiu, Kivipelto and Strauss, 2009). For example, some evidence 
suggests that both food rich in Vitamin E and Vitamin E diet supplementation may 
reduce progression of AD pathology (Zandi et al., 2004). Additionally, studies have also 
linked cardiovascular disease (CVD) with dementia, with some studies even referring to 
AD as a vascular disorder (De La Torre, 2012; Ng, Turek and Hakim, 2013). For example, 
individuals with hypertension, and hypercholesteremia are at a higher risk of developing 
AD (Livingston et al., 2020). Impaired blood flow due to CVDs can aid both Ab and 
hyperphosphorylated tau protein accumulation in the brain which can lead to the 
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creation of neurofibrillary tangles (De La Torre, 2012; Ng, Turek and Hakim, 2013). 
Although CVD increases the risk of developing dementia, pre-clinical studies and clinical 
trials reveal that use of statins to lower cholesterol levels did not provide conclusive 
results in reducing cognitive decline linked to dementia (Hajjar et al., 2002; Li et al., 
2010; Sano et al., 2011). In contrast, a cohort conducted in 2015 revealed that 
individuals carrying the APOE4 alleles taking antihypertensive compounds, specifically 
calcium channel blockers (CCBs), showed reduction in cognitive decline as assessed via 
a cognitive test (Lovell et al., 2015).  Individuals with diabetes, which is also a CVD risk 
factor, have also shown an increased risk of AD (Qiu, Kivipelto and Strauss, 2009). A 
population study which followed individuals from around ~50 years of age for an 
average of 30 years, revealed that individuals with a reduced insulin response have a 
significantly increased risk of dementia (Rönnemaa et al., 2008). In support, biochemical 
evidence using  insulin degrading enzyme (IDE) knockout mice revealed that IDE not only 
regulates insulin levels, but can also control Ab degradation, with a reduction in IDE 
linked to a reduction in Ab degradation (Farris et al., 2003). Another study revealed that 
the density of amyloid plaques, a hallmark of AD, in individuals living with both AD and 
diabetes was higher than those suffering with AD alone; this links insulin pathology with 
AD incidence and progression (Janson et al., 2004).  In addition to CVD, diabetes and 
inflammation, lifestyle factors such as low physical activity, increased alcohol 
consumption, and socioeconomical status, such as low educational level have also been 
identified as AD risk factors (Qiu, Kivipelto and Strauss, 2009; Etnier et al., 2018; 
Livingston et al., 2020). Etnier et al. proposed that physical activity improved cognitive 










1.1.3. Alzheimer’s pathology 
 
Individuals with mild-cognitive impairment (MCI), which display a noticeable 
reduction in cognitive function which would not be expected with normal ageing 
process, are believed to be at higher risk of developing dementia (Petersen et al., 2001). 
A 2-year longitudinal study, revealed that in a group of 269 individuals diagnosed with 
mild cognitive impairment that exhibit memory deficits (amnesic MCI), around 20% 
develop AD per year (Perri et al., 2007). AD is known to affect both grey and white brain 
matter (Serra et al., 2010). Hippocampal grey matter atrophy is detected in both MCI 
and AD individuals (Serra et al., 2010). Post-mortem brain tissue and MRI (magnetic 
resonance imaging) scans from individuals diagnosed with AD has revealed a significant 
degree of brain atrophy in cortical regions such as within the frontal and temporal lobes, 
whereas the primary motor and somatosensory regions remain largely unaltered 
(Bozzali et al., 2002; Serra et al., 2010; DeTure and Dickson, 2019). In contrast, in MCI 
individuals, brain atrophy is observed at lower degree, with significant white matter 
atrophy mainly seen in the temporal lobe (Serra et al., 2010).  Cognitive impairment 
observed at early stages of AD is believed to occur due to early stages of synaptic 
dysfunction, and neuronal loss seen within the temporal regions of the brain (Braak and 
Braak, 1997; DeTure and Dickson, 2019). For example, evidence obtained from human 
post-mortem studies, and work carried out on APP transgenic mice, reveals that early-
stage synaptic dysfunction could occur due to presence of Ab oligomers that can change 
the expression of synaptic proteins such as vesicle-associated membrane protein-2 
(VAMP-2), a SNARE protein linked to neurotransmitter vesicle trafficking (Pham et al., 
2010). Immunohistochemistry analysis has proposed that the two main hallmarks of AD, 
also used for post-mortem AD diagnosis, are extracellular amyloid plaques containing 
Ab and intracellular neurofibrillary tangles consisting of hyperphosphorylated tau 
protein. In response to inflammation, microglia can change morphology, becoming 
activated to phagocytose any ‘pathogens’ (Newcombe et al., 2018). As inflammation 
can be noted in AD, activated microglia have also been found around both amyloid 
plaques and neurofibrillary tangles (Stalder et al., 1999; Hopperton et al., 2018; DeTure 
and Dickson, 2019). Similarly to this, in response to accumulation of Ab in the brain and 
subsequent neuronal damage, ‘reactive’ astrocytes due to their role in providing 
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neuronal support, are also found surrounding amyloid plaques (DeTure and Dickson, 
2019; Katsouri et al., 2020). The main AD hallmarks, the accompanied oxidative stress, 
activation of microglia and presence of reactive astrocytes can eventually induce 
synaptic decline and neuronal loss, which causes the brain atrophy and cognitive 
impairment seen in AD (Podlisny et al., 1995, 1998; Shao et al., 1999; Urbanc et al., 
2002; Barghorn et al., 2005; Finder and Glockshuber, 2007; Ryan et al., 2010; Nimmrich 
and Eckert, 2013; Nichols et al., 2015; DeTure and Dickson, 2019).  
Amyloid plaques are split into two main types known as dense core plaques or 
diffuse plaques, the latter of which are not usually accompanied by reactive astrocytes 
and activated microglia (Pike, Cummings and Cotman, 1995; DeTure and Dickson, 2019). 
Dense core plaques, rich in fibrillar Ab, have been linked to neuronal cytotoxicity 
(Urbanc et al., 2002). Staining such as Thioflavin (ThT) can allow both the in vitro and in 
vivo visualisation of amyloid plaques within brain tissue, and the monitoring of Ab 
aggregation kinetics within the laboratory environment (Walsh et al., 1999; Urbanc et 
al., 2002; Younan and Viles, 2015; Xue et al., 2017; DeTure and Dickson, 2019). Dense 
core plaques, also known as neuritic or senile plaques, contain an Ab core, surrounded 
by degenerated neurites and microglia activated in response to neuroinflammation, 
aiding the theory that Ab drives AD progression through neurodegeneration (Pike, 
Cummings and Cotman, 1995; Urbanc et al., 2002; DeTure and Dickson, 2019).  In some 
neuritic plaques, the presence of tau has also been noted (Guo, Noble and Hanger, 2017; 
DeTure and Dickson, 2019). In AD tau undergoes hyperphosphorylation and 
consequently impaired folding, therefore (as an essential cytoskeleton protein) is 
unable to support microtubules within axons (Guo, Noble and Hanger, 2017). Evidence 
suggests that presence of neurofibrillary tangles correlates to AD severity (Nelson et al., 
2012). Findings reveals the presence of activated microglia and amyloid plaques in non-
cognitive impaired individuals, whereas reactive astrocytes and tau pathology was only 
detected in individuals with confirmed AD, suggesting that tau pathology correlates 
better with AD progression, whereas changes in microglia may occur at early stages of 
the disease (Vehmas et al., 2003).  
To evaluate and identify AD status and progression, studies have proposed use of 
staging schemes. For example, Braak and Braak in the late-1990s suggested a staging 
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scheme to investigate AD spread in the brain, and therefore identify disease 
progression. Stage 1 (I)  of AD consists of MCI seen due to  Ab deposition and 
hyperphosphorylated tau seen within the basal frontal and temporal entorhinal regions 
of the brain, the second stage (II) involves spreading to limbic regions such as the 
hippocampus, stage 3 (III) involves significant neuronal loss of the cortex, whereas lastly, 
stage 4 (IV) involves full disease spread, with AD pathology also seen in sensory, visual 
and motor regions of the brain (Braak and Braak, 1997; Suva et al., 1999; Guo, Noble 
and Hanger, 2017; Xu et al., 2019). In contrast, some studies suggest that changes in the 
primary sensory and visual regions of the brain can be seen earlier in AD-related mild 
cognitive decline and therefore could be considered for early diagnosis of AD (Stephen 





























1.1.4. Ab production  
A number of physiological roles have been identified for APP including a role in cell 
proliferation, and more specialised roles such as in neuronal synapse development and 
a role in early-stages of memory formation (Moya et al., 1994; Luo et al., 1996; Mileusnic 
et al., 2000; Cárdenas-Aguayo et al., 2014). The transmembrane protein APP can be 
cleaved differentially via two pathways known as the non-amyloidogenic and 
amyloidogenic pathway (Finder and Glockshuber, 2007; Cárdenas-Aguayo et al., 2014). 
Through the non-amyloidogenic pathway APP is cleaved via a-secretase to produce s-
APPa that has shown to have a role in neuronal development and to produce  
neuroprotective effects against excitotoxicity (Mattson et al., 1993; Mattson, 1997; 
Gakhar-Koppole et al., 2008; Chow et al., 2010). Following this, the cleavage via g-
secretase leads to the production of the amino-terminal APP intracellular domain (AICD) 
and p3 (Cárdenas-Aguayo et al., 2014). Whereas the amyloidogenic pathway leads to 
the production of Ab of mainly 40 or 42 amino acids long. The amyloidogenic pathway 
cleaves APP via b-secretase giving rise to s-APPb and CT99 or CT89, followed by g-
secretase, leading to the production of Ab and AICD (Fig. 1.1.4.1) (Podlisny et al., 1995, 
1998; Shao et al., 1999; Finder and Glockshuber, 2007; Ryan et al., 2010; Cárdenas-
Aguayo et al., 2014; Nichols et al., 2015). The biology of the AICD fragment is not fully 
understood, however it is believed that further cleavage of AICD via caspases, can lead 
to the production of fragments which can induce cytotoxicity via DNA fragmentation 
(Bertrand et al., 2001; Lu et al., 2003). In contrast to s-APPa, s-APPb role is not fully 
understood, although a role in axon pruning and neuronal death during development 
has been proposed (Nikolaev et al., 2009). Analysis of plasma and CSF (cerebrospinal 
fluid) from individuals with MCI or AD have proven that Ab is not only produced during 
pathological conditions, but it is also present in healthy aged individuals, with a 
significant increase in Ab, especially Ab1-42, seen in CSF of both MCI and AD individuals 
compared to control individuals (Giedraitis et al., 2007). Dependent on the 
concentration, aggregation status and species, studies have shown that Ab can exhibit 
either neurotrophic or neurotoxic effects such as those seen in AD. Similarly to APP, 
neurotrophic effects of Ab (pM or low nM concentrations) include a role in cell 
proliferation, differentiation and memory formation (Luo et al., 1996; Plant et al., 2003; 
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Chen and Dong, 2009; Garcia-Osta and Alberini, 2009; Fonseca et al., 2013; Bernabeu-
Zornoza et al., 2019). For example, non-aggregated Ab1-40 (1.5 µM; 24-48hr) was shown 
to induce cell proliferation and induce murine neural progenitor cell (NPG) and neural 
stem cell (NSC) differentiation into neurons (Chen and Dong, 2009; Fonseca et al., 2013). 
Whereas, treatment of either human or rodent NSCs with the non-aggregated Ab1-42 at 
low µM concentrations increased cell proliferation and caused NSCs to favour 
differentiation into glial cells (Fonseca et al., 2013; Bernabeu-Zornoza et al., 2019). Due 
to the neurotrophic role of Ab1-40, it is believed that changes in the ratio of Ab1-40/Ab1-
42, with a noted increase in Ab1-42 production, may be partly responsible for neuronal 
loss seen in AD. Evidence indicates that Ab production can be induced during hypoxic 
and oxidative stress conditions, with unaggregated Ab shown to act as an antioxidant 
(Zou et al., 2002; Pearson and Peers, 2006; Cárdenas-Aguayo et al., 2014). In contrast, 
abnormal APP processing in AD involving changes in the ratio of Ab1-40/1-42 produced, 
increased production, and impairment in degradation and clearance of the peptide from 
the brain can aid its accumulation (Hardy and Selkoe, 2002; Dubnovitsky et al., 2013). 
Abnormally high levels of Ab in the brain have been linked to numerous neurotoxic 
mechanisms seen in AD (Ueda et al., 1997; Barghorn et al., 2005; Puzzo et al., 2005; 
Hermann et al., 2013; Carrillo-Mora, Luna and Colín-Barenque, 2014). For example, 
downregulation of brain derived neurotrophic factor (BDNF) expression through 
changes in the phosphorylation of the transcription factor CREB (cAMP response 
element-binding protein), have been linked to cognitive decline via changes in 
neurotransmission, synaptic density and neuronal viability (Garzon and Fahnestock, 
















































































































































































































































































1.1.5. Amyloid-b cascade hypothesis  
 
The ‘amyloid-b cascade hypothesis’ proposes that AD pathology largely results 
due to increased deposition of Ab in the brain, aiding its aggregation into what is 
believed to be its cytotoxic form (Hardy and Selkoe, 2002). As a consequence, this 
initiates a number of neurotoxic mechanisms such as synaptotoxicity, excitotoxicity, 
mitochondrial dysfunction and oxidative stress that can all ultimately lead to neuronal 
loss  (Hardy and Selkoe, 2002; Barghorn et al., 2005; Nimmrich and Eckert, 2013; 
Carrillo-Mora, Luna and Colín-Barenque, 2014). Evidence from both in vitro and in vivo 
using transgenic animal models, where APP is overexpressed or where the 
amyloidogenic pathway is promoted, provide support for the amyloid-b hypothesis 
(Finder and Glockshuber, 2007). Although evidence clearly demonstrates that Ab has a 
major role in AD pathology, some studies have shown that tau pathology (and 
subsequent neuronal loss) is more evident at early Braak I/II stages in the frontal, 
temporal endorhinal regions of the brain, and the hippocampus compared to  presence 
of Ab plaques (Arriagada et al., 1992; Gómez-Isla et al., 1996). Even though evidence 
indicates that tau pathology can precede Ab plaque formation, and therefore may 
better correlate to disease progression and severity, some studies have suggested that 
tau deposition is still dependent on Ab accumulation and aggregation and that Braak 
stages I/II may correspond to pre-clinical AD (AD dependent MCI) rather than fully-
developed AD; such studies support a critical role for Ab in AD (Petersen et al., 2006; 
Bolmont et al., 2007; Fein et al., 2008; Wu et al., 2018). Even though it is widely accepted 
that Ab has a significant role in AD pathology, there is also some debate as to whether 
the toxic effects seen in preclinical animal model studies are a true representation of 
human pathology. For example, animal models such as the previously mentioned 
transgenic animal model with the London APP mutation induced to overexpress APP, 
are being genetically manipulated to exhibit AD characteristics (Bales et al., 1999; 
Daschil et al., 2013). As a number of animal models used for studying AD require genetic 
manipulation, opposing views exist as to whether different mechanisms underlie 
disease pathology in animals compared to humans.  Another reason which has caused 
doubt in the Ab hypothesis, is that some animal models are able to display synaptic loss 
and cognitive impairment prior to amyloid plaque formation (DaRocha-Souto et al., 
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2011). In contrast to the belief that amyloid plaques correlate with disease progression, 
Boncristiano and colleagues in 2005 revealed that in a transgenic animal expressing the 
APP gene with Swedish mutation, which is known to favour amyloidogenic processing 
of APP, although Ab plaque formation was evident, no significant degree of synaptic loss 
was observed (Boncristiano et al., 2005; Shin et al., 2010).  Human iPSC  (induced 
pluripotent stem cell) derived neurons are now widely used as a human in vitro model 
to research AD pathology (Arber, Lovejoy and Wray, 2017). Additionally, work 
conducted in humans on post-mortem tissue revealed that in individuals with MCI, 
synaptic dysfunction was evident without the presence of amyloid plaques, therefore 
raising the question whether amyloid plaque formation is indeed a key event correlating 
to synaptic loss and therefore disease severity (Counts et al., 2014). One possible 
explanation for the poor correlation of amyloid plaques with cognitive impairment, 
could be that smaller Ab aggregates such as oligomeric and protofibrillar Ab and not 
mature fibrils (seen in amyloid plaques) are responsible for cytotoxicity (Hardy and 
Selkoe, 2002; Ryan et al., 2010, 2013; Morris, Clark and Vissel, 2014; Müller-Schiffmann 
et al., 2016). Due to this, a number of studies are now focusing in investigating the 
effects of smaller Ab aggregates, such as Ab oligomers and protofibrils, due to the lack 
or reduced degree of toxicity observed with larger aggregates (Barghorn et al., 2005; 














1.1.6. Ab assemblies  
 
Studies conducted on post-mortem tissue and isolated-Ab from serum and CSF 
have helped in identifying the various lengths of Ab sequence found within the brain 
(Podlisny et al., 1995; Finder and Glockshuber, 2007; Nichols et al., 2015). Analysis 
revealed that Ab can be present in various lengths ranging from 40 to 43 amino acid 
long (Pachahara et al., 2012). Although 90% of Ab found in the human brain consists of 
the 1-40 sequence, as the 1-42 sequence is more prone to aggregation, a lot of the 
research on AD pathology has focused on Ab1-42 (Shao et al., 1999; Barghorn et al., 2005; 
Pachahara et al., 2012; Cárdenas-Aguayo et al., 2014).  
It is well documented that Ab can exist as a number of different assemblies, 
dependent on its aggregation status (Pachahara et al., 2012; Nicoll et al., 2013). Ab can 
exist in its monomeric form, where following changes to its secondary structure, it can 
then change from a-helices or random coils into b-sheets which are more prone to 
aggregation (Shao et al., 1999; DeTure and Dickson, 2019). Following changes to its 
secondary structure, monomeric Ab  (4kDa) can then aggregate into dimers or small 
soluble and larger oligomers known as the nucleated polymerisation process. Following 
this, the elongation process starts, which involves Ab oligomers further rearranging into 
elongated structures known as protofibrils and eventually mature fibrils displaying 
crosslinking of b-sheets, which is primarily what is found within amyloid plaques (Fig. 
1.1.6.1) (Sandberg et al., 2010; DeTure and Dickson, 2019). Various oligomeric species 
of Ab exist, ranging from dimers to higher oligomeric assemblies (up to ~3000 kDa) 
displaying differential degrees of cytotoxicity (Nicoll et al., 2013; Nichols et al., 2015). 
Dahlgren and colleagues revealed that reduction in neuronal viability was significantly 
higher when small soluble oligomers (10nM to 1µM) were added compared to treating 
neuroblastoma cells with larger aggregates (>50kDa) such as Ab fibrils  (Dahlgren et al., 
2002). Similarly, research has shown that it is not amyloid fibrils seen in amyloid 
plaques, but Ab in its oligomeric state that can induce synaptic dysfunction through 
changes in neurotransmission and eventually neuronal loss (Nimmrich et al., 2008; 
Hermann et al., 2013).  
A large number of research studies are now using synthetic Ab which can 
undergo aggregation in a similar manner to Ab found in vivo, with also similar neurotoxic 
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effects observed (Ryan et al., 2010). However, even though studies agree that 
aggregated Ab  can cause neurotoxicity, there is still some dispute as to which 
aggregated assembly of the peptide is the most toxic and whether a single or multiple 
assemblies are needed to confer the highest degree of cytotoxicity (Nicoll et al., 2013). 
In addition, evidence proposes that the neurotoxic effects displayed by aggregated Ab 
are not only species dependent, but also concentration-dependent and that this may 
also influence aggregation status of the peptide (Verma, Vats and Taneja, 2015). For 
example, Deshpande et al. revealed that small oligomers of 15 to 20 monomers in size, 
can cause mitochondrial dysfunction and therefore initiate cytotoxic pathways at 10nM, 
although neuronal loss is only seen at higher concentrations (Deshpande et al., 2006). 
Contradictory to oligomers and Ab-derived diffusible ligands (ADDLs), a type of small 
oligomers, Ab protofibrils require higher concentrations and longer incubation duration 
to achieve the same degree of cortical neurotoxicity (Deshpande et al., 2006). 
Although there is disagreement regarding the degree in which Ab correlates to 
disease progression, there is strong evidence that aggregated Ab indeed has an 
important role in AD pathology. Therefore more work is needed in order to aid our 
understanding of Ab pathology and focusing on Ab downstream targets may also 
provide a better understanding of disease progression (Nimmrich et al., 2008; Carrillo-































































































































































































































































































1.1.7. Alzheimer’s diagnosis and therapies  
 
Currently AD diagnosis aims to identify individuals at high risk of developing 
dementia and to diagnose individuals at early stages. Diagnosis involves 
neuropsychological tests, such as the mini-mental state examination (MMSE) that aim 
to assess cognition through testing language fluency, orientation, reasoning and 
language construction, and patient and carers interviews, and imaging techniques such 
as MRI and PET (positron emission tomography) scans to quantify brain atrophy (Jack et 
al., 1999; Ward et al., 2000; Scarmeas et al., 2006; Cerejeira, Lagarto and Mukaetova-
Ladinska, 2012; Creavin et al., 2016; Weller and Budson, 2018). Although 
neuropsychological tests have been routinely used in dementia diagnosis, they can be 
time-consuming and may not always be able to give a clear indication of an individual’s 
cognitive abilities or distinguish between dementia types. For example, an individual 
with lower education level but who is healthy, may score lower during a 
neuropsychological test. An epidemiology study conducted in the early 1990s which 
followed individuals over 5 to 10 years, revealed that neuropsychological tests were 
able to accurately predict individuals at risk of developing AD (Tierney et al., 2005). 
Similarly, a recent systematic review and meta-analysis revealed that 
neuropsychological tests, especially tests that assess verbal episodic memory and 
language, are good predictors of individuals at early-stages of dementia (Belleville et al., 
2017). The use of radiolabelled amyloid biomarkers (e.g. Pittsburgh compound B;PiB) in 
combination with imaging techniques such as PET scans are now also used to identify 
AD severity by checking for amyloid plaque presence in the brain (Ikonomovic et al., 
2008; Weller and Budson, 2018; Suppiah, Didier and Vinjamuri, 2019). Although PET 
scanning has a high degree of accuracy, this process is very costly and therefore not 
readily available (Clark et al., 2012; Yeo et al., 2015). Moreover, although PET scans 
using amyloid biomarkers can identify amyloid plaque burden in the brain, this may also 
lead to mis-diagnosis as other dementia types such as Lewy body dementia may also 
consist of amyloid plaques in the brain (Kantarci et al., 2012). CSF evaluation measuring 
the amount of Ab and both total and hyperphosphorylated tau present within the CSF, 
and serum tests are now also in development for AD diagnosis, with similar degree of 
accuracy as PET scans (Palmqvist et al., 2015; Weller and Budson, 2018).  
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AD pathology has been linked to synaptic loss of cholinergic neurons in regions 
such as the basal forebrain and hippocampus (Whitehouse et al., 1982; Haam and Yakel, 
2017). Neurotransmission in cholinergic neurons occurs via the neurotransmitter 
acetylcholine which has been implicated in learning and memory (Haam and Yakel, 
2017). Studies have shown that both synaptic dysfunction and also reduced 
acetyltransferase production or changes in the activity of acetylcholinesterase can lead 
to acetylcholine depletion therefore aiding AD progression (Wilcock et al., 1982; Strada 
et al., 1992; Wong et al., 1999; Bell et al., 2006). At the present time, therapeutics 
available for AD treatment, approved for early and mid-moderate stages of AD, are 
acetylcholinesterase (AChE) inhibitors (e.g. donepezil) which aim to prolong the levels 
of acetylcholine in the brain (Cacabelos, 2007; Parsons, Stöffler and Danysz, 2007; Birks 
and Harvey, 2018; Weller and Budson, 2018). Drugs approved for later stages of AD, for 
targeting mechanisms such as excitotoxicity, are NMDA (N-methyl-D-aspartate) 
receptor antagonists (e.g. memantine) due to overactive NMDA receptors (Cacabelos, 
2007; Parsons, Stöffler and Danysz, 2007; Birks and Harvey, 2018; Weller and Budson, 
2018). Although these compounds have been approved for AD treatment for several 
years and have shown promise in providing symptomatic relief, they have only shown 
limited effectiveness, and have also been linked to a number of side effects (Ali et al., 
2015). Due to this, there is considerable interest in developing other agents that not 
only delay progression, but may also target specific AD-related cytotoxic mechanisms, 
with minimal side effects, therefore halting disease progression (Weller and Budson, 
2018).  
At the moment, drugs which are either in development or tested in clinical trials 
includes drugs against amyloid, tau, neuroinflammation and also cognitive enhancers 
(Huang, Chao and Hu, 2020). Drugs that target amyloid aim to either decrease its 
production or aid amyloid clearance from the brain (Swerdlow, 2007; Doody et al., 2013; 
Huang, Chao and Hu, 2020). Pre-clinical studies have shown that enzymes that can 
degrade Ab such as neprilysin, whose expression and activity is downregulated in AD, 
have the potential of becoming novel therapeutics for AD (El-Amouri et al., 2008). 
Compounds that target secretases are also currently under investigation with b-
secretase as the main target candidate (May et al., 2011). Although secretases have 
been considered as a target candidate to treat AD, clinical trials such as that with 
 34 
verubecestat revealed that b-secretase inhibitors proved ineffective  in non-Familial AD 
(which accounts for the majority of AD cases) (Egan et al., 2018; Volloch and Rits, 2018). 
This suggests that production of Ab is induced by differential pathways in early-onset 
versus late-onset AD, and therefore therapeutics that target the production of Ab would 
not be an effective treatment for both AD types. One of the main reasons for failed or 
interrupted clinical trials such as the ones that target secretases, is the development of 
unexpected adverse effects (Doody et al., 2013; Salloway et al., 2014; May et al., 2015). 
For example, targeting g-secretase brings forward issues such as adverse effects as this 
secretase also participates in Notch-3 activation, a peptide with critical developmental 
roles (Swerdlow, 2007). For example, a phase-3 clinical trial using semagacestat (g-
secretase inhibitor) reported gastrointestinal, infection and even skin cancer related 
adverse effects believed to occur due to changes in Notch-3 signalling (Henley et al., 
2014). Therefore, there is considerable interest in developing new therapeutics with 
increased selectivity and therefore less potential adverse effects. NSAIDs (non-steroidal 
anti-inflammatory drugs) such as ibuprofen with anti-inflammatory actions are also 
investigated as potential treatments (Swerdlow, 2007).  Although neuroinflammation is 
a major feature of AD pathology, anti-inflammatories such as NSAIDs in randomized 
trials have not shown promising results (Pasqualetti et al., 2009; Deardorff and 
Grossberg, 2017). 
In AD, Ab deposition has also been noted within blood vessels of the CNS 
(DeTure and Dickson, 2019). Due to this, a number of pre-clinical and clinical studies are 
investigating the use of antibodies against Ab. Currently, immunization vaccines against 
Ab to induce clearance are been tested, with mixed findings indicating a therapeutic 
effect (Swerdlow, 2007; Salloway et al., 2014; Huang, Chao and Hu, 2020). Ab 
immunization in the PDAPP mouse models (which overexpress human APP with a 
mutation at aa717) led to a significant reduction in cortical amyloid plaque formation 
and also activation of microglia and reactive astrocytes (Schenk et al., 1999). 
Contradictory to pre-clinical studies, a double-randomised clinical trial (2001) 
investigating the effect of Ab immunization (AN1792) in individuals with AD, although it 
revealed beneficial effects in reducing hyperphosphorylated tau burden and improving 
cognitive function, it had to be prematurely stopped due to adverse effects. One of the 
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serious adverse effects noted in some individuals was the development of encephalitis 
(Gilman et al., 2005). Post-mortem studies conducted by Masliah and colleagues on an 
individual who was previously enrolled in the 2001 Ab immunization clinical trial 
reported by Gilman et al. 2005, but who did not develop encephalitis, revealed a 
significant reduction in amyloid plaque burden in the frontal and smaller degree of 
reduction in the temporal regions of the cortex (Masliah et al., 2005). This provides 
evidence that Ab immunotherapy may indeed delay AD pathology, although more work 
is needed in order to develop immunotherapies that do not cause activation of immune 
response such as those seen in individuals who developed encephalitis. More recently, 
BIIB037 (drug name: aducanumab), a monoclonal antibody against Ab has been filed for 
FDA approval. Although initial results from two late-phase clinical trials revealed mixed 
findings, re-evaluation of some findings revealed that aducanumab can improve 
cognitive decline through reduction in amyloid plaque burden (Schneider, 2019). 
Although these findings suggested it could be an effective therapeutic against AD, it was 
recently announced it unfortunately was not granted FDA approval. In addition to Ab 
immunotherapy, some clinical trials are testing therapies against tau (Congdon and 
Sigurdsson, 2018; Boxer et al., 2019). 
























Calcium (Ca2+) has been linked to a number of physiological processes such as cell 
viability, differentiation, gene expression, secretion of hormones, muscle contraction, 
neurotransmitter release and synaptic plasticity within excitable cells (Chin, 1998; Birks 
and López-Arrieta, 2002; Schneider et al., 2005; Sinnegger-Brauns et al., 2009; Resende 
et al., 2010; Xu et al., 2011; Daschil et al., 2013; Dolphin, 2013; Brini et al., 2014).   
Ca2+ influx can be accomplished via at least three types of plasma membrane 
channels. One type of calcium permeable membrane channels, is the voltage-gated 
calcium channels (VGCCs) which open in response to changes in the membrane 
potential (Brini et al., 2014; Zamponi, 2016). Two other types include store-operated 
calcium channels (SOCs) such as RyRs (ryanodine receptors) present on the ER 
(endoplasmic reticulum) that allow release of Ca2+ from internal stores, and the 
receptor-operated calcium channels (ROCs) such as ligand-dependent ionotropic 
receptors (e.g. NMDA receptors) that allow Ca2+ influx into the cells from the 
extracellular space in response to ligand binding (Brini et al., 2014; Zamponi, 2016). For 
















1.2.2. Voltage-gated calcium channel structure 
 
In the 1980s evidence of the structure of VGCCs had started to emerge. Purification 
studies and structural analysis of VGCCs revealed three main subunits of ~200 (pore-
forming), ~50 and ~30 kDa (accessory subunits) molecular weight, therefore revealing 
that the VGCCs exist as a complex of various proteins (Curtis and Catterall, 1984; 
Flockerzi et al., 1986; Takahashi et al., 1987; Witcher et al., 1993; Brini et al., 2014). 
Further analysis revealed that VGCCs consist of the a1 pore-forming subunit, and the  
accessory subunits;  the intracellular b subunit, the extracellular transmembrane a2d 
complex connected via disulphide bonds (Fig. 1.2.2.1) and  sometimes an extracellular 
g subunit may also be present (Kamp et al., 2005; Dolphin, 2013; Sousa et al., 2013; Brini 
et al., 2014; Zamponi, 2016; Qian et al., 2017). The g subunit has been found to be 
expressed in skeletal muscle Cav1 channels (Kamp et al., 2005; Striessnig et al., 2014; 
Zamponi, 2016). The pore-forming subunit, which allows for Ca2+ entry, consists of 4 
domains (I – IV) each containing 6 transmembrane regions (S1-S6) (Sousa et al., 2013; 
Zamponi, 2016; Qian et al., 2017). The accessory subunits on the other hand, are 
responsible for channel trafficking and modulating the gating properties of the channel 



































Figure 1.2.2.1: Schematic diagram of voltage-gated calcium channels. Voltage-gated calcium channels consist of the 
a1 pore-forming subunit, the intracellular b subunit, the transmembrane a2d  complex and also a transmembraneg 
subunit may also be present. 
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1.2.3. VGCC subtypes and tissue expression 
 
VGCCs can be divided into three main groups based on their a1 pore-forming 
subunit, and their biophysical and pharmacological properties (Zamponi, 2016). The 
Cav1 channels, which form L-type currents, consist of Cav1.1, Cav1.2, Cav1.3 and Cav1.4 
(Nimmrich and Eckert, 2013; Zamponi, 2016). The Cav2 subfamily consists of the Cav2.1 
(P/Q-type current), Cav2.2 (N-type current) and Cav2.3 (R-type current) (Nimmrich and 
Eckert, 2013; Zamponi, 2016). Lastly, Cav3 channels which form T-type (transient/tiny) 
currents, consist of Cav3.1, Cav3.2 and Cav3.3 (Barnes and Haynes, 1992; Chin, 1998; 
Perez-Reyes et al., 1998; Sousa et al., 2013; Zamponi, 2016). VGCCs can also be 
subdivided into HVA (high-voltage activated) or LVA (low-voltage activated) depending 
on their activation threshold. Cav1 and Cav2 channels require larger membrane 
depolarizations to activate, and therefore belong to the HVA group, whereas Cav3 
belong to the LVA group with activation seen at lower depolarizations (Nowycky, Fox 
and Tsien, 1985; Soong et al., 1993; Ertel et al., 2000; Zamponi, 2016). Figure 1.2.3.1 
summarizes the nomenclature of the various members of the VGCCs and the genes that 
encode the a1 subunit of these channels, based on Ertel et al. 2000. 
VGCCs have been linked to a number of different roles within the nervous system, 
often dependent on the subfamily. Cav1.1 channels are primarily expressed within 
skeletal muscle, whereas Cav1.2 and Cav1.3 are expressed within the cardiac and 
skeletal muscle, neurons, and also sensory and endocrine cells (Striessnig et al., 2014; 
Zamponi, 2016). In contrast, Cav1.4 is primarily expressed within immune and retinal 
cells (Striessnig et al., 2014). Cav1.2 and Cav1.3 expression has also been detected 
within the central nervous system (CNS), with high variability in biophysical properties 
of these channels due to subunit splicing and isoform variance as well as association 
with different b accessory subunits (Striessnig et al., 2014). The majority of Cav1 
channels expressed in the brain are Cav1.2, whilst only approximately 10% representing 
Cav1.3 (Striessnig et al., 2014; Qian et al., 2017). Cav1 channels have been shown to 
have a role in gene expression and neuronal development, such as during synapse 
formation and strengthening (Resende et al., 2010; Brini et al., 2014; Striessnig et al., 
2014; Zamponi, 2016; Qian et al., 2017). Cav1 channels are known to show sensitivity 
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to dihydropyridine inhibition, whereas Cav2 and Cav3 are dihydropyridine inhibition 
insensitive (Nowycky, Fox and Tsien, 1985; Zhang et al., 1993). 
All members of the Cav2 subfamily are primarily expressed within neurons and 
endocrine cells, with several cellular roles (Striessnig et al., 2014). The first evidence of 
the role of VGCCs in neurotransmission came from studies carried out on squid axons 
by Katz and Miledi in the 1970s, where it was shown that vesicular fusion and 
neurotransmitter release was dependent on Ca2+ influx through opening of voltage-
dependent ion channels (Katz and Miledi, 1970). Cav2.2 was shown to interact directly 
with the synaptic proteins syntaxin and SNAP25 (synaptosomal-associated protein), 
proving that Ca2+ influx via VGCCs is required for neurotransmitter release (Sheng et al., 
1996). A role in neurotransmission has also been observed for Cav2.1, and to a lesser 
extent Cav2.3, with Cav2.1 also regulating gene expression of proteins such as syntaxin 
(Kamp et al., 2005; Nimmrich and Eckert, 2013; Brini et al., 2014; Zamponi, 2016). In 
contrast to Cav1 channels, which can be found predominately in postsynaptic sites, Cav2 
channels are predominately found at presynaptic sites (Witcher et al., 1993; Nimmrich 
and Eckert, 2013; Striessnig et al., 2014; Zamponi, 2016). In addition to 
neurotransmission, Cav2.3 channels have also been shown to have a role in cell 
apoptosis (Kamp et al., 2005). Inhibition of Cav2 channels has been achieved using a 
range of toxins, including conotoxins and agatoxins derived from cone snail and spider 
venom, respectively, and other divalent cations such as Ni2+ and Cd2+ a global-VGCC 
modulator (Witcher et al., 1993; Zhang et al., 1993; Randall and Tsien, 1995; Ertel et al., 
2000).  
Both Cav3.1 and Cav3.3 are primarily found within CNS neurons (Soong et al., 1993; 
Perez-Reyes et al., 1998; Striessnig et al., 2014). Cav3.1 is also expressed within cardiac 
cells. Cav3.2 on the other hand, is predominantly found within kidney and liver cells 
(Striessnig et al., 2014). Evidence has shown that the expression of Cav3 channels is 
higher during early stages of neuronal development (Aguado et al., 2016). A role for 
Cav3 channels within neuronal excitability has also been proposed (Aguado et al., 2016; 
Zamponi, 2016). Inhibition of Cav3 channels has been observed with Ni2+ and 
pharmacological agents such as mibefradil dihydrochloride  (Soong et al., 1993; Perez-
Reyes, Lee and Cribbs, 1999). 
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A number of pathways have been reported to change the expression and activity 
of VGCCs. For example, post-translational modifications of VGCCs such as 
phosphorylation, N-glycosylation of asparagine and redox modulation have been 
reported to change the activity of VGCCs (Takahashi et al., 1987; Scragg et al., 2008; 
Lazniewska and Weiss, 2017; Qian et al., 2017).  Studies starting as early as the 1980s 
revealed several phosphorylation sites within the a1 subunit (Takahashi et al., 1987). 
Recent studies, further revealed Ser1928 as one of the site by which PKA (protein kinase 
A) can phosphorylate Cav1.2 channels, an event which can lead to an increase in Ca2+ 
influx (Qian et al., 2017). Numerous sites in both the pore-forming subunit and 
accessory subunits have been noted as sites of N-glycosylation (Lazniewska and Weiss, 
2017). For example N-glycosylation of the a2d accessory subunit is believed to occur as 
a process for stabilizing the interaction of this complex with the a1 pore-forming 









































Figure 1.2.3.1: Nomenclature of VGCCs. VGCCs are split into three subgroups; Cav1 (Cav1.1 - Cav1.4) also known as the 
L-type currents, the Cav2 (Cav2.1 - Cav2.3) also known as P/Q, N and E/R-type respectively, and lastly the Cav3 (Cav3.1 
– Cav3.3) channels also known as T-type currents. Members of the Cav1 and Cav2 subfamilies belong to the high voltage 
activated (HVA) group, whereas members of the Cav3 sufamily belong to the low voltage activated (LVA) group. The 
various genes that encode the a1 subunit of each member of the VGCC subfamily are also shown in the figure. 
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1.2.4. VGCC impairment in Alzheimer’s disease 
 
Calcium dyshomeostasis has been linked to several vascular and cardiovascular 
conditions such as stroke, myocardial infarction, and also neurodegenerative conditions 
such as AD, Parkinson’s disease, psychiatric disorders, epilepsy and pain (Kim and Rhim, 
2011; Zamponi, 2016). 
An abundance of in vivo and in vitro studies revealed that aggregated Ab can cause 
neuronal dysfunction, synaptic loss and eventually neuroapoptosis  (Ueda et al., 1997; 
Dahlgren et al., 2002b; Shin et al., 2010; Mezler et al., 2012; Valerie et al., 2013). There 
is accumulating evidence that suggests that part of Ab’s pathological effects seen in AD 
involves modulation of ion channels. In AD, the ‘calcium hypothesis’ proposes that one 
of the toxic effects of Ab includes Ca2+ dyshomeostasis; this can potentially lead to cell 
apoptosis, due to Ca2+ being fundamental in maintaining correct cell function. One 
prominent way by which Ab can cause changes in Ca2+ influx, is through modulation of 
VGCCs (Anekonda et al., 2011; Kim and Rhim, 2011; Nimmrich and Eckert, 2013).  
A mechanism by which Ab has been proposed to cause calcium dysregulation is 
through change in VGCC expression. For example, a study conducted by Anekonda et al. 
(2011) revealed that oligomeric Ab can cause overexpression of Cav1.2 at both mRNA 
(messenger RNA) and protein level, which can result in neurotoxicity. Neurotoxicity was 
reduced with the Cav1 blocker isridipine (Anekonda et al., 2011). In support, Chiou 
(2006), revealed that 20µM Ab25-35 treatment caused a time-dependent upregulation in 
Cav1.2, Cav2.1 and Cav2.2 at both mRNA and protein level in SH-SY5Y neuroblastoma 
cells. This upregulation, was suggested to involve activation of NF-kB and subsequent 
upregulation of VGCC a1 subunit expression (Chiou, 2006). In contrast, Daschil et al., 
(2013) proposed that VGCC-dependent Ca2+ dysregulation does not form part of the 
mechanism by which Ab causes cytotoxicity, but occurs as a result of the Ab-mediated 
cytotoxicity. Daschil and colleagues revealed that in transgenic mice which exhibit both 
APP and Ab upregulation (due to London V717I) and Swedish (K670M/ N671L) APP 
mutations, respectively, an upregulation in Cav1.2 a1 was only seen at late disease 
stages, where plaque formation in reactive astrocytes was reported (Daschil et al., 
2013). These findings may suggest a differential pattern in Ab-mediated neuronal and 
glial Ca2+ dysregulation. Ueda and colleagues revealed that incubation of both cortical 
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and hippocampal neurons with protofibrillar 10µM Ab25-35 induced a significant Ca2+  
influx, which in turn induced ROS production, initiating cell apoptosis (Ueda et al., 1997). 
Ueda proposed that the increase in Ca2+ influx by Ab25-35 through L-type channels 
observed via electrophysiological studies could be through increasing Cav1 expression 
at protein level, or via Ab changing channel kinetics, and therefore allowing more Ca2+  
influx (Ueda et al., 1997). 
Another potential mechanism by which Ab can modulate VGCCs is through 
subunit/protein-protein interaction. Kim and Rhim demonstrated that treatment with 
nM concentrations of Ab25-35 caused an upregulation of Cav1.2 at the mRNA level, 
accompanied by an increase in the number of functional channels present at the cell 
membrane of hippocampal neurons. Further experiments in Cav1.3-transfected HEK293 
cells (containing a1D and b3 subunits) with Ab25-35 acute treatment caused a marked 
increase in both Cav1.3 amplitude and conductance, but did not significantly change the 
activation and deactivation voltages (Kim and Rhim, 2011). Immunoprecipitation 
experiments supported that this effect could be due to direct interaction with the b3 
subunit of the VGCCs (Kim and Rhim, 2011). 
Alzheimer’s and Prion (PrP) diseases are both linked to impaired peptide 
processing (Ab and PrP respectively) which can lead to neuronal dysfunction and 
eventually apoptosis (Westergard, Christensen and Harris, 2007; Senatore et al., 2012). 
Due to this, it has been suggested that similar pathogenic mechanisms may underlie 
these diseases. Under physiological conditions PrP can interact and block b-secretase; 
whilst under pathological conditions, such as AD, Ab accumulation can hinder this 
process, causing a further upregulation in its production (Kellett and Hooper, 2009). 
Senatore et al. (2012) proposed a direct interaction of misfolded-PrP with the accessory 
a2d subunit, preventing VGCC translocation to the cell membrane, and consequently 
reducing neurotransmitter release (Senatore et al., 2012). This direct interaction of PrP 
with VGCCs, raises the question whether Ab may also modulate VGCCs in a similar 
manner.  
Another potential mechanism by which Ab may impair VGCC function is via 
modulating VGCC channel kinetics. In 2008, Nimmrich et al., noted that incubation with  
globulomer Ab1-42 did not cause a decrease in neurotransmitter release through pore 
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formation, as proposed by the amyloid-pore formation hypothesis, but rather through 
a decrease in VGCC-dependent Ca2+ influx (Nimmrich et al., 2008).  Electrophysiological 
experiments indicated that Ab-mediated reduction in Ca2+ influx occurred through 
changes in P/Q-type channel kinetics, with slope and Vhalf (half activation voltage) 
remaining unaltered (Nimmrich et al., 2008). By contrast, Mezler et al. (2012), showed 
that treatment of Xenopus laevis oocytes with oligomeric Ab increased both the 
amplitude, and also caused a hyperpolarized shift in the activation of recombinant 
Cav2.1 channels, through interacting with the pore-forming a1 subunit (Mezler et al., 
2012).  In support of Mezler’s work, Hermann and colleagues, through whole-cell patch 
clamp, revealed that Ab globulomers not only modulated Cav2.1 kinetics, but also 
increased the activity of Cav2.2 channels, through an increase in amplitude and also 
shift of Vhalf towards more hyperpolarized values (Hermann et al., 2013). This effect of 
Ab on Cav2.2 channels could be prevented through the use of VGCC blockers (Hermann 
et al., 2013), suggesting that CCBs may be beneficial in preventing Ab-mediated synaptic 
dysfunction via impairment in neurotransmission. Contradictory findings concerning the 
mechanism by which Ab affects Cav2 kinetics could be due to differences in the 
concentration of the peptide used, the aggregation state of the peptide, and also 
whether the channel was within its conducting or non-conducting state.  
It is widely accepted that Ca2+ dyshomeostasis constitutes part of the AD 
pathology (Lopez et al., 2008; Daschil et al., 2013; Gholamipour-Badie et al., 2013). 
Several studies have demonstrated that CCBs can suppress Ab toxicity in the brain, as 
seen in various in vivo animal models and cell lines (Ueda et al., 1997; Yagami et al., 
2004; Anekonda et al., 2011; Mezler et al., 2012; Gholamipour-Badie et al., 2013; 
Hermann et al., 2013; Nimmrich and Eckert, 2013). Currently, several pharmaceutical 
agents which target VGCCs and interfere with their pathophysiological action, have 
already been tested or are currently in clinical trials to combat AD (Zamponi, 2016).  
Although it has been shown that CCBs can suppress Ab neurotoxicity mediated through 
VGCCs, as yet clinical trials with VGCC blockers have failed to exhibit significant effects 
in interrupting or delaying AD pathology (Birks and López-Arrieta, 2002; Anekonda et 
al., 2011; Gholamipour-Badie et al., 2013). A systematic review conducted by Birks and 
Lopez-Arrieta in 2002 (updated in 2010), revealed that the Cav1 blocker nimodipine was 
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only beneficial in short term improvement of cognitive function. One reason that clinical 
trials have failed to exhibit significant findings could be due to drug low brain 
bioavailability of the CCB currently tested (Anekonda et al., 2011). Selectivity issues may 
also be a reason for a failed clinical trial (Nimmrich and Eckert, 2013). Formulation 
changes may increase drug bioavailability, and therefore may make compounds more 
effective against AD. 
Overall there is contradictory evidence as to the mechanism(s) by which Ab may 
modulate VGCCs, possibly due to methodological differences or differential effects 
dependent on the VGCC subtype. Identifying endogenous signalling molecules, or 
developing new compounds which may be able to interfere with VGCC-dependent Ab-
mediated neurotoxicity without disturbing the physiological activity of other ion 
channels, may be of therapeutic interest in improving, delaying or even halting AD 


























1.3. Carbon Monoxide 
 
1.3.1. Carbon Monoxide as an exogenous gas 
 
Carbon monoxide (CO) is an odourless and colourless gas, most widely known 
for its deleterious effects, but as described more fully below can also act as a 
endogenous gasotransmitter. Exogenous CO gas can be produced from carbon-based 
fuels, from various home appliances and vehicles (Wilkinson and Kemp, 2011). In the 
UK alone, around 50 individuals die annually due to exogenous CO-poisoning, with 
around 200 individuals requiring hospitalization (Wilkinson and Kemp, 2011). A large 
number of worldwide deaths reported due to CO poisoning were due to CO-release 
from running vehicles in enclosed spaces. Cigarette smoking can also be a source of CO, 
with smoking for 5mins leading to up to 4% oxygen displacement from haemoglobin 
(Omaye, 2002). Toxic levels of CO consist levels higher than 200ppm for acute, and 
30ppm for chronic exposure (Wilkinson and Kemp, 2011). Exposure to 1000ppm or 0.1% 
CO for as low as an 1h can lead to respiratory failure, hypoxia and even death (Peterson 
and Stewart, 1975; Omaye, 2002). 
CO poisoning has determinantal effects to the human body. CO-dependent 
cytotoxicity involves CO binding onto haemoglobin to form the carboxyl-haemoglobin 
complex, which can cause a reduction in the amount of oxygen transported and can be 
released to tissue by RBCs (red blood cells) causing hypoxia (Omaye, 2002). 
Haemoglobin shows an approximate 200-fold higher affinity to CO compared to oxygen 
(Omaye, 2002; Gorman et al., 2003; Motterlini, 2007). Moreover, CO can act 
cytotoxically via block of cytochrome oxidase of complex IV of the electron transport 
chain, causing the body to switch to anaerobic respiration, causing tissue damage and 








1.3.2. Carbon monoxide as a gasotransmitter 
 
Although CO as a toxic gas, can cause cytotoxicity through a hypoxia-related 
manner, endogenously as a product of heme catabolism, it can have vital roles in 
metabolism (Wu and Wang, 2005; Peers, Dallas and Scragg, 2009). CO as an important 
participant in cell signalling, within physiological levels, can be critical for correct cell 
function (Wu and Wang, 2005; Zeynalov and Doré, 2009). 
Endogenously, the majority of CO is released through heme processing. RBC 
heme catabolism can be catalyzed by the enzyme heme oxygenase (HO-1 or HO-2 
isoforms), an enzyme of 30kDa in size, which can be found in a number of cells, including 
glial cells and neurons (Schipper, Cissé and Stopa, 1995; Maines, 1997). A third HO 
isoform exists, known as HO-3 with limited heme catabolism activity (McCoubrey and 
Maines, 1994; Hayashi et al., 2004). Heme oxygenase uses oxygen to catabolize heme 
into biliverdin, ferrous ion (Fe3+) and CO due to the cleavage of the porphyrin ring A and 
B (Tenhunen, Marvel and Schmid, 1969; Maines, 1997). Biliverdin is then further 
metabolised into bilirubin, both known antioxidants (Maines, 1997; Omaye, 2002; 
Jayanti et al., 2020). All of the products generated during heme catabolism are known 
to have a role in both iron and bile metabolism. Although heme catabolism comprises a 
physiological process, stressful conditions can also cause an upregulation in heme 
oxygenase, prompting heme processing. Heme oxygenase expression has been shown 
to upregulate in response to events that induce oxidative stress, due to an increase in 
metals ions such as heme and also due to presence of sulfhydryl compounds (Applegate, 
Luscher and Tyrrell, 1991; Schipper, Cissé and Stopa, 1995; Schipper, 2000). 
CO as a gasotransmitter, can act as a signalling molecule to maintain cell 
function, similarly to the gasotransmitter nitric oxide (NO).  Within the cardiovascular 
system, it has been shown that CO can act as a vasodilator by inducing muscle relaxation 
(e.g. via cGMP (cyclic guanosine monophosphate) pathways) and also induce changes 
in platelet aggregation (Motterlini, 2007; Kaczara et al., 2020).  CO has also shown to 
have anti-inflammatory properties. For example, studies using animal models of 
ischemic stroke, showed that 125 or 250ppm CO inhalation (less than 24hr) led to a 
reduction in both inflammation and cell damage, during restoration of oxygen flow 
(Vieira, Queiroga and Alves, 2008; Zeynalov and Doré, 2009; Wang et al., 2011; Mahan 
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et al., 2012). One potential mechanism by which CO may exhibit these cytoprotective 
effects, is through activation of antioxidant pathways, such as activation of Nrf2 
pathways that induces transcription of antioxidant genes including HO and SOD 
(superoxide dismutase) (Wang et al., 2011). CO has been shown to have anti-
inflammatory and anti-apoptotic effects in preventing rejection of lung transplants 
(Song et al., 2003). In addition to anti-inflammatory properties, CO has also shown to 
have a role within cell proliferation. Duckles and colleagues noted that CO reduced 
proliferation of smooth muscle cells via inhibition of Cav3 channels (Duckles et al., 
2015). Moreover, CO has also shown to prevent apoptosis.  For example, pre-treating 
astrocytes with CO prior to induction of oxidative stress prevented cell death through 
changes in the expression of anti-apoptotic proteins (e.g. bcl-2) (Almeida et al., 2012). 
In another study, it was shown that CO, generated using the CO-releasing molecule 
CORM2, had anti-apoptotic effects by preventing neuroblastoma cell death induced by 
Ab1-42 (Hettiarachchi et al., 2014). Kim et al. (2018) revealed that CO is not only able to 
prevent some of the toxic effects of Ab, but it can also reduce Ab production through 
reducing the expression of b-secretase via a pathway that involves block of NF-kB 





















1.3.3. Carbon monoxide as a novel therapeutic 
 
As a number of papers have proposed that CO can have vast cytoprotective 
roles, there is considerable interest in investigating CO as a novel therapeutic in treating 
various diseases, such as AD. Due to the concerns associated with the use of CO gas as 
a treatment, there is some stigma in using CO as a therapeutic. In order to study CO 
cytoprotective effects in a safe and controllable environment with the laboratory, 
Moterllini’s research group started developing compounds in the early 2000s that allow 
the release of CO in a trackable manner, so-called carbon monoxide releasing molecules 
(CORMs) (Motterlini et al., 2002; Motterlini, 2007; Wilkinson and Kemp, 2011). The first 
compounds to be developed, CORM1 (manganese decacarbonyl) and CORM2 
(tricarbonyldichlororuthenium(II) dimer) were manganese and ruthenium based 
respectively. Both of these compounds are capable of rapid CO release, in response to 
light or ligand substitution respectively (Motterlini et al., 2002; Motterlini, 2007). In 
contrast to CORM1 and CORM2 which require DMSO as a solvent, compounds CORM-
A1 (sodium boranocarbonate) and CORM3 (tricarbonylchloro(glycinato)ruthenium (II)) 
were developed as water soluble compounds (Motterlini et al., 2002; Motterlini, 2007). 
Similarly to CORM2, CORM3 is also a ruthenium based compound capable of rapid CO 
release (Clark et al., 2003). Contrary to the transition-metal containing CORM 
compounds, CORM-A1 contains a carboxylic group capable of slow CO release in 
response to changes in the pH or temperature (Motterlini, Mann, et al., 2005; 
















1.3.4. Heme oxygenase and Alzheimer’s disease 
 
Numerous neurodegenerative diseases have shown that part of their 
pathogenesis involves induction of oxidative stress and presence of free radicals 
(Schipper, Cissé and Stopa, 1995). A downregulation in antioxidants, an upregulation in 
lipid peroxidation products and also redox active iron that can induce ROS release has 
been noted in AD (Schipper, Cissé and Stopa, 1995; Wojsiat et al., 2018). It is believed 
that oxidative stress comprises one of the pathways that lead to cell dysfunction and 
eventually neuronal death, although it is still not fully understood at which stage in 
disease progression this occurs (Schipper, Cissé and Stopa, 1995; Pappolla et al., 1998; 
Schipper, 2004). The increase in heme, and oxidative stress observed in AD brains 
induces HO-1 expression which is proposed to act as a defence mechanism against free 
radicals (Schipper, Cissé and Stopa, 1995; Wojsiat et al., 2018). Ca2+ dysregulation 
mediated oxidative stress (through changes in Ca2+ influx)  may also account for the 
increase in HO-1 expression seen in AD (Ueda et al., 1997; Pappolla et al., 1998; 
Schipper, 2004). 
Findings obtained from experimental work done on mice has revealed that 
during ageing, an upregulation in HO-1 expression in the liver is seen in response to 
oxidative stress, although no change in brain HO-1 expression is noted  (Barnes et al., 
1998). Immmunohistochemistry and fluorescence imaging studies on slices from human 
AD brains reveal HO-1 upregulation in the cerebral cortex, hippocampus and subcortical 
white matter compared to brains of healthy age matched controls; these studies 
suggest that elevated expression of HO-1 in the brain is not a physiological event 
observed during normal ageing (Schipper, Cissé and Stopa, 1995; Schipper, 2000). Co-
localisation of HO-1 in human brain regions where amyloid plaques and neurofibrillary 
tangles were evident, indicated a link for HO-1 with the presence of these two main 
hallmarks of AD  (Schipper, Cissé and Stopa, 1995; Schipper, 2000). An upregulation in 
HO-1 expression has also been noted in astrocytes and microglia in response to 
neuroinflammation (Schipper, Cissé and Stopa, 1995; Fernández-Mendívil et al., 2020). 
Oxidative stress is known to increase HO expression, therefore co-localisation of HO-1 
within regions where amyloid plaques and neurofibrillary tangles are present, may 
occur as a neuroprotective measure (Schipper, Cissé and Stopa, 1995; Hettiarachchi et 
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al., 2014). In support, another study, revealed co-localisation of both HO-1 and also 
CuZn-superoxide dismutase 1 (CuZn-SOD1), another marker of oxidative stress, in 
regions where amyloid plaques are present in animals overexpressing mutant APP 
(Pappolla et al., 1998; Peers, 2011). As upregulation of HO-1 was also observed in areas 
with low amyloid plaque density it was proposed that HO-1 upregulation occurs as a 
response to amyloid accumulation and aggregation and therefore precedes plaque 
formation (Pappolla et al., 1998).  
Upregulation of HO-1 in AD is believed to occur as a protective measure. Infante 
et al. (2010) revealed that HO-1 can halt cholesterol-dependent increase in Ab 
generation by inducing glial cholesterol conversion into oxysterols, and consequently 
activating liver-X receptor-b (LXR-b) which in turn cause changes in gene expression and 
eventually reduction in Ab  (Infante et al., 2010).  Interestingly, individuals with a specific 
polymorphism at the promoter region of HO-1 (-413), and LXR-b polymorphisms in 
introns 2 (rs2695121), 5 (rs1052533), and 7 (rs1405655), exhibit an increased risk of 
developing AD (Infante et al., 2010).   
It is widely accepted that HO-1 can exhibit antioxidant properties. In transgenic 
animals that suffered an ischemic stroke, HO-1 overexpression minimized cell damage 
and maintained cell viability by reducing release of ROS and also upregulating 
expression of pro-apoptotic proteins such as bcl-2 (Panahian, Yoshiura and Maines, 
1999; Schipper, 2004). Moreover, heme catabolism by HO-1 leads to the production of 
products such as biliverdin with known antioxidant properties (Maines, 1997; Takahashi 
et al., 2000; Schipper, 2004; Jayanti et al., 2020). 
Although evidence suggest that HO-1 upregulation in AD occurs as a protective 
measure, some studies reveal that function of HO-1 in AD is impaired and therefore 
cannot exhibit its protective effects. Co-immunoprecipitation experiments revealed 
that HO-1 can interact with APP (Takahashi et al., 2000). This demonstrates that 
especially in Familial AD where APP mutations can be present, upregulation of HO-1 as 
a defence mechanism against oxidative stress will be unable to  confer cytoprotection 
due to APP interacting with HO-1 consequently aiding neuronal toxicity (Schipper, 2000; 
Takahashi et al., 2000). Animal models that lack HO and express mutant APP can display 
similar features to late onset AD. 
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1.3.5. Carbon monoxide modulation of ion channels 
 
There is considerable evidence that suggests that some of the cytoprotective 
effects elicited by HO-1 are partly due to CO (Wu and Wang, 2005; Hettiarachchi et al., 
2014). It has been proposed that one mechanism by which CO acts cytoprotectively is 
through modulation of ion-channels (Wu and Wang, 2005; Peers, 2011). 
Zeynalov and Doré (2009) revealed that following an ischemic stroke, degree of 
cerebral tissue damage and oedema decreases with inhalation of physiological levels of 
CO. It was suggested that the mechanism by which CO confers these protective effects 
is through activation of Ca2+-dependent K+ channels that causes vasodilation of blood 
vessels. Kv2.1 channels are known to have a role in cell apoptosis (Al-Owais et al., 2012). 
Elevated K+ efflux initiates pro-apoptotic pathways, such as caspase activation, and 
upregulates endonuclease function (Szabò, Zoratti and Gulbins, 2010). Al-Owais et al. 
(2012) demonstrated that both HO-1 and its heme catabolism product CO have 
important roles in maintaining cell survival. Oxidative stress-mediated cell death was 
inhibited by CO through an ion channel-dependent manner that involved inhibition of 
neuronal Kv2.1 channels (Al-Owais et al., 2012). In contrast to K+ channels, in a study 
investigating the effect of CO on cardiac arrythmias revealed that it can activate Nav1.5 
channels through a NO, nitrosylation pathway (Dallas et al., 2012). In support to this, Al-
Owais and colleagues demonstrated that CO modulation of ion channels, in this case, 
Kv1.5, not only involves NO, it also involves the activation of guanyl cyclase and 
therefore CO-mediated inhibition of these channels also involves the cGMP pathway 
(Al-Owais et al., 2017). Similarly, Viera’s study revealed that activation of mitochondrial 
KATP through a sGC (soluble guanylyl cyclase) and NO-dependent pathway is part of the 
mechanism by which CO is able to reduce tissue damage and cell death following an 
ischemic stroke (Vieira, Queiroga and Alves, 2008). 
It has been widely accepted that part of the amyloid pathology seen in AD 
involves calcium dysregulation through modulation of VGCCs (Zamponi, 2016). As 
several studies have revealed that CO can modulate VGCCs, there is considerable 
interest in investigating the mechanism(s) by which CO may interfere with Ab-mediated 
calcium impairment through VGCCs seen in AD.   
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Although it has been proposed that CO-mediated prevention of apoptosis is 
through K+ channels, VGCCs have also been implicated. For example, Hettiarachchi et al. 
(2014), revealed that both HO-1 and CO prevented protofibrillar Ab1-42-mediated 
neuronal cell apoptosis through caspase activation. Part of the Ab1-42 neurotoxicity 
involved increasing the activity of Cav1 channels, which in turn caused activation of 
CAMKKII and subsequent phosphorylation and activation of AMPK (Hettiarachchi et al., 
2014). CO released through CORM2 treatment inhibited both the phosphorylation and 
subsequent activation of AMPK (Hettiarachchi et al., 2014).   
Within the cardiovascular system, CO has been shown to decrease myocardial 
infarction-mediated tissue damage (Scragg et al., 2008; Peers, 2011). As inhibition of 
Cav1 channels expressed in HEK293 cells induced neuroprotection, it was proposed that 
CO protective effects are through a Cav1-dependent manner (Peers, 2011). Work 
carried out by Scragg and colleagues revealed that specific cysteine residues (1787 -
1818 aa) residing within the pore-forming subunit of Cav1 channels are essential for CO 
modulation of cardiac Cav1 channels (Scragg et al., 2008; Peers, 2011). Supporting this, 
it was shown that both CO released from CORM2 and also dissolved CO changed L-type 
channel kinetics via inhibition of L-type currents seen in both recombinant and native 
Cav1 channels (Scragg et al., 2008). However, in disagreement to Scragg et al., another 
study demonstrated that administering low levels of exogenous CO to both intestinal 
smooth muscle cells that natively express these channels, and Cav1 stably transfected 
HEK293 cells caused an increase in L-type current amplitude (Lim et al., 2005). It was 
proposed that this increase in Ca2+ influx occurred through an increase in NO release 
(via NO synthase) and a subsequent increase in cGMP production through sGC and 
activation of PKA (Lim et al., 2005). In contrast, Scragg et al. (2008) revealed that CO-
mediated inhibition of Cav1 channels was through release of ROS from complex III of 
the electron transport chain, as the use of MnTMPγP, an antioxidant halted its inhibitory 
effect, revealing that CO works through a redox-dependent pathway. Differences in the 
effect of CO on Cav1 channels seen within studies, could be due to differences in the 
source and dose of CO used, the subunit composition of the Cav1 channels investigated 
and also CO exhibiting tissue specific effects.  It has long been known that T-type 
channels have a role in cell proliferation (Duckles et al., 2015). Duckles et al. (2014) 
revealed that CO (through HO-1) can have anti-proliferative effects in smooth muscle 
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cells by a mechanism involving a reduction in Cav3 current conductance. A reduction in 
Cav1 conductance was also seen, although was not correlated to proliferation (Duckles 
et al., 2015). Unlike other studies, Boycott and colleagues, revealed that CO modulation 
of Cav3 channels involves hindering Trx (thioredoxin)-mediated redox modulation of 
Cav3.2 channels, by interacting with it,  therefore inhibiting T-type currents (Boycott et 
al., 2013).  
 To summarise, it is well established that CO can influence cell function and also 
confer cytoprotection. CO modulation of ion channels depends on tissue specificity and 
the ion channel targeted. It is widely accepted that calcium dysregulation through 
impairment of VGCC function consists one of the pathways by which Ab confers 
neurotoxicity. As the manner by which CO modulates ion channels is not fully 
understood, it is therefore important to further investigate the effects of CO on VGCCs, 
























1.4. Aims and Objectives 
 
This project was divided into two sections. It is widely accepted that one mechanism by 
which Ab in AD confers cytotoxicity may be through calcium dysregulation (Zamponi, 
2015). Although studies have shown that one way by which Ab can cause calcium 
dysregulation is through changes in the expression and activity of VGCCs, studies report 
differences in the mechanism by which Ab modulates these channels. Therefore, as a 
first step in the study, the effect of Ab on our neuronal cell line model (SH-SY5Y cells) 
was investigated. Thus the aims were to: 
 
• Define VGCC expression profile within undifferentiated and RTA-differentiated 
SH-SY5Y cells 
• Identify which VGCC subtypes have a role in cell viability and activity 
• Establish a consistent protocol for Ab aggregation into protofibrils 
• Identify changes in VGCC expression and activity with Ab1-42 protofibril 
treatment 
 
CO as an endogenous signalling molecule has been shown to have a number of 
important roles in metabolism. For example, studies have demonstrated CO can act 
cytoprotectively by preventing cell death, displaying anti-inflammatory effects and 
prevent oxidative stress-dependent cell dysfunction (Vieira, Queiroga and Alves, 2008; 
Zeynalov and Doré, 2009; Hettiarachchi et al., 2014).  CO cytoprotection has been 
shown to occur through several mechanisms, including ion channel modulation, such as 
through redox modulation and nitrosylation (Lim et al., 2005; Scragg et al., 2008). Due 
to this, there is considerable interest in testing CO as a potential therapeutic for 
neurodegenerative diseases such as AD. Therefore, the second step of this study was to 
investigate the effect of CO on our neuronal cell line model and also on Cav2.2 stably 
transfected HEK293 cells in order to identify the mechanism by which CO modulates 
presynaptic Cav2.2 channels. Aims here were to: 
 
• Identify non-neurotoxic CO concentrations via the use of CORM2 
• Investigate the effect of CO in preventing protofibrillar Ab1-42-mediated 
neurotoxicity in SH-SY5Y cells 
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• Identify CO-mediated changes in N-type channel kinetics in Cav2.2-stably 
transfected HEK293 cells 
• Identify the mechanism by which CO changes VGCC channel kinetics 
 
This work aims to further our understanding of protofibril Ab1-42-mediated changes in 
VGCC expression and activity, as well as investigate the mechanism by which CO may 
interfere with the noted Ca2+ dysregulation.  This will aid our understanding of AD by 
identifying changes in Ca2+ homeostasis mediated by Ab. Moreover identifying how CO 
may modulate VGCCs may help in the development of better therapeutics that not only 
aim to provide symptomatic relief, but also target Ab-mediated cytotoxic mechanisms, 


























































2.1. Cell Culture 
 
2.1.1. Cell Lines 
 
SH-SY5Y human neuroblastoma cells 
 SH-SY5Y neuroblastoma cells (ECACC, UK) were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM)-GlutaMAX (Life Technologies, UK) with low glucose 
concentration (1g/L), containing 2mM L-glutamine (Life Technologies, UK) and 
supplemented with 10% fetal bovine serum (FBS; Life Technologies, UK) and 1% 
penicillin/streptomycin (Life Technologies, UK). 
Differentiation medium was DMEM-GlutaMAX supplemented with 10µM RTA 
(retinoic acid), to allow SH-SY5Y differentiation. Following cell passaging, cells were 
allowed to settle in T75 flasks overnight, and then the medium was replaced with RTA-
containing medium. Cells were left in differentiation medium for 3 days prior to 
experimental use. 
 
Cav2.2 ((a1B (Cav2.2), b1b, and a2d subunits))-stably transfected HEK293 cells 
Stably-transfected HEK293 expressing Cav2.2 calcium channels (a1B (Cav2.2), b1b, 
and a2d subunits) (McDavid and Currie, 2006), were cultured in Minimum Essential 
Medium (MEM; Life Technologies, UK) supplemented with 2mM L-glutamine (Life 
Technologies, UK) , 0.5mg/ml geneticin (G418; Sigma Aldrich, UK), 10% FBS (Life 
Technologies, UK) and 1% penicillin/streptomycin (Life Technologies, UK).  
 
BV2 mouse-microglia cells 
 Microglia BV2 cells (gift by Dr Eder, St. George’s University) were cultured in 
DMEM-GlutaMAX (Life Technologies, UK) with low glucose concentration (1g/L), 
containing 2mM L-glutamine (Life Technologies, UK), supplemented with 10% FBS (Life 







2.1.2. Cell Passaging and Plating 
 
All cell lines were incubated at 37oC with 5% CO2 (95% O2), and were passaged 
when reaching approximately 80% confluency. Once desired confluency had been 
reached, cells were then washed in phosphate-buffered saline (PBS; Life Technologies, 
UK) twice prior to passaging and plating. TrypLE-express (Life Technologies, UK) was 
used for detachment of cells. Following detachment, cells were resuspended in 
appropriate medium, and then centrifuged at 1500rpm for 5min at room temperature 
for cell collection. The medium was then discarded, and cells (pellet) were resuspended 
in fresh media for experimental use or cell passaging. For cell passaging, cells were 
resuspended in 5ml medium and placed in T75 flasks to allow growth at 1:5-1:25 dilution 
for SH-SY5Y and HEK293 cells, and 1:50-1:100 dilution for BV2 cells. For experimental 
use, cells were resuspended in 1ml medium for cell counting and then plating. 
All cell work was performed under sterile conditions. 
 
 
2.1.3. Cell Counting   
 
Cell count was quantified using Moxi Flow (Orflo, USA) or a standard 
haemocytometer. Desired number of cells were plated for each experiment. Cells were 
plated onto 96-well plates for cell viability experiments (25,000-50,000 cells/well) and 
6-well plates for quantitative polymerase chain reaction (qPCR) experiments (200-
400,000 cells/well). For electrophysiology experiments, cells were resuspended in 5ml 




For cryopreservation the cell passaging protocol was followed up to the cell 
collection step (centrifugation). Media was then removed, and cells (pellet) were 
resuspended in FBS-containing 10% dimethyl sulfoxide (DMSO; Thermo Fisher Scientific, 
UK) for cryopreservation (4.5ml per confluent T75 flask). Cells in freezing medium were 
then transferred into cryovials (1.5ml/cryovial) and placed in a -80oC freezer overnight, 
in a polyethylene foam container, to allow gradual freezing. Following this, the cryovials 
were transferred into liquid nitrogen tanks to allow long-term cryopreservation. 
For cell thawing, cryovials were placed in a water bath at 37oC to allow gradual 
thawing. Cells were then placed in T25 flasks, containing appropriate medium to allow 
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expansion. Over a few days, the medium was gradually replaced with fresh medium, to 
achieve complete removal of DMSO. Once desired confluency had been reached, cells 
were then transferred into T75 flasks and passaged. 
 
 
2.2. Calcium Channel Blocker Preparation 
 
For studying VGCC activity, various calcium channel blockers (CCBs) were used. 
Nifedipine (Cav1 blocker), w-agatoxin IVA (Cav2.1 blocker), w-conotoxin GVIA (Cav2.2 
and to a less extent Cav2.1 blocker) and mibefradil dihydrochloride (Cav3 blocker but 
also with actions at Cav1) were prepared as stocks, aliquoted out, and placed in -20oC 
for long-term storage. Whenever a blocker was needed, one aliquot would be thawed 
for experimental use. Cadmium chloride (CdCl2) was prepared fresh prior to each 
experiment. Final working concentrations were prepared in DMEM medium. A list of 
the various blockers, their supplier, stock concentration, working concentration and 
solvent used can be found in Table 2.2.1.  
 
Table 2.2.1: CCB preparation. List of the VGCC modulators used, their supplier, stock concentration and VGCC 
target(s). Cadmium chloride was prepared fresh prior to each experiment. All other CCBs were prepared, aliquoted 
out and stored at -20oC for long-term storage.  
Pharmacological 
Tools 
Supplier Stock/Solvent Working 
Concentration 
Target 
Cadmium Chloride Sigma Aldrich, UK 50mM in dH2O 100nM - 50µM Pan-VGCC blocker 
(Chow, 1991) 
Nifedipine Abcam, UK 100mM in DMSO 
 
5mM in medium 
5µM Cav1 
(Ortner and Striessnig, 
2016) 
w-Agatoxin IVA Abcam, UK 50µM in dH2O 50nM and 200nM Cav2.1 
(Bourinet et al., 1999) 
w-Conotoxin GVIA Abcam, UK 10µM in dH2O 10nM and 1µM Cav2.2 
(Lewis et al., 2000) 
Mibefradil 
Dihydrochloride 
Sigma Aldrich, UK 5mM in dH2O 5µM Cav3 & Cav1 
(Cribbs et al., 1998; 




2.3. CORM2/iCORM2 preparation 
 
 
To minimise loss of CO, CORM2 (Sigma Aldrich, UK) was prepared as 100µM-100mM 
stocks (in DMSO) immediately prior to experimental use. To achieve working 
concentration, an initial 1:1000 dilution of the stock was carried out in medium, 
followed by a serial dilution to achieve lower concentrations. For electrophysiology 
experiments, dilution of stock into working concentration was carried out in 
extracellular solution. For the inactive form (iCORM2), CORM2 was left at room 
temperature at least overnight, with the lid loosely attached to allow CO release. 
 
 
2.4. Redox agents 
Stocks of the oxidising agent dithiodipyridine (DTDP; Sigma Aldrich, UK) and 
reducing agent dithiothreitol (DTT; Sigma Aldrich, UK) were prepared fresh in DMSO, 
prior to each experiment. For electrophysiology experiments, in order to achieve 




2.5. Amyloid-b preparation 
 
2.5.1. NH4OH protocol 
 
Human synthetic Ab (Abcam: Ab1-42 #ab120301, Ab42-1 #ab120481) was dissolved in 
1% ammonium hydroxide (NH4OH; Sigma Aldrich, UK) (in PBS), to obtain 1mg peptide 
film. The percentage of purity of the peptide was taken into consideration when 
calculating the volume of NH4OH needed to be used. Following this, the Ab was left at 
room temperature for 30min and then placed in a speed-vac until the peptide film is 
obtained (~20min). Peptide film was then dissolved into the 5mM stock using 10mM 
sodium hydroxide (in dH2O) (NaOH; Sigma Aldrich, UK). Ab was then sonicated for 10min 
in order to prime the peptide for aggregation. Control Ab kept as ‘monomeric’ did not 
undergo any sonication.  Both the peptide film and the 5mM stock were stored at -20oC 
until use. 
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Prior to experimental use, the 5mM stock was sonicated for a further 10min and 
then further diluted into the 100µM usable stock over a 48hr incubation period. Firstly, 
the 5mM stock was diluted in PBS and 2% sodium dodecyl sulfate (SDS; Invitrogen, UK), 
and then incubated over 24hr. The volume of SDS was 10% of the 400µM Ab minus the 
5mM stock volume. Following this, the 400µM Ab was then diluted into the 100µM 
usable stock using PBS and incubated for another 24hr. 
In order to minimise chances of potential aggregation, monomeric (control) Ab was 
diluted from the 5mM stock directly to the 100µM usable stock prior to experimental 
use. 
For experimental purposes, in order to achieve various working concentrations 
(1nM - 10µM), the 100µM Ab1-42/Ab42-1 stock was further diluted in medium. 
 
 
2.6. Transmission Electron Microscopy 
 
Aggregation process of both Ab1-42 and Ab42-1 preparations was investigated using a 
transmission electron microscope (TEM; Jeol 2100 Plus, 200kV). Firstly, the Ab 
preparations (30µl) were loaded onto 300-mesh sized carbon grids (HC300Cu films, EM 
Resolutions, UK). Following this, the grids were then stained with 1-2% w/w uranyl 
acetate (Agar, UK) in dH2O for visualisation purposes (~1min). The grids were then 
washed with dH2O to remove excess stain (for ~1min) and then left to dry prior to use 
(~5min). Image analysis, via measuring protofibril length, was achieved using Image J. 
 
 
2.7. Cell viability assays 
 
For investigating metabolic activity, and specifically cell respiration, XTT or MTT cell 
viability assays were carried out. Here on onwards, for simplification purposes, 






2.7.1. XTT assay 
 
SH-SY5Y/BV2 cells were plated in sterile standard flat-bottom 96-well plates and 
left to adhere overnight. Cells were then treated with 1-100nM, or 1-10µM 
concentrations of Ab1-42/Ab42-1, CCBs (CdCl2, nifedipine, w-agatoxin IVA, w-conotoxin 
GVIA, and mibefradil dihydrochloride) or CORM2/iCORM2, their corresponding vehicle 
controls and 10mM hydrogen peroxide (H2O2; Thermo Fisher Scientific, UK). Working 
concentrations of the treatments were prepared using the cells corresponding medium.  
Following 24hr treatment of the cells, 1:10 XTT solution in DMEM serum-free 
medium was added to the cells, with a total well volume of 100µl. Cells were incubated 
with the XTT solution for 3-4hr. For the preparation of the final XTT solution 1:200 PMS 
(phenazine metholsulfate) was added to the XTT. The XTT solution consisted of 1mg/ml 
XTT (Molecular Probes, UK) dissolved in DMEM serum-free medium, and 5mM PMS 
(Sigma Aldrich, UK) dissolved in PBS. Plates were read at 450nm (650nm reference 
readings) using a standard colorimetric reader (Molecular Devices, SPECTRAmax 340 
PC). For analysis purposes, results were normalised and plotted as a percentage of their 
corresponding vehicle control. 
 
 
2.7.2. MTT assay 
 
SH-SY5Y cells were plated in sterile standard flat-bottom 96-well plates and left 
to adhere overnight. Cells were then treated with combinations of various 
concentrations of Ab1-42 and CCBs (CdCl2, nifedipine, w-agatoxin IVA, w-conotoxin GVIA, 
and mibefradil dihydrochloride) or CORM2/iCORM2, and their corresponding vehicle 
controls for 24hr. Additionally, 10mM H2O2 as a positive control was used. Working 
concentrations of the treatments were prepared using the cells corresponding medium. 
Following the treatment of cells, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Sigma Aldrich, UK) was prepared as a 5mg/ml stock in 
PBS. The MTT solution was loaded onto the cells at 1:10 dilution in their corresponding 
medium. Cells were incubated with the MTT solution for 3-4hr. Following incubation, 
once the formazan crystals are formed, the MTT solution was removed from the cells, 
and the formazan crystals are dissolved in 50µl DMSO, carefully to avoid the formation 
of bubbles. Plate were then pulse-span using a standard plate centrifuge. The plate was 
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then incubated for 5-10min and read at 575nm (650nm reference readings) using a 
standard colorimetric reader (Molecular Devices, SPECTRAmax 340 PC). For analysis 





2.8. Polymerase Chain Reaction 
 
2.8.1. RNA extraction 
 
SH-SY5Y cells were plated in standard flat-bottom 6-well plate and left to adhere 
overnight. Cells were then treated with 100nM and 1µM Ab1-42 and their corresponding 
vehicle control (PBS) for 24hr. Following this, the treatments were removed and 1ml 
Trizol (Thermo Fisher Scientific Scientific, UK) was added directly onto the cells for 5min 
for cell lysis and lysates were then transferred into Eppendorf tubes. RNA separation 
from protein and DNA was achieved via adding 200µl chloroform (Thermo Fisher 
Scientific, UK) into each tube. Samples were then mixed vigorously for 20s and 
centrifuged at 12,000G for 10min at 4oC. Following centrifugation, the RNA ‘layer’ was 
carefully removed from each tube and was then placed into new Eppendorf tubes. 
Isopropanol (Thermo Fisher Scientific, UK) 500µl was added in each tube, and tubes 
were then mixed and centrifuged at 17,000G for 14min at 4oC. The supernatant was 
then discarded, and 75% ice-cold ethanol was added into each tube. The tubes were 
mixed and then centrifuged at 17,000G for 5min at 4oC, supernatant was removed and 
the isolated RNA extracts (pellets) were then left to air dry for ~20min. RNA was then 
resuspended in 15µl nuclease-free water and heated at 60oC for 10min using a heat 
block. The Eppendorf tubes were then pulse-spun and kept on ice for total-RNA 
measurement.  
Total-RNA (ng/µl) was measured via loading 1.5µl per sample onto a Nanodrop 2000 
(Applied Biosystems/Thermo Fisher Scientific, UK). Nuclease-free water was used for 
Nanodrop blanking. Samples were read at 260nm (for DNA) and 280nm (for protein) 
with an ideal wavelength ratio of 1.8 to 2.1 for RNA.  
Results where then used to calculate the volume of total-RNA which is required to 
achieve a concentration of 1000ng/sample. The required amount was then transferred 
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into new Eppendorf tubes and was topped-up to total volume of 3.85µl (using nuclease-
free water) ready for complementary DNA (cDNA) synthesis. 
For long-term storage (up to a year), RNA extracts were kept at -20oC. 
 
 
2.8.2. cDNA synthesis 
 
Total RNA (1000ng/sample) was reverse-transcribed into cDNA using TaqMan® 
reverse transcription reagents (Applied Biosystems/Thermo Fisher Scientific, UK) in a 
T100 Thermal cycler (Biorad). In each 200µl PCR-tube a total of 6.15µl Master mix and 
1000ng total RNA in 3.85µl was added (Table 2.8.2.1). cDNA synthesis protocol steps 





Following reverse transcription, samples were diluted 1:5 in nuclease-free water 
for qPCR. For long-term storage (up to a year) both RNA and cDNA was kept at -20oC. 
cDNA synthesis steps involve; hexamer primer annealing for ensuring that the whole 
RNA template is ready for reverse transcription, reverse transcription (Reverse 
transcriptase, dNTPs, RT buffer) of RNA template into cDNA, and also enzyme 
deactivation step. 
 
Table 2.8.2.1: Master Mix for cDNA synthesis. 
 Volume µl (per sample) Final concentration  
10x Reverse transcription buffer 1 1x 
2.5mM dNTPs 2 0.5mM 
25mM MgCl2 2.2 5.5mM 
50 µM Random Hexamers 0.5 2.5µM 
20U/µl RNase Inhibitor 0.2 0.4U/µl 
50U/µl Reverse Transcriptase 0.25 1.25U/µl 
 TOTAL: 6.15µl  
RNA (1000ng) 3.85  
 TOTAL: 10µl  
 
 





Standard qPCR with Sybr Green (Sigma Aldrich, UK), using PCR compatible 96-
well plates (MicroAmp Fast Optical 96-well reaction plates, Applied Biosystems, UK) was 
carried out. PCR plates were run using StepOne Plus Real-Time PCR System (Applied 
Biosciences). List of primers and master mix used for running the PCR plates can be 
found in Table 2.8.3.1 and 2.8.3.2 respectively. A total of 2µl cDNA (or nuclease-free 
water as a negative control) and 8µl Master mix was added into each well for qPCR. PCR 






qPCR steps involve; a denaturation step where the double stranded DNA 
template strands separate, the annealing step where primers bind to the target DNA 
sequence, and the extension step where new DNA strands are made. This cycle is 
repeated 40 times for amplification. 
Relative gene expression was calculated using Ct values (cut-off point Ct 37) and 
data were normalised to the housekeeping gene β-actin. Changes in gene expression 
were presented as an mRNA fold-change in VGCC expression of vehicle control treated 
(PBS) compared to Ab1-42 treated cells. Nuclease-free water was used as the negative 
control (no template control). Reaction specificity (e.g. exclusion of presence of primer-
dimers) was done by looking at melting curves. 
 
Table 2.8.3.1: Primer design for VGCC mRNA expression analysis via qPCR. Previously described primers were used 
(Sousa et al., 2013). Amplicon size (nt = nucleotides) and primer melting temperature (Tm) are also shown in the table. 
Primer pairs for b-actin, Cav1.3, Cav1.4, Cav2.1, Cav2.2, Cav3.2, Cav3.3 are exon-exon spanning primers. 
 
Forward Primer  Reverse Primer 
B-actin 5’-CCAACCGCGAGAAGATGA-3’ 5’-CCAGAGGCGTACAGGGATAG-3’ 
(97nt) Tm: 65.2 o Tm: 63.5 o 
Cav1.1 5’-TCATCCTCAGTGAGATCGACA-3’ 5’-TCCACCCAGGCAATACAGTC-3’ 
(62nt) Tm: 63.6 o Tm: 64.9 o 
Cav1.2 5’-CGTGGCTGCTCCTCCTATTA-3’ 5’-GGCTCCCATAGTTGGAACCT-3’ 
(103nt) Tm: 64.1 o Tm: 64.1 o 
Initial denaturation Denaturation Annealing Extension 
Final Extension 
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Cav1.3 5’-GGCTGGACAGATGTGCTCTAC-3’ 5’-CCCAAAGATGACGAGACTGAC-3’ 
(87nt) Tm: 63.8 o Tm: 63.7 o 
Cav1.4 5’-AACACACCCCTCAAGAATGC-3’ 5’-GCCGTGACACGTCTCCAT-3’ 
(63nt) Tm: 63.9 o Tm: 65.2 o 
Cav2.1 5’-TGGAACATCTTCGACTTTGTGA-3’ 5’-GCTCAGGTTGATGAAGTTATTCG-3’ 
(93nt) Tm: 64.5 o Tm: 63.6 o 
Cav2.2 5’-AACAGAGATTGCGGAAACGA-3’ 5’-GATGCGGATGGTGTAGCC-3’ 
(106nt) Tm: 64.6 o Tm: 64.3 o 
Cav3.1 5’-GGTGTGGTGGTGGAGAACTT-3’ 5’-CATCGTCCAGCATTAGATTCC-3’ 
(124nt) Tm: 63.9 o Tm: 63.3 o 
Cav3.2 5’-CGCTGCTCATGCTCTTCAT-3’ 5’-AACTTGCAGCCGAAAAGGT-3’ 
(64nt) Tm: 64.4 o Tm: 63.7 o 
Cav3.3 5’-CAATGGACTGGATGCTGTTG-3’ 5’-ATCCAGGGGTTGTGGTTG-3’ 
(60nt) Tm: 64.2 o Tm: 63.4 o 
 
Table 2.8.3.2: Master Mix for qPCR. 
 
Volume µl (per well)  Final Concentration  
FastStart Universal Sybr Green 
Master (ROX) 2x 
5 1x 
10µM Forward Primer 0.5 0.5µM 
10µM Reverse Primer 0.5 0.5µM 






 TOTAL: 10µL  
 
 
2.8.4. PCR gel 
 
qPCR products were subjected to gel electrophoresis in order to identify 
whether the various VGCCs are expressed within undifferentiated and differentiated 
SH-SY5Y cells.  
Firstly a 1.5% agarose gel was prepared, consisting of 0.9g agarose (Invitrogen/ 
Thermo Fisher Scientific, UK) and 60ml 1x Tris-acetate-EDTA (TAE; Promega). The 
agarose mix was subjected to heat (1-3min) to allow complete dissolution and allowed 
to cool down to 50oC. Sybr ‘Safe’ 6µl (Invitrogen/ Thermo Fisher Scientific, UK) was then 
added to the agarose mix, and the agarose was then poured into an agarose gel casting 
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tray and left to solidify. Samples were run on agarose gels of 7x7cm in size (Mini-Sub 
Cell GT, BIO-RAD, UK) with space for 15 samples. 
For sample preparation, qPCR products (10µl) were mixed with 2µl DNA loading 
buffer dye (6x; Thermo Fisher Scientific, UK). Additionally, a ladder (ACTGene 100bp PCR 
DNA ladder; Thermo Fisher Scientific, UK) sample was also prepared, consisting of 2µl 
DNA ladder, 2µl DNA loading buffer and 8µl nuclease-free water. Once the gel was 
submerged in 1x TAE, the samples were loaded into the wells. The gels were ran at 70V 
for approximately 40min, to allow samples to run down ¾ of the gel. Following gel 
electrophoresis, images of the PCR bands were taken using a gel doc (Syngene U:Genius-






2.9.1. Cell preparation 
 
For electrophysiology, both SH-SY5Y cells and stably-transfected HEK293 cells 
were plated on uncoated sterile coverslips (22x22mm) at 1:40, 1:80 or 1:100 dilutions 
using their corresponding medium. Cells were left to adhere overnight at 37oC and 5% 
CO2 in a sterile 6-well plate.  
 
2.9.2. Preparation of glass electrodes 
 
Glass electrodes (O.D. 1.5mm, I.D. 0.86mm, 10cm length borosilicate glass 
capillaries; Intracel) were fabricated using an Intracel P-1000 micropipette puller. 
Electrodes used for whole cell patch clamp experiments had a resistance range between 
4 and 10 MW. Resistance was monitored throughout the duration of the experiment. 
Glass electrodes were filled with intracellular solution composed of: 120mM CsCl;  
20mM TEA; 10mM EGTA; 2mM MgCl2; 10mM HEPES; 2mM ATP (pH 7.2 using CsOH) 
using a MF34G micro-loader tip (World Precision Instruments), attached to a 0.2µm 
filter and a non-metallic syringe needle. Glass electrodes were tapped for removal of 
any bubbles prior to use. 
Fresh intracellular solution was prepared approximately each month, and 
osmolarity ( ~270 mOsm) was monitored using a standard osmometer (OSMOMAT 030, 
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Gonotec). The intracellular solution was aliquoted (5ml/vial) and kept at -20oC until use. 
Whenever needed, an aliquot was thawed and used for a max of 5 days (short-term 
storage 4oC).  
 
2.9.3. Earth electrode 
 
The earth electrode consisted of a silver chloride wire which was routinely 




2.9.4. Whole-cell patch clamp 
 
Prior to the start of whole-cell patch clamp experiments, coverslips were 
transferred to a bath containing extracellular solution composed of: 95mM NaCl 
(ThermoFischer Scientific, UK); 10mM BaCl2; 2mM MgCl2; 10mM HEPES; 10mM glucose; 
5mM TEA (pH 7.4 using NaOH). All chemicals for electrophysiology solutions were 
purchased from Sigma Aldrich (UK), unless otherwise stated. Barium (Ba2+) was used as 
the ‘drive force’ to study VGCCs as it is known to keep cells stable and prevent channel 
inactivation, therefore, allowing the study of the currents for a longer period of time. 
Fresh extracellular solution was prepared approximately every month, and 
osmolarity (~270 mOsm) was measured using an osmometer. The extracellular solution 
was kept at 4oC for short-term storage. Both intracellular and extracellular solutions 
were left to reach room temperature (21oC) prior to experimental use. 
Once the coverslip was placed in the extracellular solution, the glass electrode 
was slowly lowered into the extracellular bath (Fig. 2.9.4.1A).  Prior to this, positive 
pressure was applied to the glass electrode using a 5ml syringe. The pressure was held 
via closing the syringe valve. Using the microscope, the glass electrode was then 
lowered and focused above the cell. Continuous monitoring of pipette offset was carried 
out, in order to make sure all recordings start at baseline 0pA. Following this, the glass 
electrode was then slowly lowered onto the cell (Fig. 2.9.4.1B). To help achieve a giga-
seal (>1GW), negative pressure was applied using the syringe, which was released to aid 
seal formation. Once a giga-seal was formed, resting potential was changed to -70mV 
(Fig. 2.9.4.1C). In order to achieve whole-cell configuration, small negative pressure was 
then applied via the syringe, to ‘break the membrane’ (Fig. 2.9.4.1D). Cell stability was 
monitored throughout the experiment.  
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2.9.5. Whole-cell patch clamp protocols 
 
To study VGCC currents, a multi-step protocol was applied, from a holding 
potential of -70mV, in 10mV increments from -70 to +50mV (200ms). Data from multi-
step recordings were used to plot the current/voltage (I/V) relationship. Additionally, a 
single-step protocol, to +10mV from a holding potential of -70mV, was also applied. 
Recordings of cells demonstrating a poor quality seal or high current leakage were not 
included in data analysis. Extracellular solution was applied via a continuous tube-
perfusion system. Working concentration of the various compounds, was achieved 
using extracellular solution and perfused. 
All electrophysiology experiments were carried out at room temperature 
(~21oC). Whole cell patch clamp recordings were acquired using Axopatch 200B (Axon 
Instruments), using the software Clampex10.3 via a Digidata 1440A (Axon Instruments). 







































































































2.10. Statistical Analysis 
 
Statistical analysis and plotting of graphs was performed using GraphPad Prism 
7.0.  For statistical analysis all data were firstly tested for normality (Shapiro-Wilk) and 
examined for outliers (Grubb’s). Data are plotted as average ± SEM with number of 
biological replicates (n) stated in Figure legends. At least 3 technical replicates per 
treatment were performed. Values of P£0.05 were considered significant.   
For both Ab protofibril length analysis and cell viability experiments, One-way 
ANOVA followed by Tukey post-hoc test was used for multiple comparison of data 
demonstrating normal distribution. For data not following normal distribution unpaired 
T-test followed by Kolmogorov-Smirnov was used.  
For qPCR data comparison of only two treatment groups unpaired Welch T-test 
was performed.   
 For electrophysiology experiments, I/V relationships were first fitted with a 
modified Boltzmann fit equation (Y=(Gmax*(X-Vrev))/(1+exp((X-V50)/k)) (Vogl et al., 
2015). Data obtained from the Boltzmann fit analysis were then subjected to one-tailed 
unpaired Welch T-test for the population studies (Ab experiments) and one-tailed 










Chapter 3: Voltage-gated calcium channel 













SH-SY5Y human neuroblastoma cells, subcloned from SK-N-SH first isolated from a 
bone-marrow biopsy in 1970,  demonstrate characteristics of an immature neuronal 
phenotype and can easily be differentiated into terminally differentiated cells (Biedler 
and Schachner, 1978; Morton et al., 1992; Kovalevich and Langford, 2013; Sousa et al., 
2013; de Medeiros et al., 2019). This allows the study of a more representative mature 
neuronal phenotype, therefore providing an excellent in vitro model for use within the 
neuroscience field and studying neurodegenerative diseases such as AD (Morton et al., 
1992; Kovalevich and Langford, 2013; de Medeiros et al., 2019). SH-SY5Y cells can easily 
be manipulated, expanded, and can be differentiated into specific neurons (Kovalevich 
and Langford, 2013). Treating cells with 10µM retinoic acid (RTA) for ~3 days is widely 
used for inducing SH-SY5Y differentiation towards a phenotype more closely 
representing primary cholinergic neurons. Differentiation consists of changes in cell 
activity including reduced proliferation and neurochemical phenotype changes such as 
neurite creation, expression of both neuronal and cholinergic-specific markers (e.g. 
tyrosine hydroxylase, NeuN, AChE and ChAT) (Lopes et al., 2010; Kovalevich and 
Langford, 2013; de Medeiros et al., 2019). Additionally, as SH-SY5Y cells are not primary 
cells, no ethical considerations are linked with their use (de Medeiros et al., 2019).   
Both electrophysiological and molecular approaches have shown that SH-SY5Y 
neuroblastoma cells express VGCCs and therefore are considered a good model for 
investigating Ca2+ homeostasis (Spoerri, Dozier and Roisen, 1990; Morton et al., 1992; 
Chiou, 2006; Sousa et al., 2013). VGCCs are known to have a role in cell viability, cell 
proliferation and differentiation, gene expression, and neurotransmission (Chin, 1998; 
Sinnegger-Brauns et al., 2009; Resende et al., 2010). Due to the involvement of both 
Ca2+ and VGCCs in AD amyloid pathology, as a first step in this study, the expression and 
the role of the individual VGCCs in neuronal differentiation and survival was 
investigated. Better understanding of VGCCs involvement in neuronal survival and 
differentiation can aid our understanding of their role in neurodegenerative diseases 






The aim of the study was to firstly verify and identify VGCC subtype expression 
in the neuronal model SH-SY5Y cells, and also identify their role in overall neuronal cell 
function. Moreover, the effect of physiological CO levels on maintaining neuronal 




• To identify which VGCC subtypes are expressed at mRNA level in SH-SY5Y cells 
in contrasting differentiation states. 
• To investigate which VGCC subtypes have a role in neuronal activity using SH-
SY5Y cells in contrasting differentiation states. 
• To investigate VGCC expression at the functional level in undifferentiated SH-
SY5Y cells. 
• To examine the effect of physiological CO levels in neuronal activity using SH-
SY5Y cells in contrasting differentiation states. 
• To investigate the effect of CO in modulating CCB-mediated changes in neuronal 




• Inhibiting VGCCs using either the global-VGCC blocker CdCl2 or more selective 
blockers (CCBs) should impair neuronal cell (metabolic) activity. 
• CO, through CORM2 treatment, at physiological levels should not impair cell 











3.2.1. VGCC expression profile and activity in neuroblastoma cells 
 
For the purpose of this study, SH-SY5Y neuroblastoma cells of both 
undifferentiated and RTA-differentiated state were used. Verification of SH-SY5Y 
differentiation was done via monitoring morphological changes. Morphological 
observations in this study reveal that undifferentiated cells grow in clusters and show 
neuroblast-like phenotype, whereas RTA-differentiated cells form processes and 
therefore appear more elongated, with an accompanied reduction in cell proliferation 
(Fig. 3.2.1.1).  
In order to verify that SH-SY5Y indeed express VGCCs, gene expression analysis 
via PCR was carried out in order to identify which VGCCs were present at mRNA level in 
both undifferentiated and differentiated SH-SY5Y cells. Representative PCR gels (using 
end-point qPCR products) revealed mRNA expression of Cav1.2, Cav1.3, Cav2.2 and 
Cav3.1 within undifferentiated cells (Fig. 3.2.1.2A). On the other hand, in differentiated 
cells a loss in Cav3.1 expression was seen. Moreover, low mRNA expression for Cav1.4 
was also detected (Fig. 3.2.1.2B). Quantification analysis of the qPCR data revealed no 
significant fold-change in mRNA expression of Cav1.2, Cav1.3 and Cav2.2 upon SH-SY5Y 
differentiation (n=7) (Fig. 3.2.1.3A-C). Whereas, a significant reduction in Cav3.1 mRNA 
expression of 0.7 ± 0.1 fold-change was seen upon SH-SY5Y differentiation (n=7; 
P<0.0001) (Fig. 3.2.1.3D). 
Undifferentiated SH-SY5Y cells (n=6) were also confirmed to express inward 















































Figure 3.2.1.1: Undifferentiated and RTA-differentiated SH-SY5Y cells. Representative images of SH-SY5Y cells prior 














































Figure 3.2.1.2: Neuroblastoma VGCC gene expression. Representative images of gels from end-point qPCR products 
indicating VGCC mRNA expression in neuroblastoma cells of both differentiation states. (A) Within undifferentiated 
SH-SY5Y cells Cav1.2, Cav1.3, Cav2.2 and Cav3.1 expression was detected at mRNA level. (B) Within differentiated 
cells Cav1.2, Cav1.3, Cav1.4, Cav2.2 and a loss of Cav3.1 mRNA expression was observed. For gene expression 






























Figure 3.2.1.3: Changes in VGCC expression dependent on neuroblastoma differentiation state. Changed in VGCC 
mRNA expression with SH-SY5Y differentiation were investigated via qPCR. No change in the mRNA expression of 
(A) Cav1.2 (n=7), (B) Cav1.3 (n=7) and (C) Cav2.2 (n=7) was seen with SH-SY5Y differentiation. (D) In contrast, a 
significant reduction in Cav3.1 (n=7) mRNA expression was seen with SH-SY5Y differentiation. Data (mean ±SEM) 











































Figure 3.2.1.4: Inward currents in neuroblastoma cells. Inward currents recorded within undifferentiated SH-SY5Y 
cells via whole-cell patch clamp. (A) Example trace of a mixture of inward currents recorded within an untreated SH-
SY5Y cell (-70 to +50mV at 10mV intervals) (B) Current-voltage relationship of inward currents recorded within 
undifferentiated SH-SY5Y cells fitted with the Boltzmann fit equation (n=6). Clampfit 10.3 was used for trace analysis, 
and GraphPad for plotting current-voltage relationship and Boltzmann fit analysis. 
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3.2.2. VGCC role in overall cell activity 
 
Ca2+ is important in maintaining cell homeostasis, with a number of cellular roles. 
As a first step in studying calcium homeostasis, the role of VGCCs in cell (metabolic) 
activity of SH-SY5Y cells of both differentiation states was investigated via XTT and MTT 
viability assays. 
A significant reduction in cell activity by 51.6 ± 8.7% (n=7; P<0.05), 65.0 ± 8.6% 
(n=5; P<0.01) and 66.2 ± 9.0% (n=5; P<0.01) was seen in undifferentiated SH-SY5Y 
treated with the global VGCC blocker CdCl2 at 50, 100 and 200µM with the (IC50= 
27.7µM) compared to vehicle control treated cells. Within differentiated SH-SY5Y cells, 
a reduction in activity was seen by 26.4 ± 11.8% (n=5; P<0.05), 70.0 ± 13.5% (n=5; 
P<0.001) and 70.9 ± 13.5% (n=5; P<0.001) was seen with CdCl2 at 50, 100 and 200µM 
(IC50= 45.6µM) respectively compared to vehicle control treated cells. Interestingly, 
lower concentrations of CdCl2 caused a significant increase in RTA-differentiated SH-
SY5Y cell activity. A significant increase by 48.3 ± 13.5 (n=5; P<0.05), 58.6 ± 14.3% (n=4; 
P<0.01) and 46.5 ± 13.5 % (n=5; P<0.05) was seen with CdCl2 at 100nM, 1 and 10µM 
respectively. Further comparison of changes in cell activity seen by CdCl2 reveal no 
significant differences between undifferentiated (HillSlope: 2.0 ± 0.9) compared to 
differentiated (HillSlope: 5.9 ± 18.4) cells (Fig. 3.2.2.1).  
In order to identify which VGCC subtypes have a role in cell activity, more specific 
VGCC blockers (CCBs) were used. Within undifferentiated cells a significant reduction in 
activity was seen with 1µM w-conotoxin-GVIA (26.5 ± 8.0%; n=3; P<0.05) and 5µM 
mibefradil dihydrochloride (74.5 ± 6.8%; n=5; P<0.0001), blockers of Cav2 and Cav3 
channels respectively. No change in activity of undifferentiated SH-SY5Y cells was seen 
with 5µM nifedipine (15.5 ± 6.8%; n=5), 10nM w-conotoxin-GVIA (15.2 ± 6.8%; n=5), 50 
or 200nM w-agatoxin-IVA (21.0 ± 6.8%; n=5 and 15.1 ± 8.0%; n=3) (Fig. 3.2.2.2A). Within 
differentiated cells, a significant reduction in activity was only observed with 1µM w-
conotoxin-GVIA, of 27.5 ± 5.6% (n=5; P<0.001). In contrast to undifferentiated cells, 
treatment with 5µM mibefradil dihydrochloride did not cause any change in activity of 
differentiated cells (13.0 ± 5.6%; n=5). No change in activity was seen in differentiated 
cells with 5µM nifedipine (1.3 ± 5.6%; n=5), 10nM w-conotoxin-GVIA (4.1 ± 5.6%; n=5), 
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and 50 or 200nM w-agatoxin-IVA (3.6 ± 5.6%; n=5 and 5.8 ± 5.6; n=5) treatment 


















































Figure 3.2.2.1: CdCl2 mediated cytotoxicity in neuroblastoma cells. The effect of CdCl2 was investigated in both 
undifferentiated and RTA-differentiated SH-SY5Y cells via XTT assay. A significant reduction in undifferentiated SH-SY5Y 
activity was seen with 50, 100 and 200μM (24hr; n=5-7). Within differentiated cells, a similar effect was seen with the 
same concentrations, whereas 100nM, 1 and 10 μM significantly increased cell activity (24hr; n=5). HillSlope analysis of 
dose-response curves for undifferentiated and differentiated SH-SY5Y cells treated with CdCl2 revealed no significant 
difference. Data (mean ±SEM) were normalised to the corresponding vehicle control (dH2O). Statistical analysis for 
undifferentiated cells was carried out via Kruskal-Wallis and post-hoc Dunn’s test. Statistical analysis for differentiated 











































Figure 3.2.2.2: Calcium channel blocker (CCB) mediated cytotoxicity in neuroblastoma cells. The effect of selective-
VGCC blockers was investigated in both undifferentiated and differentiated SH-SY5Y cells via XTT and MTT assay 
respectively (24hr). (A) A significant reduction in undifferentiated SH-SY5Y viability was observed with 
1µM w-conotoxin-GVIA (n=3) and 5µM mibefradil dihydrochloride (n=5). (B) Within differentiated cells, only 
1µM w-conotoxin-GVIA (n=5) significantly reduced viability. Data (mean ±SEM) were normalised to the corresponding 
vehicle control (DMSO/dH2O).  Statistical analysis was carried out via One-way ANOVA and post-hoc Tukey test. 
(*=P<0.05, ***=P<0.001, ****=P<0.0001)   
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3.2.3. Effect of CO on neuronal cell activity 
 
CORM2, a carbon-monoxide releasing molecule was used to study the effects of 
CO in SH-SY5Y neuroblastoma cell (metabolic) activity (via MTT) of cells of both 
differentiation states.  
In both undifferentiated and differentiated SH-SY5Y cells, 1-100µM CORM2 
(n=5) did not significantly alter cell activity (Fig. 3.2.3.1A and B). The positive control 
10mM H2O2 caused a 97.5 ± 5.6% (n=5; P<0.0001) reduction in undifferentiated SH-SY5Y 
activity. A similar degree in reduction in activity (97.5 ± 3.9%; n=5; P<0.0001) was also 
seen when differentiated cells were treated with 10mM H2O2. 
Similar to CORM2, no change in activity was also observed when the inactive 
control (1-100µM iCORM2; n=5) was added to SH-SY5Y of both differentiation states 
(Fig. 3.2.3.1C and D). Whereas the 10mM H2O2 caused a 97.5 ± 4.2% and 97.4 ± 5.8% 
(both n=5; P<0.0001) reduction in activity in undifferentiated and differentiated SH-


























































Figure 3.2.3.1: Carbon monoxide (CO) effect on neuroblastoma cells. The effect of CO, through CORM2, was 
investigated in neuroblastoma cells of both differentiation states, via MTT assay. (A+B) No significant change in SH-
SY5Y activity of both differentiation states was observed with 1- 100µM CORM2 (24hr; n=5). (C+D) No significant 
change in SH-SY5Y viability of both differentiation states was observed with 1- 100µM inactive control (iCORM2) 
(24hr; n=5). Hydrogen peroxide (10mM) was used as a positive control in cell activity  experiments. Data (mean ±SEM) 
were normalised to the corresponding vehicle control (DMSO).  Statistical analysis was carried out via One-way 
ANOVA and post-hoc Tukey test. (****=P<0.0001)   
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3.2.4. Effect of CO on CCB-mediated changes in cell activity 
 
Following the identification of a distinct VGCC mRNA profile in SH-SY5Y cells 
dependent on differentiation state, and verifying that CORM2 at the concentrations 
tested does not alter SH-SY5Y activity, the effect of CO on CCB-mediated changes in cell 
(metabolic) activity was investigated via MTT assay. 
Within undifferentiated and differentiated cells CORM2 (1-100µM; n=5) was 
unable to prevent changes in cell activity induced by the pan-VGCC blocker CdCl2 . CdCl2 
alone caused a 81.7 ± 3.3% (n=10; P<0.0001) reduction in undifferentiated SH-SY5Y 
activity, whereas CdCl2 in combination with 1µM, 10µM and 100µM caused a 79.0 ± 
4.2% (n=4), 81.7 ± 4.2% (n=4) and 90.0 ± 3.9% (n=5) reduction, which was not 
significantly different than CdCl2 treated cells alone. No significant changes in CdCl2-
mediated changes in activity were also seen when undifferentiated cells were treated 
with CdCl2 in combination with 10µM and 100µM iCORM2 (78.3 ± 4.2%; n=4 and 89.5 ± 
3.9%; n=5), compared to CdCl2 alone (Fig. 3.2.4.1A). Within differentiated cells, CdCl2 
alone caused a 52.9 ± 7.7%  (n=5; P<0.0001) reduction, whereas CdCl2 in combination 
with 1µM, 10µM and 100µM iCORM2 caused a  59.3 ± 7.7% (n=5),  55.0 ± 7.7% (n=5) 
and  71.2 ± 7.7% (n=5) in cell activity in differentiated SH-SY5Y cell activity respectively. 
No significant change in CdCl2-mediated changes in activity were seen when 
differentiated cells were treated with CdCl2 in combination with 1µM (49.3 ± 7.7%; n=5), 
10µM (52.6 ± 7.7%; n=5) and 100µM iCORM2 (53.3 ± 7.7%; n=5) compared to CdCl2 
alone (Fig. 3.2.4.1B). Additionally, a significant reduction by 97.7 ± 3.3% (n=10; 
P<0.0001) in undifferentiated and by 97.4 ± 7.7% (n=5; P<0.0001) in differentiated cell 
viability were seen with the positive control 10mM H2O2.  
Similar to CdCl2, 1 and 10µM CORM2 were also unable to prevent changes in cell 
activity induced by CCBs (n=4) in both undifferentiated (Fig. 3.2.4.2A-D) and 
differentiated SH-SY5Y cells (Fig. 3.2.4.3A-C). Additionally, 10mM H2O2 caused a 
significant reduction in cell activity by 95.7 ± 11.5% (n=4; P<0.0001) in undifferentiated 












































Figure 3.2.4.1: CO effect in modulating CdCl2 mediated neurotoxicity. The effect of CO, via CORM2, was 
investigated on CdCl2 mediated changes in cell activity, via MTT assay. Both (1-100µM) CORM2, and its inactive 
form (10 and 100µM) were unable to prevent reduction in activity, mediated by 50µM CdCl2 in both (A) 
undifferentiated (n=5-10) and (B) differentiated SH-SY5Y cells  (24hr; n=5). A significant reduction in activity was 
observed with the positive control 10mM H2O2. Data (mean ±SEM) were normalised to the corresponding vehicle 
control (DMSO + dH2O).  Statistical analysis was carried out via One-way ANOVA and post-hoc Tukey test. 











































Figure 3.2.4.2: CO effect in modulating CCB mediated neurotoxicity in undifferentiated SH-SY5Y cells. The effect of 
CO, via CORM2 was investigated on CCB mediated changes in cell activity, via MTT assay. Both (1 and 10µM) CORM2, 
and its inactive form (10 µM) were unable to prevent changes in cell activity mediated by (A) 200nM w-agatoxin-IVA 
(B) 10nM w-conotoxin-GVIA (C) 1µM w-conotoxin-GVIA, and (D) 5µM mibefradil dihydrochloride (24hr; n=4). A 
significant reduction in activity was observed with the positive control 10mM H2O2. Data (mean ±SEM) were 
normalised to the corresponding vehicle control (DMSO + dH2O).  Statistical analysis was carried out via One-way 











































Figure 3.2.4.3: CO effect in modulating CCB mediated neurotoxicity in differentiated SH-SY5Y cells. The effect of 
CO, via CORM2 was investigated on CCB mediated changes in cell activity, via MTT assay. Both (1 and 10µM) 
CORM2, and its inactive form (10 µM) were unable to prevent changes in cell activity mediated by (A) 200nM w-
agatoxin-IVA (B) 10nM w-conotoxin-GVIA (C) 1µM w-conotoxin-GVIA (24hr; n=4). A significant reduction in activity 
was observed with the positive control 10mM H2O2. Data (mean ±SEM) were normalised to the corresponding 
vehicle control (DMSO + dH2O).  Statistical analysis was carried out via One-way ANOVA and post-hoc Tukey test. 





VGCC expression in neuroblastoma cells 
 
• Morphological observations verify retinoic acid-dependent SH-SY5Y differentiation. 
• VGCC gene expression profile in SH-SY5Y cells of both differentiation states reveals loss of Cav3.1 
expression with cell differentiation, resembling VGCC expression in neurons with roles in neuronal 
development and differentiation. 
 
For the purposes of this study, SH-SY5Y neuroblastoma cells in both 
undifferentiated and RTA-differentiated state were used as in vitro neuronal models for 
studying neurodegeneration. As a first step, SH-SY5Y RTA-differentiation was verified 
via monitoring morphological changes. Morphological observations in this study reveal 
that undifferentiated SH-SY5Y cells grow in clusters and show neuroblast-like 
phenotype. By contrast, RTA-differentiated cells form processes and therefore appear 
more elongated, with an accompanied reduction in cell proliferation. In support of this, 
previous research where RTA was added to SH-SY5Y cells as a methodology to induce 
cell differentiation, revealed similar morphological changes (Lopes et al., 2010; de 
Medeiros et al., 2019). These findings support the use of SH-SY5Y as an immature 
neuronal cell line model that can be differentiated into neuronal-like cells more closely 
resembling primary neurons for studying AD. 
Similar to primary neurons, SH-SY5Y cells are known to express an array of VGCC 
subtypes, with evidence indicating that VGCC-dependent Ca2+ influx is important in 
regulating neuronal survival, development and differentiation (Spoerri, Dozier and 
Roisen, 1990; Morton et al., 1992; Reeve, Vaughan and Peers, 1994; Pravettoni et al., 
2000; Chiou, 2006; Resende et al., 2010; Sousa et al., 2013; Aguado et al., 2016). In the 
current study, expression of Cav1.2, Cav1.3, Cav1.4 (very low), Cav2.2 and Cav3.1 at 
gene level was noted in undifferentiated cells. Whereas RTA differentiation led to a 
significant reduction or even in some instances, complete loss of Cav3.1 expression. Lack 
of expression of Cav1.1, Cav2.1, Cav3.2 and Cav3.3 within SH-SY5Y of both 
differentiation states could indicate either complete lack of expression or primer failure. 
In support of a role for VGCCs in neuronal development and differentiation, Spoerri and 
colleagues revealed that VGCC-dependent Ca2+ influx is needed for mouse 
neuroblastoma Neuro-2A cell neuritogenesis, assessed via cell imaging and use of 
pharmacological tools (Spoerri, Dozier and Roisen, 1990). Agreeing with findings in this 
study, differential VGCC expression profile is observed dependent on the stage of cell 
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development and differentiation (Spoerri, Dozier and Roisen, 1990; Morton et al., 1992; 
Reuveny and Narahashi, 1993; Reeve, Vaughan and Peers, 1994; Pravettoni et al., 2000; 
Bertolesi et al., 2003; Sousa et al., 2013).  
In this study, gene expression analysis revealed Cav1 VGCC a1 subunit mRNA 
expression for only Cav1.2 and Cav1.3 in both undifferentiated and differentiated SH-
SY5Y cells, indicative of either very low or no expression for Cav1.1 and Cav1.4. Whole-
cell patch clamp recordings reveal a mixture of inward currents, which once plotted with 
the Boltzmann fit analysis, I/V relationship resembles HVA currents, with similar 
biophysical properties (activation voltage (V) and Vmax) to Cav1 channels recorded as 
those noted by Reeve and colleagues in undifferentiated SH-SY5Y cells (Reeve, Vaughan 
and Peers, 1994). It is known that in contrast to their Cav2 and Cav3 counterparts, Cav1 
channels are not as widely expressed within the CNS (Chin, 1998; Resende et al., 2010; 
Aguado et al., 2016). Despite this, Cav1 channels play a key role in neuronal 
proliferation, development and subsequent differentiation (Chin, 1998; Resende et al., 
2010; Aguado et al., 2016). In support to findings in the current study, as Cav1.1 is 
predominantly expressed in skeletal muscle (Striessnig et al., 2014), it is expected that 
very low or no expression at all for Cav1.1 will be seen in neuronal cell lines such as SH-
SY5Y cells.  Evidence has shown that Cav1 channels not only have a role at early stages 
of neuronal development such as neurite outgrowth and synapse formation, but also in 
gene transcription (eg CREB-dependent transcription) and subsequent regulation of 
synaptic plasticity and strengthening of differentiated neurons (Spoerri, Dozier and 
Roisen, 1990; Pravettoni et al., 2000; Bertolesi et al., 2003; Zhang et al., 2006; Striessnig 
et al., 2014). In support of this, when murine CSC (embryonal carcinoma) and MSC 
(mesenchymal) stem cells were induced to undergo neuronal differentiation, BayK8644 
Cav1 agonist increased cell proliferation and neuronal differentiation as assessed via 
monitoring nestin levels, a marker of neuronal development and differentiation 
(Resende et al., 2010). In contrast, Cav1 blockers  such as nifedipine reduced cell 
proliferation and neuronal differentiation (Resende et al., 2010). Therefore, in this study 
expression of Cav1 channels within undifferentiated cells may suggest a role for Cav1 in 
cell proliferation and development. In further support of findings in this study where 
expression of Cav1.2 and Cav1.3 is detected within undifferentiated neuroblastoma 
cells, in 1992, Barnes and Haynes confirmed the expression of Cav1 channels at the 
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functional level within undifferentiated Y79 retinoblastoma cells, which are capable of 
undergoing neuronal differentiation (Barnes and Haynes, 1992). This suggests a role for 
Cav1 channels at early stage of neuronal development. More recently, a rodent whole 
brain genome analysis study revealed very low mRNA expression for Cav1.1 and Cav1.4 
in comparison to Cav1.2 and Cav1.3 in the CNS (Sinnegger-Brauns et al., 2009). Cav1.2 
and Cav1.3 are expressed throughout the hippocampus, and are also detected in the 
cerebral cortex and cerebellum, with Cav1.2 being the most expressed L-type channel 
in the CNS (Hell et al., 1993). A 2014 review conducted by Striessnig et al., revealed that  
the majority of L-type channels expressed in the brain are Cav1.2, with approximately 
10% due to Cav1.3 and that site of expression is predominantly postsynaptic (Striessnig 
et al., 2014). Moreover, recently, alternative splicing of  the VGCC a1 subunit has been 
identified as a factor that can add heterogeneity in VGCC subtype expression in the CNS 
(Bock et al., 2011). These observations support this study where expression of only 
Cav1.2 and Cav1.3 was detected in SH-SY5Y cells of both differentiation states, 
confirming SH-SY5Y cells as an appropriate ‘neuronal’ cell model closely resembling 
VGCC expression seen in primary neurons, and therefore an excellent in vitro model for 
studying neurodegeneration. Sousa et al. (2013) revealed that from the Cav1 subfamily, 
only Cav1.3 mRNA expression was detected in undifferentiated SH-SY5Y cells, with 
expression also confirmed at the functional level via binding assays and the use of 
pharmacological tools (Sousa et al., 2013). Although in our study Cav1.2 expression was 
also detected, possible explanations for discrepancies within this study and the study 
conducted by Sousa et al., could be due to differences in the cell line supplier, 
heterogeneity within the cell population, and also Sousa et al. failed to specify whether 
the cDNA synthesized underwent any dilutions prior to PCR, therefore Cav1.2 although 
expressed might have been too low for detection. Gene expression detection via qPCR 
here, rather than conventional PCR could be more sensitive in picking up expression of 
genes at very low levels. In further support of our findings, a previous study on 
undifferentiated SH-SY5Y cells, confirmed mRNA expression of Cav1.3, with lower 
Cav1.2  expression which remained undetected in some technical experimental repeats 
(Chiou, 2006), suggesting heterogeneity within the cell population. In agreement to this 
study, where Cav1.2 and Cav1.3 mRNA expression was also confirmed not only in 
undifferentiated, but also differentiated cells, findings by Morton et al. (1992), revealed 
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functional Cav1 channels within RTA-differentiated SH-SY5Y cells, although which Cav1 
subtypes are present was not addressed. 
It is known that Cav2 channels are highly expressed in the CNS, with the 
predominant Cav2 channels being Cav2.2 which is found throughout the brain (Sheng 
et al., 1996; Chin, 1998; Pravettoni et al., 2000). In this study, from the Cav2 channel 
subfamily only mRNA expression of Cav2.2 a1 subunit was detected in both 
undifferentiated and differentiated SH-SY5Y cells. Given the lack of evidence for Cav2.3 
expression in neuroblastoma cells, and due to its limited expression in various parts of 
the nervous system (Schneider et al., 2005; Sousa et al., 2013), Cav2.3 expression was 
not investigated in this study. Numerous studies have linked Cav2 channels to neuronal 
development (Pravettoni et al., 2000). In contrast to neurite outgrowth during early 
stages of neuronal development which requires Cav1 channel opening, Cav2.2 channels 
are needed at later stages, such as during synaptic vesicle recycling (Pravettoni et al., 
2000).  In support of findings from this study, Sousa et al. (2013) confirmed Cav2.2 
expression at both mRNA and protein level, evident from electrophysiology and CCB 
radioligand binding assays, whereas no mRNA expression was detected for Cav2.1 and 
Cav2.3 in undifferentiated SH-SY5Y cells (Sousa et al., 2013). Cav2 channels have also 
shown a prominent role in terminally differentiated cells (Pravettoni et al., 2000). 
Neurotransmitter release, seen in differentiated neurons, is highly regulated by Cav2 
channels (Sheng et al., 1996; Pravettoni et al., 2000; Kamp et al., 2005). For example, 
Sheng et al., in isolated rat brain synaptosomes, revealed that Cav2.2 channels are able 
to interact with syntaxin and SNAP25, and consequently participate in neurotransmitter 
release (Sheng et al., 1996). Therefore, in support of a role for Cav2 channels in 
terminally differentiated cells, in this study, Cav2.2 expression was also confirmed 
within RTA-differentiated SH-SY5Y cells which are known to express synaptic markers 
once they undergo terminal differentiation (Kovalevich and Langford, 2013; Teppola et 
al., 2016; Jahn et al., 2017).  
In contrast to the expression of both Cav1 and Cav2 channels and their role in 
neuronal development and differentiation, studies agree that expression of Cav3 
channels is primarily observed within undifferentiated cells, with a proposed role for 
Cav3 channels in cell proliferation and development prior to cells undergoing terminal 
differentiation (Barnes and Haynes, 1992; Bertolesi et al., 2003; Aguado et al., 2016; Kim 
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et al., 2018). Findings in this study indicate a significant reduction, or in some instances 
a complete loss of Cav3.1 mRNA expression upon cell differentiation. Cav3.2 and Cav3.3 
were not detected in SH-SY5Y of either differentiation states. Evidence from studies 
conducted on neural progenitor cells (NPCs) isolated from Sprague-Dawley rat embryos, 
reveal only Cav3.1 and Cav3.2 mRNA expression at early embryonic stages of 
development compared to later stages of neuronal development in the cortex (Kim et 
al., 2018). This agrees with findings from this study, and the notion that Cav3 channels 
are needed at early stages for cell proliferation and for induction of differentiation, 
where differentiation may lead to either a loss or reduction in Cav3 expression. In 
further agreement, previous studies have revealed Cav3.1 and Cav3.2 gene expression 
in Y79 retinoblastoma cells is significantly reduced when cells are induced to terminally 
differentiate into neurons (Barnes and Haynes, 1992; Bertolesi et al., 2002). Bertolesi et 
al. detected significantly higher expression of Cav3.1 compared to Cav3.2 in 
undifferentiated Y79 cells  (Bertolesi et al., 2002). Differences in findings within these 
studies and our study could be due to differences in the primers used, and also although 
Cav3.2 mRNA expression was not detected, Cav3.2 might still be expressed in SH-SY5Y 
cells, but at very low levels. Cav3 channels are also known to have a role in cell viability 
and proliferation (Valerie et al., 2013). In support of this, a study conducted by Valerie 
and colleagues showed that siRNA-induced knock-down of all Cav3 subtypes can result 
in a reduction in glioblastoma cell number (Valerie et al., 2013). Immunohistochemistry 
analysis revealed high expression of Cav3.1 in the cerebellum and Cav3.3 in the 
hippocampus of mice (Aguado et al., 2016; Dumenieu et al., 2018). It is known that  
Cav3.2 is primarily expressed in cardiac, kidney and liver cells, and not predominantly 
found in neurons like the other Cav3 counterparts (Striessnig et al., 2014). Consistent 
with findings from this study, and further supporting the expression and role of Cav3 
channels in cell proliferation in undifferentiated cells, Sousa et al. only detected Cav3.1 
mRNA expression out of all the members of the Cav3 subfamily within undifferentiated 
SH-SY5Y cells (Sousa et al., 2013). 
To conclude, in support of only Cav1.2 and Cav1.3 expression of the Cav1 family 
detected in the CNS, this study has detected Cav1.2 and Cav1.3 at transcript level in SH-
SY5Y cells of both differentiation states. Moreover, in agreement with the role of Cav2 
channels during neuronal development, and more specialised neuronal functions such 
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as neurotransmission following neuronal differentiation, Cav2.2 was detected in SH-
SY5Y of both differentiation states. Lastly, Cav3 channels have been shown to have an 
important role during early stages of neuronal development and differentiation, 
suggesting that terminal differentiation would cause loss or reduction in expression. 
Indeed, in this study, SH-SY5Y differentiation led to a significant reduction in Cav3.1 
expression. These findings provide evidence that SH-SY5Y VGCC expression profile is 
similar of that seen in undifferentiated cells capable of undergoing neuronal 
differentiation, and terminally differentiated neurons, therefore supporting the use of 




































VGCC role in cell survival and activity 
 
• Global VGCC blocker CdCl2 significantly alters SH-SY5Y activity of both differentiation states. 
• Selective CCBs reveal a role for Cav2.2 and Cav3.1 in SH-SY5Y cell activity and survival. 
 
A plethora of studies have investigated the role of Cd2+, a metal divalent ion, in 
calcium-related induced neurotoxicity in primary neurons and neuronal cell lines via a 
VGCC-dependent manner, with different signalling cascades being proposed (Swandulla 
and Armstrong, 1989; Chow, 1991; Thévenod and Jones, 1992; Taylor, Batten and Peers, 
1999; Xu et al., 2011; Saddala et al., 2017). In this study, treatment with the pan-VGCC 
modulator CdCl2 led to a concentration-dependent reduction in cell (metabolic) activity 
in SH-SY5Y cells of both differentiation states, with a significant reduction seen from 
50µM CdCl2. Studies in the late 1990s, conducted in chicken sensory neurons and frog 
sympathetic neurons, reveal that the effect of Cd2+  (20 and 1µM respectively) is voltage-
dependent, with Cd2+ modulating VGCCs during their activation state, changing this into 
‘an opened blocked state’ (Swandulla and Armstrong, 1989; Thévenod and Jones, 1992). 
Inhibition could be reversed at very high hyperpolarised or positive voltage values 
(Swandulla and Armstrong, 1989; Thévenod and Jones, 1992). Further studies proposed 
that  Cd2+, at high µM concentrations, can reversibly block squid calcium currents by 
permeating the VGCC pore and binding onto a specific site in the pore, hence preventing 
the entry of Ca2+ (Chow, 1991). Similarly to findings in this study where reduction in cell 
activity was seen from 50µM CdCl2 and higher, Taylor and colleagues demonstrated that 
Cav2.2-dependent Ca2+ influx in PC12 (pheochromocytoma) cells was inhibited by 
200µM Cd2+ (Taylor, Batten and Peers, 1999). In a study where CHO cells were stably 
transfected with the Cav1 channel, acute treatment with 50-100µM Cd2+ caused cell 
death due to accumulation of Cd2+ intracellularly, an effect that could be blocked with 
the Cav1 blocker nimodipine, suggesting that Cd2+ can cause cell apoptosis through a 
VGCC-dependent manner at µM  concentrations (Marchetti, 2013). Building on this, 
more recently, Saddala and colleagues demonstrated that use of the Cav1 blocker 
amlodipine was able to prevent Cd2+ entry through VGCCs, and therefore neurotoxicity, 
by acting as a CdCl2 antagonist preventing its binding onto the VGCC pore (Saddala et 
al., 2017). Due to the important role of VGCCs in cell activity and survival, taken 
together, these findings suggest that the concentration-dependent reduction in cell 
activity seen in this study is due to CdCl2 modulation of VGCCs. In contrast to other 
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studies, Xu et al. (2011) demonstrated that CdCl2 ,in a concentration-dependent manner 
(>2.5µM), induced cell death of SH-SY5Y, PC12 and primary mouse neurons partly 
through an increase in intracellular Ca2+, and subsequent activation of MAPK (mitogen-
activated protein kinase) and mTOR (mammalian target of rapamycin) pathways, 
mediated by ROS release and oxidative stress (Xu et al., 2011). Although unlike other 
studies Xu and colleagues proposed Cd2+ neurotoxic mechanism partly involves an 
increase in Ca2+ influx from the extracellular, rather than a reduction, the manner by 
which CdCl2 directly modulates VGCCs at the functional level was not investigated. 
Differences in findings between Xu et al. 2011 compared to other studies could be due 
to differences in the metholodology such as treatment duration. For example, Xu and 
colleagues studied the effect of Cd2+ over 24hr whereas studies involving 
electrophysiology experiments investigated the effect of Cd2+ over a short period of 
time (<1hr) suggesting that Cd2+ may have differential effect on VGCCs dependent on 
treatment duration.  
In order to further investigate and identify the role of specific VGCC subtypes in 
regulating cell (metabolic) activity, a number of studies have used pharmacological tools 
with a higher degree of selectivity. In the current study, Cav2.2 and Cav3.1 channels, as 
revealed by pharmacological blockage by w-conotoxin-GVIA and mibefradil 
respectively, have been identified as VGCCs with an important role in SH-SY5Y viability 
and activity. Calcium dyshomeostasis has been linked to cancer progression (Zawadzki 
et al., 2008).  In 2015, a meta-analysis, using a microarray database, showed that in a 
number of cancers, a change in the expression of various VGCC isoforms is detected; 
this indicates a pivotal role for VGCCs in promoting cell survival and growth (Valerie et 
al., 2013; Wang et al., 2015). For example, in glioblastomas a 5.8 fold upregulation of 
Cav2.1 gene expression was detected (Wang et al., 2015). Similarly, an upregulation in 
Cav3 expression is also detected in glioblastoma tumours (Valerie et al., 2013). A study 
conducted on both primary colon cancer cells and a widely-used colon cancer cell line 
(HT-29), revealed that use of the Cav1 agonist Bay K8644 induced cell death in a manner 
involving increase in Ca2+ entry (Zawadzki et al., 2008). Whereas, the use of the CCB 
verapamil prevented cell death, proving that Cav1 channels have an important role in 
cell survival (Zawadzki et al., 2008). In contrast to Zawadzki et al., this study revealed 
that the use of the Cav1 blocker nifedipine did not cause any change in cell activity. 
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Differences in findings could be due to differences in the cell types tested, and 
additionally in pathological conditions such as seen in cancer, different pathways may 
control cell survival and death. Evidence from preclinical cancer models suggest that 
inhibition of Cav3 channels not only can reduce cell proliferation, it can also induce cell 
apoptosis (Sheehan et al., 2013; Valerie et al., 2013). Sheehan and colleagues showed 
that  block of Cav3 channels by mibefradil (µM concentrations), was able to reduced cell 
proliferation of C6 glioblastoma cells  both in vitro and also in vivo when cells were 
injected in Sprague-Dawley rats (Sheehan et al., 2013). Another study demonstrated 
that 5µM mibefradil caused an approximate 40% reduction in glioblastoma viability by 
initiating pro-apoptotic pathways, such as an increase in caspase3/7 activity, and 
reduction in the expression of the anti-apoptotic protein bcl-2 (Valerie et al., 2013). 
Valerie and colleagues also revealed that pharmacological inhibition of Cav3 channels 
causes a subsequent block of mTORC2/Akt pathway, through preventing 
phosphorylation of Akt (position: Ser473 and Thr308) and consequently initiating cell 
death (Valerie et al., 2013). Although through the use of mibefradil it was concluded 
that block of Cav3 channels can induce cell death, inhibition of Cav1 channels cannot be 
excluded as mibefradil is known to block both L-type and T-type channels in a 
concentration-dependent manner (Perez-Reyes, Lee and Cribbs, 1999; Valerie et al., 
2013). Studies have shown that mibefradil can block Cav3 channels at IC50 1µM, whereas 
for inhibition of Cav1 channels 14 times higher concentration is needed (Perez-Reyes, 
Lee and Cribbs, 1999; Bertolesi et al., 2002).  Valerie and colleagues, in order to  exclude 
that the effects of mibefradil could be due to block of Cav1 channels, repeated 
experiments in the presence of nifedipine and verapamil; these Cav1 blockers failed to 
prevent a similar degree of cytotoxicity (Valerie et al., 2013). Findings by Valerie et al. 
support findings from this study where 5µM mibefradil caused a significant change in 
cell activity of undifferentiated SH-SY5Y cells, whereas 5µM nifedipine treatment failed 
to cause any change in activity, suggesting that mibefradil-mediated changes in activity 
are due to inhibition of Cav3 and not Cav1 channels. Further supporting the current 
study, Kim et al. (2018) demonstrated that NPCs isolated from Sprague-Dawley rat 
embryos showed a significant degree of reduction in viability when treated with 0.15-
10µM mibefradil (5µM mibefradil - 50% reduction). Similar to Valerie’s study, Kim and 
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colleagues proposed that reduction in cell viability via inhibition of Cav3 channels causes 
a subsequent prevention of Akt phosphorylation at Ser473 and GSK3b (Kim et al., 2018). 
Incubation of NPCs with micromolar concentrations of nifedipine failed to cause a 
change in cell viability (Kim et al., 2018). On the other hand, mibefradil treatment of 
cortical neurons caused a lower degree of reduction in viability, suggesting that 
terminally differentiated cells are more resistant to Cav3 inhibition. Agreeing with the 
notion that Cav3 channels have an important role in cell proliferation and therefore 
their expression reduces with cell differentiation (Barnes and Haynes, 1992; Bertolesi et 
al., 2002, 2003; Aguado et al., 2016; Kim et al., 2018), findings from previous studies 
agree with results from the current study where no expression for Cav3.1 is detected in 
RTA-differentiated cells, and subsequently no changes in differentiated SH-SY5Y activity 
was observed with mibefradil treatment. In contrast to other studies, Bertolesi et al. 
(2002), demonstrated that treating both human retinoblastoma cells and also C6 rodent 
glioblastoma cells with mibefradil (IC50 1 and 5µM respectively) a significant reduction 
in cell growth and proliferation through a cell cycle independent pathway is observed.  
As no changes in anti-apoptoptic bcl-2 expression and pro-apoptotic bax expression was 
seen with mibefradil treatment, Bertolesi et al. (2002), suggested that its mode of action 
may involve necrosis rather than apoptosis. 
Previous studies have shown that inhibition of VGCCs with or without exposure 
to an apoptotic stimulus, can confer neuroprotection (Pringle et al., 1996; Zawadzki et 
al., 2008; Wildburger et al., 2009; Lecht et al., 2012). Cultures (8-days) of hippocampal 
neurons from E18 mice when treated with the Cav3 blocker trimethadione (TMO), 
although a very high concentration (600µM; 48hr) was needed, less reduction in 
neuronal viability compared to untreated neuronal cultures was seen via lactate 
dehydrogenase assays (Wildburger et al., 2009). A similar degree of neuronal protection 
was also observed with 1µM nimodipine treatment (Wildburger et al., 2009). Cortical 
neurons on the other hand, demonstrated a lower degree of reduction in viability with 
similar TMO concentrations, suggesting differential expression profile of Cav3 channels 
dependent on neuronal type and CNS region (Wildburger et al., 2009; Aguado et al., 
2016). Interestingly, 0.5 and 1µM mibefradil, demonstrated protection, whereas 
treatment with 10µM induced neurotoxicity (Wildburger et al., 2009). Treating ‘aged-
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neuronal cultures’ (15-day cultures) with nimodipine, also exhibited neuroprotective 
effects, whereas TMO was unable to prevent significant neuronal loss (Wildburger et 
al., 2009). This suggests that ageing may be linked to changes in the expression of 
specific VGCC subtypes. In neuron differentiated PC12 cells, oxygen/glucose deprivation 
(up to 5hr) to mimic ischaemic hypoxia conditions, caused an increase Ca2+ influx, where 
exposure to micromolar concentrations of the Cav1 CCBs nifedipine and nimodipine 
reduced caspase activation and lactate dehydrogenase release (Lecht et al., 2012). 
Additionally, nifedipine at concentrations as low as 1µM conferred neuroprotection to 
hippocampal neurons exposed to similar ischaemic conditions (Lecht et al., 2012). 
Similarly, Pringle and colleagues showed that hippocampal organotypic slice cultures 
exposed to 3hr of hypoxia or 1hr of ischemic conditions treatment with 300nM w-
conotoxin-MVIIA (EC50= 50nM) an N-type CCB, lower degree of neuronal loss was 
observed (Pringle et al., 1996). Whereas co-incubation of hippocampal neurons with 
nifedipine, failed to prevent neuronal loss, suggesting neuronal loss due to stressful 
stimuli such as hypoxia involve an increase in Ca2+ influx through Cav2 and not Cav1 
channels (Pringle et al., 1996).  
In parallel with previous findings, this study indicated lack of neurotoxicity with 
nifedipine, and in line with the absence in Cav2.1 expression in SH-SY5Y cells, lack of 
toxicity with the Cav2.1 blocker w-agatoxin-MVIA. In contrast, a significant reduction in 
cell activity was observed with 1µM w-conotoxin-GVIA, a Cav2.2 blocker in line with 
Cav2 channel expression in both undifferentiated and differentiated SH-SY5Y cells and 
its role in neuronal development and specialised neuronal functions such as 
neurotransmission seen post-differentiation. A reduction in SH-SY5Y activity was also 
noted with the Cav3.1 blocker mibefradil dihydrochloride in undifferentiated cells. In 
support of no Cav3.1 expression in differentiated cells, mibefradil was unable to cause 







CO effect on CCB-mediated neurotoxicity 
• Physiological levels of CO do not change SH-SY5Y cell activity of either differentiation states. 
• CO is unable to prevent changes in SH-SY5Y activity mediated by CCBs in cells of either differentiation 
states. 
 
Although CO is commonly known as a toxic odourless gas, endogenously it has a 
number of important cellular roles, with preclinical studies investigating the use of CO 
as a potential therapeutic. It has been proposed that one mechanism by which CO can 
act cytoprotectively is through modulation of VGCCs (Lim et al., 2005; Scragg et al., 
2008; Boycott et al., 2013; Hettiarachchi et al., 2014; Duckles et al., 2015). In the current 
study, as a first step in investigating the cytoprotective role(s) of CO in neuroblastoma 
cells, SH-SY5Y of both differentiation states, were treated with either CORM2 or its 
inactive control (iCORM2) for 24hr at concentrations 1-100µM. The CORM2 
concentrations tested, which correspond to physiological CO levels, did not confer any 
neurotoxicity in SH-SY5Y of either differentiation states. Further experiments revealed 
that CORM2 was unable to modulate CCB-mediated changes in SH-SY5Y cell (metabolic) 
activity.  
A study conducted in 2005 showed that administration of low levels of 
exogenous CO solution to Cav1.2 (a1 and b2 subunits) stably transfected HEK293 cells, 
and intestinal smooth muscle cells that natively express VGCCs, caused an increase in 
intestinal Cav1 currents (Lim et al., 2005). CO-mediated increase in intestinal Cav1 
currents involves increasing NO production via NOS (nitric oxide synthase) and 
subsequent increase in cGMP  via sGC and ultimately activation of PKA (Lim et al., 2005). 
In contrast to Lim’s research, Scragg et al. (2008)  revealed that CORM2 , and dissolved 
carbon monoxide, can both inhibit the activity of recombinant and native cardiac Cav1 
channels via a redox manner, rather than a NO, cGMP and PKG pathway (Scragg et al., 
2008). This involved an increase in release of ROS from complex III of the electron-
transport chain, which caused changes in channels kinetics via modulation of specific 
cysteine residues (a.a. 1787-1818 region), with the a1 pore-forming subunit essential 
for CO sensitivity of the L-type channels (Scragg et al., 2008). Opposing finding in 
Scragg’s vs Lim’s study, where activation of Cav1 channels via CO was observed, could 
be due to differences in the source and dose of CO used. Additionally expression of 
accessory subunits of these channels could also have an effect in how CO modulates 
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Cav1 channels. Lim’s study also focused on the effect of CO on Cav1.2 channels 
expressed within intestinal smooth muscle cells, whereas Scragg’s study focused on the 
effect of CO within cardiomyocytes. Although both studies agree CO can act as a VGCC 
modulator, differences in the manner in which it modulates these channels could be 
due to tissue specific differences in the mechanism underlying its activity. Interestingly, 
a study conducted on low-voltage activated VGCCs revealed that CO can indirectly 
inhibit Cav3.2 (T-type channels) through CO interacting with thrioredoxin (Trx), and 
therefore hindering Trx regulatory activity on these channels (Boycott et al., 2013). 
Similarly to Boycott et al. (2013), research done by Duckles proposed that CO can 
modulate VGCCs by reducing Cav3.1 and Cav3.2 channel conductance, and therefore 
exhibiting anti-proliferative properties (Duckles et al., 2015). A similar reduction in 
channel conductance was also seen in Cav1 channels (Duckles et al., 2015). Although 
these studies prove that CO can act as a VGCC modulator, they fail to address whether 
CO confers cytoprotection in a VGCC manner. In contrast to the previously mentioned 
studies, Hettierachchi et al. (2014), showed that CO has the potential to act 
cytoprotectively against Ab toxicity in a VGCC-dependent manner. It was revealed that 
part of Ab1-42- mediated apoptosis involved an increase in Cav1 channel activity, which 
in turn caused activation of CAMKKII and subsequent phosphorylation and activation of 
AMPK. CORM2 was able to prevent Ab-mediated apoptosis via prevention of 
phosphorylation and the consequent activation of AMPK (Hettiarachchi et al., 2014). 
Although previous research has shown that CO can act as a VGCC modulator through 
modulating VGCC activity, the current study was unable to prove CO cytoprotection 
through preventing CCB-mediated changes in SH-SY5Y cell activity. Contradictory 
findings could be due to differences in methodology between studies, but it may also 
suggest that even though CO may modulate VGCC activity, in this case, CO 
cytoprotection may occur through a VGCC-independent manner. For example, Zeynalov 
and Doré (2009), through the use of rodent animal models, demonstrated that 
administration of high physiological concentrations of CO (125 and 250ppm), 
immediately following an ischemic stroke and during times of oxygen flow restoration, 
protected cerebral tissue from further damage. This cytoprotection occurred through 
arteriole dilation through activation of Ca2+-dependent K+ channels which prevented 
further cerebral tissue damage by preventing inflammation and maintaining cell viability 
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(Zeynalov and Doré, 2009). Similarly, another study was able to show that in an animal 
model of lung transplants, CO exhibited anti-inflammatory effects through reduction in 
mRNA expression of pro-inflammatory genes such as IL-6, therefore reducing 
inflammation and cell death, ultimately preventing transplant rejection (Song et al., 
2003). In support of this, another study revealed that inhalation of physiological levels 
of CO prior to ischemic injury reduces neuronal loss observed in the hippocampus and 
the cortex (Mahan et al., 2012). Although a number of studies suggest that CO may 
confer cytoprotection through a VGCC independent pathway, some studies have 
suggested that CO may not directly target VGCCs, but may target Ca2+ influx dependent 
pathways such as through changes in mitochondria activity. One manner by which CO 
may confer these anti-apoptotic effects, may be through antioxidant pathways, 
including through an increase in NOS (nitric oxide synthase) activity and NO production, 
and activating mitochondrial KATP channels, rather than VGCCs (Vieira, Queiroga and 
Alves, 2008; Wang et al., 2011). Moreover, studies conducted on primary astrocytes 
treated with CO, CO prevented oxidative stress or inflammation induced apoptosis 
through mitochondrial targeting involving an increase in bcl-2 anti-apoptotic protein, 
accompanied by an increase in ATP production, changes to COX (cyclooxygenase) 
activity and lastly mitochondria biogenesis (Zuckerbraun et al., 2007; Almeida et al., 
2012). In further support of a role of CO on mitochondria, Lo Iacono et al. showed that 
administration of CORM3 (µM range) upregulates mitochondrial respiration, 
accompanied by a reduction in membrane potential and reduction in H2O2 production 
from complex II (Iacono et al., 2011). CO pre-treatment of isolated mitochondria from 
primary astrocytes prevented oxidative stress-dependent cell death due to 
mitochondrial permeabilization through glutathionylation of adenine nucleotide 
translocase, the antiporter found on the inner membrane of mitochondria responsible 
for ADP intake and ATP export  (Queiroga et al., 2010).  Another study revealed that in 
primary hippocampal neurons, pre-treatment with CO was able to prevent hypoxia 
induced cell death through caspase 3, through upregulation of anti-apoptotic bcl-2 
expression and subsequent inhibition of ROS production and cytochrome c release 
(Queiroga et al., 2012). In further support of CO’s role in inhibition of cell apoptosis, 
Song et al. revealed that 250ppm CO not only prevents T-lymphocyte activation and 
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proliferation, it also inhibits cell apoptosis through block of caspase 3 and 8, in a cGMP 
and MAPK independent pathway (Song et al., 2004). 
Although a number of studies suggest that CO can act cytoprotectively through 
ion channels, in the current study CORM2 was unable to prevent CCB-mediated changes 
in SH-SY5Y activity. This suggests that although CO may modulate VGCC activity, CO 






































VGCC-dependent calcium dyshomeostasis is a pathway that has been linked to 
AD pathology. Treating SH-SY5Y cells with RTA suggests that cells can differentiate into 
cells more closely representing primary neurons, with differential VGCC expression 
profile dependent on differentiation state. In support of a role for both Cav1 and Cav2 
channels during neuronal development, and also in more specialised roles following 
neuronal differentiation, Cav1.2, Cav1.3 and Cav2.2 expression was confirmed in SH-
SY5Y of both differentiation states. In contrast, agreeing with the idea that Cav3 
channels are required during early stages of development (Barnes and Haynes, 1992; 
Bertolesi et al., 2003; Aguado et al., 2016; Kim et al., 2018), a reduction in Cav3.1 
expression was seen with RTA differentiation of SH-SY5Y cells. This suggests that the SH-
SY5Y neuroblastoma VGCC profile closely resembles that of primary neurons, therefore 
SH-SY5Y neuroblastoma cells are an appropriate system for studying VGCC-dependent 
calcium dyshomeostasis in neurodegenerative diseases. 
It is widely accepted that VGCCs have a key role in neuronal activity and survival 
(Pringle et al., 1996; Wildburger et al., 2009; Kim et al., 2018). This study, through the 
use of the global VGCC blocker CdCl2 and selective CCBs w-conotoxin-GVIA and 
mibefradil identified Cav2.2 and Cav3.1 to have a role in SH-SY5Y cell activity. These 
results support the hypothesis that blocking selective VGCCs, due to their important 
roles within cell development, differentiation and survival, will have an impact on 
overall neuronal metabolic activity. 
Agreeing with the hypothesis that CO (via CORM2 treatment) at physiological 
concentrations should not alter overall neuronal activity, this study has proven that 
CORM2 treatment alone has no effect on neuronal metabolic activity.  Although a 
number of studies have proposed that CO can act neuroprotectively through an ion 
channel-dependent manner (Scragg et al., 2008; Vieira, Queiroga and Alves, 2008; 
Zeynalov and Doré, 2009; Boycott et al., 2013; Hettiarachchi et al., 2014; Duckles et al., 
2015), CORM2 was unable to change CCB-mediated changes in SH-SY5Y metabolic 
activity of cells of either differentiation states. This suggests that although CO may 
modulate VGCC activity, in this case, CO cytoprotection may occur through a VGCC-
independent manner.  
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 To conclude, these findings aid our understanding of the role of individual VGCC 
members in neuronal viability and differentiation. Further experiments aim to focus on 



















































































Ab cytotoxicity plays a key role in Alzheimer’s disease pathology, with evidence 
suggesting that it is the aggregated form of the peptide that is responsible for the noted 
neurotoxicity (Hardy and Selkoe, 2002). Ab can exist as a number of species and 
assemblies (Deshpande et al., 2006; Nimmrich et al., 2008; Pachahara et al., 2012; 
Hermann et al., 2013; Nichols et al., 2015) (see Introduction). Although Ab1-40 consists 
the majority of Ab species found in the brain, Ab1-42 is the species most prone to 
aggregation, therefore a number of studies have focused in studying cytotoxicity 
exerted by the 42 amino acid long sequence (Shao et al., 1999; Barghorn et al., 2005; 
Pachahara et al., 2012; Cárdenas-Aguayo et al., 2014). For this reason, this study 
focused on Ab1-42 with the reverse sequence Ab42-1 used as a control. 
Ab can exist in its monomeric form, where following changes to its secondary 
structure, it can undergo a conformational change from a-helices and random coils into 
b-sheets, which are more prone to aggregation (Shao et al., 1999; DeTure and Dickson, 
2019). The C-terminus of the Ab peptide has a role in inducing the conformational 
change into b-sheets (Chen et al., 2017). Following this, the peptide can then aggregate 
into dimers and small soluble oligomers, this is known as the nucleated polymerisation 
process. Oligomers can then  further rearrange into elongated structures known as 
protofibrils and eventually mature fibrils, displaying crosslinking of b-sheets, which are 
primarily found within amyloid plaques (Fig. 1.1.6.1) (Podlisny et al., 1998; Sandberg et 
al., 2010; DeTure and Dickson, 2019). Evidence suggests that smaller Ab aggregated 
assemblies such as small oligomers and protofibrils are more cytotoxic than mature 
fibrils, with neurotoxic mechanisms including synaptotoxicity, mitochondrial 
dysfunction, oxidative stress and ultimately neuronal loss (Hardy and Selkoe, 2002; 
Barghorn et al., 2005; Deshpande et al., 2006; Ryan et al., 2010; Nicoll et al., 2013; 
Hettiarachchi et al., 2014; Morris, Clark and Vissel, 2014; Nichols et al., 2015). Numerous 
studies are now using synthetic human Ab1-40/1-42  which can undergo aggregation in a 
similar manner to in vivo Ab  and can also exhibit similar degree of neurotoxicity (Ryan 
et al., 2010). For the purpose of this study, Ab neurotoxicity was investigated using 
synthetic human Ab1-42 in its protofibrillar form. Prior to investigating protofibrillar Ab1-
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42 neurotoxicity, various protocols designed to induce Ab aggregation and protofibril 
formation were assessed. 
Aggregated Ab has shown to confer neurotoxicity in a number of manners, including 
calcium dysregulation (Anekonda et al., 2011; Nimmrich and Eckert, 2013). One way by 
which it can cause calcium dysregulation is through modulation of VGCC expression and 
activity (Ueda et al., 1997; Chiou, 2006; Nimmrich et al., 2008; Kim and Rhim, 2011). The 
effect of protofibrillar Ab1-42 on neuronal VGCCs in undifferentiated and RTA-
differentiated SH-SY5Y neuroblastoma cells was also investigated here. Lastly, the 
effects of CO, generated through CORM2 treatment, on protofibrillar Ab1-42-mediated 




The aim of the study was to develop a protocol that produces consistent Ab1-42 
protofibrils and identify the effects of Ab1-42 protofibrils on VGCCs at molecular level, 





• To compare time-dependent Ab1-42 protofibril formation using the NH4OH 
protocol against the HFIP/DMSO protocol. 
• To examine the effect of SDS on Ab1-42 protofibril formation. 
• To identify Ab1-42/Ab42-1 -mediated changes in cell activity using SH-SY5Y cells in 
contrasting differentiation states. 
• To investigate changes in VGCC gene expression by Ab1-42. 
• To investigate Ab1-42 effect in modulating CCB-mediated changes in neuronal 
activity using undifferentiated and differentiated SH-SY5Y cells. 
• To investigate CO effect in modulating Ab1-42 -mediated changes in neuronal 






• SDS with its negatively charged surface, as it can mimic the cell 
microenvironment, it is expected to aid Ab1-42 aggregation. 
• Protofibrillar Ab1-42 as one of the aggregated forms of Ab is expected to impair 
neuronal cell (metabolic) activity.  
• Due to the important role of VGCCs in cell development, differentiation and 
survival, it is expected that protofibrillar Ab1-42 has an effect on VGCCs expression 
and survival. 
• As CO is known to act neuroprotectively, it may interfere with protofibrillar Ab1-






















4.2.1. Ab  Fibrillization 
 
For the purpose of this study, experiments focused on investigating the effects of 
protofibrillar Ab1-42 on a neuronal cell line (SH-SY5Y cells). As a first step, prior to 
experimental use, advanced microscopy, specifically transmission electron microscopy 
(TEM) was used to study Ab1-42 aggregation, and to determine whether the widely used 
NH4OH protocol (followed by 48hr incubation period) does indeed lead to Ab1-42 
protofibril formation (see Materials & Methods for full protocol). 
TEM images reveal that at 0hr the peptide was largely non-aggregated, which is 
observed as Ab1-42 clumps, with no fibril structures present (Fig. 4.2.1.1A). By 24hr the 
formation of small protofibrils can be seen (<100 nm length) (Fig. 4.2.1.1B) and by 48hr 
larger protofibrils were observed (Fig. 4.2.1.1C). Fibril length analysis revealed time-
dependent formation of protofibrils, with a 41.4 ± 7.1% (P<0.0001) increase in 
protofibril length from 24 to 48hr incubation. At 24hr incubation 68.0% of the 
protofibrils were below 100 nm in length (average length 93.2 ± 3.9nm; n=25), whereas 
by 48hr 89.3% of the protofibrils were above 100 nm in length (average length 131.8 ± 
5.8nm; n=28) (Fig. 4.2.1.1E and F).  
Ab1-42 protofibril formation using the NH4OH protocol was then compared to the 
widely used HFIP (hexafluoroisopropanol)/DMSO protocol (HFIP-peptide kindly 
provided by Dr Francesco Tamagnini, University of Reading). Preparing Ab1-42 using the 
HFIP/DMSO protocol also led to protofibril formation (2hr incubation), as determined 
via TEM (Fig. 4.2.1.1D). Of note, the length of the protofibrils were of similar size to the 
24hr NH4OH images rather than the 48hr protofibrils (Fig. 4.2.1.1E and F). 63.4% of 
protofibrils generated using the HFIP/DMSO protocol were less than 100 nm in length 
(average length 85.7 ± 5.2nm; n=22). Protofibrils formed following the 48hr NH4OH 
protocol were 53.7 ± 7.3% (P<0.0001) longer than the protofibrils formed following the 
HFIP/DMSO protocol. Due to this, all subsequent experiments were carried out with Ab 
prepared using the NH4OH protocol. 
Literature supports the notion that the reverse sequence of Ab1-42 does not confer 
cytotoxicity as it cannot aggregate (Paradis et al., 1996; Wei, Wang and Kusiak, 2002; 
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Takuma et al., 2004). Representative images taken via TEM revealed lack of fibrillization 
of Ab42-1 (48hr incubation) using the NH4OH protocol (Fig. 4.2.1.2A), as compared to Ab1-

























































Figure 4.2.1.1: Aβ1-42 fibrillization. Transmission electron microscopy (TEM) was used to monitor Aβ1-42 
fibrillization. Representative images, using the NH4OH protocol, show that at (A) 0hr the peptide is largely not 
aggregated, at (B) 24hr peptide fibrillization has started (protofibrils <100nm) and by (C) 48hr the peptide 
aggregated into larger protofibrils (>100nm in length). Aβ1-42 fibrillization using the NH4OH protocol was also 
compared to (D) peptide aggregation via the HFIP/DMSO protocol (HFIP-peptide kindly provided by Dr Tamagnini) 
(n=22).  (E) + (F) Image J analysis of protofibril length revealed that by 48hr (NH4OH protocol) the majority of the 
protofibrils are over 100nm in length, with protofibrils obtained from the HFIP protocol demonstrating structural 
similarity to the protofibrils formed at 24hr with the NH4OH protocol (n=22-28). Statistical analysis was carried out 

























Figure 4.2.1.2: Aβ species dependent differences in aggregation. Aβ aggregation of Aβ42-1 and Aβ1-42 was monitored 
via TEM, using the NH4OH protocol. Representative images show that (A) Aβ42-1 did not aggregate into protofibrils 





4.2.2. Use of SDS in Ab  aggregation 
 
Evidence suggests that adding sodium-dodecyl sulfate (SDS) in Ab preparations may 
promote Ab aggregation (Barghorn et al., 2005; Rangachari et al., 2006; Wahlström et 
al., 2008). In order to investigate the role of SDS in Ab1-42 aggregation, the peptide was 
prepared in the presence and absence of SDS. Representative TEM images reveal that 
lack of SDS leads to the formation of protofibrils 85.3 ± 6.9% (P<0.0001) smaller in length 
(average length 52.0 ± 2.1nm; n=21) compared to Ab1-42 prepared in the presence of 
SDS (average length 93.2 ± 3.9nm; n=25) at 24hr incubation. Although in the absence of 
SDS protofibril length was lower at 24hr incubation, Ab1-42 time-dependent 
protofibrillization was still observed, with a 49.1 ± 6.8% (P<0.0001) increase in length 
with an additional 24hr incubation (average length 103.0 ± 4.0nm; n=26).  Protofibril 
length for Ab1-42 preparations in the presence or absence of SDS was also different at 
48hr with 24.4 ± 6.3% (P<0.01) larger protofibrils seen in SDS containing Ab1-42 
preparations (average length 131.7 ± 5.8nm; n=28) (Fig. 4.2.2.1A and B). For this reason, 




























































Figure 4.2.2.1: Aβ1-42 fibrillization in the presence and absence of sodium dodecyl sulfate. Aβ1-42 fibrillization using 
the NH4OH protocol was monitored via TEM. (A) Presence and absence of SDS at 24hr (left panel) and 48hr (right 
panel). (B) Image J analysis revealed that at 24hr, absence of SDS leads to formation of exclusively smaller than 100nm 
length protofibrils, whereas a combination of different sized protofibrils are observed in the presence of SDS. At 48hr 
incubation both in the absence and the presence of SDS average protofibril length is above 100nm, with larger 
protofibrils seen in the presence of SDS (n=21-28). Statistical analysis was carried out via unpaired T-test followed by 
Kolmogorov-Smirnov post-hoc test. (**=P< 0.01, ****=P<0.0001)  
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4.2.3. Ab-mediated neurotoxicity 
 
Once protofibril formation was verified, the cytotoxic effects of both Ab1-42 and Ab42-
1, via monitoring changes in cell (metabolic) activity, were investigated on both 
undifferentiated and RTA-differentiated SH-SY5Y cells via XTT assay. Studies suggest 
that Ab can have neurotrophic or neurotoxic effects dependent on the concentration, 
with neurotrophic effects typically seen at lower (~pM) concentrations (Luo et al., 1996; 
Plant et al., 2003; Pearson and Peers, 2006; Garcia-Osta and Alberini, 2009). Therefore, 
for the purpose of this study, a range of concentrations (1nM - 10µM) were tested over 
a 24hr treatment to test for neurotoxicity.  
In undifferentiated SH-SY5Y cells a concentration-dependent neurotoxic effect was 
seen with protofibrillar Ab1-42 from nM to µM range. A significant reduction by 21.2 ± 
6.1% (n=11; P<0.05) and 23.9 ± 6.8% (n=8; P<0.01) in cell activity was seen with 3 and 
10µM Ab1-42 respectively (Fig. 4.2.3.1A). A significant change in cell activity with Ab1-42 
treatment was also seen in differentiated cells, although only 10µM Ab1-42 treatment 
caused a significant reduction in activity (36.2 ± 11.6%; n=3; P<0.01) (Fig. 4.2.3.2A). A 
more gradual reduction in cell activity was noted (HillSlope: 0.4 ± 0.2) in differentiated 
compared to undifferentiated cells  (HillSlope: 0.7 ± 0.3) (P<0.05) (Fig. 4.2.3.1D and 
4.2.3.2D), suggesting that differentiated cells are less susceptible to protofibrillar Ab1-42  
induced cytotoxicity. 
Treatment of undifferentiated cells with non-aggregated Ab1-42 also demonstrated 
a degree of cytotoxicity, with 10µM Ab1-42 significantly reducing cell activity by 21.6 ± 
6.6%; n=5; P<0.05) (Fig. 4.2.3.1B). On the other hand, within differentiated cells, no 
significant changes in cell activity was observed with non-aggregated Ab1-42 (n=3) (Fig. 
4.2.3.2B). In contrast to protofibrillar Ab1-42, no significant difference in cell activity was 
observed in undifferentiated cells (HillSlope: 0.6 ± 0.3) compared to differentiated cells 
(HillSlope: 0.3 ± 0.2) treated with non-aggregated Ab1-42 (Fig. 4.2.3.1D and 4.2.3.2D). 
Lastly, the effect of the reverse sequence (Ab42-1) as a negative control was also 
investigated in SH-SY5Y cells. No significant change in cell activity was observed in either 
undifferentiated (n=4) or differentiated (n=3) cells (Fig. 4.2.3.1C and 4.2.3.2C). 
In order to determine whether the effect of the reverse sequence on SH-SY5Y cells 
is cell-specific, the effect of Ab42-1  was also investigated on a murine microglia cell line 
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(BV2), which is widely used in both the wider neuroscience field and for Alzheimer’s 
research (Stansley, Post and Hensley, 2012). In agreement with findings in SH-SY5Y cells, 
within BV2 cells, Ab42-1 at concentrations ranging from 0.1nM to 100nM had no 
significant effect on BV2 cell activity (Fig. 4.2.3.3). By contrast, the positive control 






























































Figure 4.2.3.1: Aβ mediated cytotoxicity in undifferentiated neuroblastoma cells. The effect of Aβ was investigated 
in undifferentiated SH-SY5Y cells via XTT assay. (A) Protofibrillar Aβ1-42 significantly reduced cell activity at 3 and 10μM 
(24hr; n=8-17). (B) Non-aggregated Aβ1-42 significantly reduced activity at 10μM only (24hr; n=5). (C) The reverse 
sequence, Aβ42-1 did not cause any changes in cell activity of undifferentiated SH-SY5Y cells (24hr; n=4). (D) HillSlope 
analysis for protofibrillar Aβ1-42 (graph A) and non-aggregated Aβ1-42 (graph B). Data (mean ±SEM) were normalised 
to the corresponding vehicle control (PBS). Statistical analysis was carried out via One-way ANOVA and post-hoc Tukey 






































Figure 4.2.3.2: Aβ mediated cytotoxicity in differentiated neuroblastoma cells. The effect of Aβ was investigated in 
differentiated SH-SY5Y cells via XTT assay. (A) Protofibrillar Aβ1-42 significantly reduced cell activity at 10μM only (24hr; 
n=3). (B) Non-aggregated Aβ1-42 did not cause any significant change in cell activity (24hr; n=3). (C) The reverse 
sequence Aβ42-1 did not cause any changes in cell activity of differentiated SH-SY5Y cells (24hr; n=3). (D) HillSlope 
analysis for protofibrillar Aβ1-42 (graph A) and non-aggregated Aβ1-42 (graph B). Data (mean ±SEM) were normalised 














































Figure 4.2.3.3: Aβ mediated cytotoxicity in microglia cells. The effect of Aβ42-1 was investigated in BV2 murine 
microglia cells via XTT assay.  Aβ42-1 (24hr; n=4) did not cause any changes in BV2 cell activity. Data (mean ±SEM) were 
normalised to the corresponding vehicle control (PBS). Statistical analysis was carried out via One-way ANOVA and 
post-hoc Tukey test. (**=P<0.01) 
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4.2.4. Ab1-42 mediated changes in VGCC expression 
 
Previously, mRNA for VGCCs in both undifferentiated and RTA-differentiated SH-
SY5Y cells were detected (see Chapter 3), with differences in gene expression 
dependent on the differentiation state of the cells. Following a 24hr exposure to either 
100nM (n=6) or 1µM (n=3) Ab1-42, undifferentiated SH-SY5Y cells showed no fold-
changes in mRNA expression of Cav1.2, Cav1.3, Cav2.2 and Cav3.1 (Fig. 4.2.4.1 and 
4.2.4.2), assessed via qPCR. By contrast, treatment of differentiated cells with 100nM 
Ab1-42 caused a significant reduction in Cav1.3 mRNA expression of 0.2 ± 0.04 fold-
change (n=5; P<0.01) (Fig. 4.2.4.3). Whereas treatment of differentiated cells with 1µM 
Ab1-42 led to a significant increase in Cav1.2 mRNA expression of 0.8 ± 0.2 fold-change 
(n=3; P<0.05) (Fig. 4.2.4.4). No change in the mRNA expression of Cav2.2 and Cav3.1 
was seen in differentiated cells treated with either Ab1-42 concentrations. 
In order to identify whether the mechanism by which Ab1-42 causes reduction in cell 
(metabolic) activity involves VGCCs, Ab1-42 cytotoxicity was studied in the presence of 
various CCBs, assessed via changes in cell activity through MTT assay (Fig. 4.2.4.5A-B). 
Ab1-42 (3µM) alone caused a 44.5 ± 8.3% (n=5; P<0.001) and 42.8 ± 5.6% (n=5; P<0.0001) 
reduction in activity within undifferentiated and differentiated cells, respectively. 
Treating both undifferentiated and differentiated SH-SY5Y cells with 3µM Ab1-42 in the 
presence of selective-VGCC blockers, had no significant effect on Ab-mediated 
cytotoxicity. Also, no significant change in toxicity was seen when differentiated cells 
were treated with Ab1-42 in the presence of the global-VGCC blocker CdCl2 (10µM) (47.7 
± 5.6%; n=5) in comparison to 3µM Ab1-42 (42.8 ± 5.6%; n=5) alone (Fig. 4.2.4.5B). In 
contrast to differentiated cells, within undifferentiated cells, the combination of 3µM 
Ab1-42 and 10µM CdCl2 led to an additional 34.9 ± 8.3% (n=5; P<0.01) reduction in cell 
activity (Fig. 4.2.4.5A). The positive control 10mM H2O2 caused a 97.9 ± 8.3% (n=5; 
P<0.0001) and 98.9 ± 5.6% (n=5; P<0.0001) reduction in undifferentiated and 


































Figure 4.2.4.1: Modulation of neuronal VGCC mRNA expression in undifferentiated SH-SY5Y cells by 100nM 
protofibrillar Aβ1-42. Changes in VGCC mRNA expression by Ab1-42 were investigated via qPCR. Exposure to 100nM 
Aβ1-42 (n=6) for 24hr did not cause any change in (A) Cav1.2, (B) Cav1.3, (C) Cav2.2 and (D) Cav3.1 mRNA expression 
in undifferentiated cells, as compared to vehicle control (PBS) treated cells. Data (mean ±SEM) were normalized to 
































Figure 4.2.4.2: Modulation of neuronal VGCC mRNA expression in undifferentiated SH-SY5Y cells by 1µM 
protofibrillar Aβ1-42. Changes in VGCC mRNA expression by Ab1-42 were investigated via qPCR. Exposure to 1μM Aβ1-
42 (n=6) for 24hr did not cause any change in (A) Cav1.2, (B) Cav1.3, (C) Cav2.2  and (D) Cav3.1  mRNA expression in 
undifferentiated cells, as compared to vehicle control (PBS) treated cells. Data (mean ±SEM) were normalized to β-


































Figure 4.2.4.3: Modulation of neuronal VGCC mRNA expression in differentiated SH-SY5Y cells by 100nM 
protofibrillar Aβ1-42. Changes in VGCC mRNA expression by Ab1-42 were investigated via qPCR. Exposure to 100nM 
Aβ1-42 (n=5) did not cause any change in (A) Cav1.2, (C)  Cav2.2 and (D)  Cav3.1  mRNA expression within 
differentiated SH-SY5Y cells. (B) A significant reduction in Cav1.3 mRNA expression was seen. Data (mean ±SEM) 






















Figure 4.2.4.4: Modulation of neuronal VGCC mRNA expression in differentiated SH-SY5Y cells by 1µM 
protofibrillar Aβ1-42. Changes in VGCC mRNA expression by Ab1-42 were investigated via qPCR. (A) Exposure to 
1μM Aβ1-42 (n=3) caused a significant increase in Cav1.2 mRNA expression within differentiated SH-SY5Y cells. No 
changes in mRNA expression of (B) Cav1.3, (C) Cav2.2 and (D) Cav3.1 was seen. Data (mean ±SEM) were 
































Figure 4.2.4.5: Calcium channel blocker effect on protofibrillar Aβ-mediated changes in cell activity. Protofibrillar 
Aβ1-42 neurotoxicity in undifferentiated and differentiated SH-SY5Y cells was evaluated in the presence of calcium 
channel blockers, via MTT assay. (A) Within undifferentiated SH-SY5Y cells, 3μM Aβ1-42 in the presence of CdCl2 
demonstrated a significant reduction in cell activity, whereas Aβ1-42 in the presence of more selective-CCBs did not 
show any additional reduction in activity (24h; n=5). (B) Within differentiated SH-SY5Y cells, no additional reduction in 
activity was seen when cells were treated with 3μM Aβ1-42 in the presence of the global-CCB CdCl2 and the more-
selective CCBs (24h; n=5). Data (mean ±SEM) were normalised to their corresponding vehicle control. Statistical 
analysis was carried out via One-way ANOVA and post-hoc Tukey test. (**=P<0.01, ***=P<0.001, ****=P<0.0001) 
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4.2.5. Ab1-42 -mediated mechanism of action 
 
Once protofibrillar Ab1-42 neuronal cytotoxicity and its effect on VGCCs was 
identified, the role of CO in preventing Ab1-42-mediated reduction in cell (metabolic) 
activity was investigated in SH-SY5Y cells of both differentiation states via MTT assay.  
To investigate whether CORM2 can reduce Ab1-42-mediated reduction in cell activity 
through a change in peptide aggregation, prior to cell treatment, Ab1-42 was left to 
aggregate (48hr) in the presence of CORM2 (using methodology described by De Simone 
et al. 2019). Protofibrillar 4µM Ab1-42 alone caused a 44.0 ± 2.9% (n=4; P<0.0001) 
reduction in undifferentiated SH-SY5Y cell activity. Although at the concentrations 
tested, direct interaction of CORM2 with the peptide could not be excluded, no change 
in Ab1-42-mediated cytotoxicity was observed when undifferentiated SH-SY5Y cells were 
treated with 4µM Ab1-42 left to aggregate in the presence of CORM2 at 0.5 (39.3 ± 2.9%; 
n=4) and 2.5 (37.4 ± 2.9%; n=4) concentration ratio. Also, no significant change in 
cytotoxicity was also seen when cells were treated with Ab1-42 left to aggregate in the 
presence of iCORM2 at a 2.5 concentration ratio (38.4 ± 3.2%; n=3) compared to Ab1-42 
alone. The positive control 10mM H2O2 caused a 98.3 ± 2.9% (n=4; P<0.0001) reduction 
in cell activity (Fig. 4.2.5.1). 
When undifferentiated cells were treated with 3µM Ab1-42  in combination with 1 or 
10µM CORM2 no significant change in Ab1-42 -mediated cytotoxicity (47.7 ± 4.1%; n=4 
and 46.5 ± 4.1%; n=5 respectively) was observed compared to treatment with Ab1-42  
alone (49.6 ± 4.1%; n=5; P<0.0001). No significant change in Ab-mediated toxicity was 
also seen when undifferentiated cells were treated with Ab1-42 in combination with 1 or 
10µM iCORM2 (48.9 ± 4.1%; n=5 and 50.0 ± 4.1%; n=5 respectively). Treatment of cells 
with the positive control 10mM H2O2 led to 97.8 ± 4.4% (n=5; P<0.0001) reduction in cell 
activity (Fig. 4.2.5.2A).  
When differentiated SH-SY5Y cells were treated with 3µM Ab1-42  in combination 
with 1 or 10µM CORM2 no significant change in toxicity (28.7 ± 1.1%; n=4 and 28.4 ± 
1.9%; n=5 respectively) was observed compared to treatment with Ab1-42  alone (31.0 ± 
6.7%;n=5; P<0.01). No significant change in Ab-mediated toxicity was also seen when 
undifferentiated cells were treated with Ab1-42 in combination with 1 or 10µM iCORM2 
(29.7 ± 2.2%; n=5 and 29.1 ± 2.2%; n=5 respectively). Treatment of cells with the positive 
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Figure 4.2.5.1: Effect of CO on protofibrillar Aβ1-42 mediated neurotoxicity. Protofibrillar Aβ1-42 neurotoxicity in 
undifferentiated SH-SY5Y cells was evaluated in the presence of CORM2/iCORM2, via MTT assay. Prior to treating 
the cells, Aβ1-42  was left to aggregate in the presence of CORM2 at 0.5 and 2.5 ratio. In undifferentiated SH-SY5Y 
cells CO was unable to prevent changes in cell activity induced by 4μM Aβ1-42 (24h; n=4). Data (mean ±SEM) were 
normalised to their corresponding vehicle control. Statistical analysis was carried out via One-way ANOVA and 










































Figure 4.2.5.2: Effect of CO in combination with protofibrillar Aβ1-42 on neuronal cell activity. Protofibrillar Aβ1-42 
neurotoxicity in undifferentiated and differentiated SH-SY5Y cells was evaluated in the presence of CORM2/iCORM2, 
via MTT assay.  In both (A) undifferentiated and (B) differentiated SH-SY5Y cells CO, via CORM2, was unable to 
prevent changes in cell activity induced by 3μM Aβ1-42 (24h; n=5). Data (mean ±SEM) were normalised to their 
corresponding vehicle control. For undifferentiated SH-SY5Y cells, statistical analysis was carried out via One-way 
ANOVA and post-hoc Tukey test. For differentiated SH-SY5Y cells, statistical analysis was carried out via unpaired 




Ab Fibrillization  
 
• Pre-treatment of Ab1-42 in NH4OH led to complete dissolution of the peptide, and time-dependent 
protofibril formation. 
• Allowing Ab1-42  to aggregate in the presence of SDS led to larger in length protofibrils formed. 
• The reverse sequence (Ab42-1) was unable to undergo aggregation and consequently protofibril 
formation. 
 
In the present study, NH4OH treatment of Ab1-42 peptide followed by exposure to 
NaOH led to the complete dissolution of the peptide, and a time-dependent formation 
of Ab1-42 protofibrils. Numerous protocols have been reported for preparing and 
inducing aggregation of Ab into protofibrils (Nicoll et al., 2013; Ryan et al., 2013; 
Hettiarachchi et al., 2014). Alkalines such as NH4OH, have been widely used to pre-treat 
the peptide followed by dissolving the peptide film in NaOH for preparing Ab for 
aggregation (Barghorn et al., 2005; O’Nuallain et al., 2010; Ryan et al., 2013). The basic 
pH of NH4OH and NaOH ensure Ab is fully solubilized and kept in its monomeric state in 
preparation for subsequent aggregation, therefore ensuring no variability between Ab 
preparations which could impact degree of aggregation and subsequent experimental 
findings when investigating Ab cytotoxicity (Shirahama and Cohen, 1967; Fezoui et al., 
2000). In agreement to findings from this study, work done by Ryan et al. (2013) have 
proven that pre-treating human synthetic Ab1-42 in NH4OH leads to the formation of 
stable aggregates with a low degree of variability and consistent in vitro cytotoxicity. 
The current study revealed that using the NH4OH protocol, protofibril formation was 
evident as early as 24hr, with larger protofibrils in length seen by 48hr. Work done by 
other groups such as Nicoll et al. and Walsh et al.  provide further support to findings in 
this study by demonstrating a time-dependent aggregation of Ab1-40/1-42 into protofibrils 
under similar timeframes. Whereas, longer than 72hr incubation has been reported to 
lead to the formation of larger assemblies such as mature fibrils, identified via ThT assay 
(Walsh et al., 1999; Nicoll et al., 2013). In addition to the use of monomeric Ab1-42 (at 
0hr incubation period), we have also used the Ab reverse sequence (Ab42-1). In our study, 
supported by previous research (Paradis et al., 1996; Takuma et al., 2004), Ab42-1 failed 
to aggregate using the NH4OH protocol followed by a 48hr incubation. In contrast to use 
of NH4OH or the HFIP/DMSO protocol, Hettiarachchi et al. (2014) demonstrated that 
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synthetic human Ab1-42 dissolved in fresh DMEM media and incubated over 24hr can 
also lead to the formation of protofibrillar Ab1-42 structures ranging from 25 - 90nm in 
length. 
Although in the current study NH4OH was used for generating stable and consistent 
protofibril Ab1-42 preparations, a number of other studies have used HFIP for preparing 
Ab for aggregation and investigating cytotoxicity (Rangachari et al., 2006; Ryan et al., 
2010; Pachahara et al., 2012; Tamagnini et al., 2015). The present study revealed that 
although pre-treatment of the peptide using HFIP indeed led to protofibril formation 
after just a 2hr incubation, as described elsewhere (Tamagnini et al., 2015), HFIP 
generated protofibrils were of similar structure and length as those observed with 
NH4OH after 24hr. While it has been suggested that HFIP pre-treatment ensures Ab is 
entirely monomeric in preparation for aggregation, previous observations have 
reported that HFIP-prepared Ab can lead to premature Ab aggregation, evident by the 
formation of false ‘enhanced’ Ab aggregates, such as protofibrils and fibrils which would 
not normally form immediately post-preparation (Pachahara et al., 2012). In support of 
this, in the current study, presence of protofibrils was evident as early as with 2hr 
incubation. This may be explained by taking into consideration the effect of the pH of 
the solvent on peptide aggregation. In contrast to using NH4OH/NaOH, HFIP can alter 
pH levels to the acidic pH of Ab which can promote aggregation (Wood et al., 1996; Ryan 
et al., 2013). Previous observations also suggest that the NH4OH protocol leads to the 
formation of stable aggregates with a lower degree of variability and higher in vitro 
cytotoxicity compared to the HFIP protocol  (Ryan et al., 2013). In agreement, our work 
has revealed that NH4OH-prepared Ab  followed by a 48hr incubation creates larger 
protofibrils, with low degree of variability in protofibil length between Ab preparations. 
Moreover, due to concerns with adding DMSO in the final Ab preparation, such as 
DMSO-dependent cytotoxicity, and DMSO reported interference with Ab aggregation 
and oxidative mechanisms (Shen and Murphy, 1995; Kahler, 2000; Hanslick et al., 2009; 
Broersen et al., 2011), the NH4OH/NaOH protocol is considered more appropriate in 
studying Ab protofibril-dependent in vitro cytotoxicity. Due to all these observations, all 
subsequent experiments in this study focused on investigating the effects of protofibril 
Ab1-42 generated by the NH4OH-48hr protocol.  
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Recently, there has been considerable interest in investigating how membrane 
mimetics, such as SDS, may influence peptide aggregation (Shao et al., 1999; Wahlström 
et al., 2008; Pedersen et al., 2020). Research has shown that both synthetic human Ab1-
40/1-42 and recombinant Ab can aggregate from monomers into oligomers and larger 
aggregates when co-incubated with cells (Podlisny et al., 1998; Shao et al., 1999; 
Khondker, Alsop and Rheinstädter, 2017). These findings suggest that the interaction of 
Ab with the cell lipid bilayer may enhance peptide aggregation. In line with this, 
recently, AD has been linked to altered lipid content, such as an increase in neuronal 
membrane lipid raft composition which is known to influence APP processing and Ab 
aggregation (Rushworth and Hooper, 2011). This suggests that changes within the lipid 
membranes consists part of the AD pathology. Therefore, mimicking the 
microenvironment of biological membranes through the inclusion of negatively-charged 
SDS, capable of forming lipid micelles with an anionic surface, similarly to adding 
physiological fatty acids such as arachidonic and lauric acid, can influence peptide 
folding and aggregation.  This may allow the study of Ab aggregation and cytotoxicity in 
a manner which more closely represents the in vivo situation (Mattice, Riser and Clark, 
1976; Shao et al., 1999; Yamamoto et al., 2004; Barghorn et al., 2005; Wahlström et al., 
2008; Pedersen et al., 2020). In the present study, SDS was shown to enhance Ab1-42 
aggregation, evident by larger protofibrils formed. Currently there is contradictory 
evidence with respect to the use of SDS in Ab studies (Shao et al., 1999; Barghorn et al., 
2005; Wahlström et al., 2008). Some studies suggest that SDS micelles which mimic the 
cell lipid bilayer, work by stabilizing the a-helix conformation of Ab, a secondary 
structure favoured in monomeric Ab, therefore preventing peptide aggregation (Shao 
et al., 1999; Rangachari et al., 2006). In contrast, other studies, similar to results from 
the current study, suggest that SDS induces aggregation, possibly through a 
conformational change from random coils into b-sheets, a secondary structure which is 
favoured for peptide aggregation (Barghorn et al., 2005; Wahlström et al., 2008). A 
possible explanation for contradictory results could be that the effect of SDS on the Ab 
secondary structure and subsequent role in peptide folding and aggregation could be 
different dependent on SDS concentration used (Shao et al., 1999; Barghorn et al., 2005; 
Rangachari et al., 2006; Wahlström et al., 2008).  
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Taken together, evidence from the current study indicates that pre-treatment of 
human Ab1-42 with NH4OH leads to a time-dependent protofibril formation, with low 
variability between Ab preparations. Moreover, low levels of SDS can act as an 
aggregation and nucleation inducer potentially through stabilising changes in the Ab’s 
conformational structure. Therefore, NH4OH pre-treatment of Ab1-42, and use of SDS, 
leads to the generation of Ab1-42 protofibrils structurally and functionally similar to those 


























Ab effect on neuronal viability 
• High µM concentrations of protofibrillar Ab1-42 caused a significant reduction in cell activity of SH-
SY5Y cells of both differentiation states. 
• Reduction in cell activity could not be replicated with the reverse sequence (Ab42-1) in either SH-SY5Y 
of both differentiation states, or BV2 microglia cells. 
 
In the present study, protofibrillar Ab1-42, at a concentration-dependent manner, 
caused a significant reduction in cell (metabolic) activity of both undifferentiated and 
RTA-differentiated SH-SY5Y cells, which could not be replicated with the use of the 
reverse sequence (Ab42-1). In support of this, several studies have proven that 
protofibrillar Ab1-42 can cause cell dysfunction through investigating early-apoptotic 
pathways (Walsh et al., 1999; Sandberg et al., 2010; Jan et al., 2011; Hettiarachchi et 
al., 2017). Previous research conducted in vivo (e.g. Ab injections in rodent hippocampi) 
and in vitro models have proven that aggregated (oligomeric and protofibrillar) Ab1-40/1-
42 at µM concentrations, similar to the concentrations used in the current study, can 
induce cell death at a concentration-dependent manner via a manner involving the 
activation of caspase 3 and 7 (Takuma et al., 2004; Sandberg et al., 2010). Another 
manner by which aggregated Ab, specifically fibrillar Ab1-40/1-42  has been suggested to 
induce apoptosis is through an increase in pro-apoptotic bax and decrease in anti-
apoptotic bcl-2 expression and  also through increasing neuronal susceptibility to 
oxidative-stress induced cell damage, which has also been linked to regulation of 
calcium homeostasis (Paradis et al., 1996).  A study conducted in SH-SY5Y 
neuroblastoma cells, although they failed to specify the size of the Ab aggregates, 
revealed 50-60% neuroblastoma loss with Ab1-42 incubation (50µM) through a pathway 
involving JNK activation (Wei, Wang and Kusiak, 2002). Although cell activity 
experiments carried out in the current study are not a direct measure of cell survival 
and degree of apoptosis, but more of a measure of metabolic activity, findings from 
previous studies support the present study where µM concentrations of protofibrillar 
Ab1-42 caused cell dysfunction by reducing SH-SY5Y activity, and therefore protofibrillar 
Ab1-42 was shown to act in a neurotoxic manner. Although in the current study nM 
concentrations of protofibrillar Ab1-42 did not alter SH-SY5Y activity, changes in the 
expression of proteins which can induce cell death with longer incubation periods 
cannot be excluded. In contrast to findings from this study, Dahlgren et al. (2002) noted 
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a 50% reduction in neuronal viability with 40nM oligomeric peptide, whereas fibrillar 
Ab1-42 induced similar degree of neurotoxicity at 10 times higher concentration. 
Similarly, Huang and Liu demonstrated that incubating SH-SY5Y cells with 10µM fibrillar 
Ab1-42 for 24hr, and then measuring cell activity via MTT, did not cause cell apoptosis at 
24hr but caused significant cell death following a 48hr incubation (Huang and Liu, 2015). 
Differences in degree of toxicity seen with protofibrillar Ab treatment in this study 
compared to other studies could be due to differences in the Ab aggregates used.  
Findings from the current study and the literature prove that smaller aggregates such 
as oligomers and protofibrils are more cytotoxic than fibrillar Ab. In support of this, 
another study revealed a 60% reduction in viability of neuro-2A neuroblastoma cells 
with 20µM oligomeric Ab1-42 treatment, whereas fibrillar Ab1-42 caused significantly less 
toxicity, hence demonstrating that smaller Ab aggregates are more toxic-potent (Tizon 
et al., 2010). Similar effects by oligomeric and fibrillar Ab1-42 were observed in primary 
rat hippocampal neurons, although lower concentration of Ab1-42 were needed to 
induce toxicity (Tizon et al., 2010). This suggesting that hippocampal neurons, as 
primary terminally differentiated neurons show higher susceptibility to Ab-induced 
cytotoxicity. In contrast to Tizon et al., our study suggests that although higher degree 
of toxicity was seen in differentiated cells with 10µM Ab1-42, a more gradual reduction 
in cell activity was seen in differentiated compared to undifferentiated cells. Differences 
in the Ab1-42 assembly used could be responsible for differences in the toxicity observed 
between studies. In contrast, another study demonstrated that co-incubation of rat 
primary cortical neurons with protofibrillar Ab caused a significant reduction in viability 
with as low as 2hr treatment (Walsh et al., 1999). Even though 20% reduction in viability 
was observed with less that 24hr treatment, concentrations higher than ~20µM were 
needed to achieve cell death (Walsh et al., 1999). In our study, similar to other studies 
such as Jan et al. (2011) and Hettiarachchi et al. (2014) on SH-SY5Y cells, an approximate 
30% reduction in cell activity was observed with protofibrillar Ab1-42 incubation with 3-
7 times lower concentrations, although a longer treatment duration was needed. 
Interestingly, Jan et al. reported a reduction in degree of neurotoxicity when Ab1-42 
monomers were removed from the protofibrillar preparation (Jan et al., 2011). This 
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suggests that Ab toxicity is not dependent on just one type of Ab assembly, but a 
combination of Ab assemblies are needed to induce maximum degree of toxicity. 
 In the current study, although non-aggregated (monomeric) Ab1-42 was expected 
to not change SH-SY5Y activity, 10µM Ab1-42 caused reduction of undifferentiated SH-
SY5Y activity. Agreeing with results from this study, observations from other studies 
reveal that monomeric Ab1-42 either does not have any effect on neuronal function, or 
marginally induces an increase in caspase activity (Podlisny et al., 1995; Shao et al., 
1999; Sandberg et al., 2010). The reduction in cell activity noted by non-aggregated Ab1-
42 in our study and the literature, may be justified by some degree of unavoidable 
aggregation when cells are co-incubated with the peptide, as it is known that exposure 
of Ab to cell cultures can promote peptide aggregation. In contrast to our work, 
Dahlgren et al. (2002), showed that monomeric Ab1-42 at nM concentrations not only 
does not confer neurotoxicity, but it displayed neurotrophic properties, identified via 
MTT assay performed on mouse neuro-2A neuroblastoma cells. 
Agreeing with the notion that the reverse sequence as it cannot undergo 
aggregation it therefore cannot induce cytotoxicity, previous observations from other 
studies (Paradis et al., 1996; Wei, Wang and Kusiak, 2002; Takuma et al., 2004) are in 
support to findings from the current study where Ab42-1 did not change BV2 microglia or 
SH-SY5Y cell activity. This proves that the reverse Ab sequence can be used as an inactive 
control in AD research.  
Taken together, although cell metabolic activity experiments carried out in the 
current study are not a direct measure of cell death, findings from this study prove that 
acute treatment with protofibrillar Ab1-42, although high µM concentrations are needed, 
can indeed cause neurotoxicity through changes in SH-SY5Y cell activity. The 
observation that no changes in either BV2 microglia or SH-SY5Y cell activity was seen 
when cells were treated with Ab42-1, which cannot undergo aggregation, proves that 






Ab -mediated changes in neuronal VGCCs 
 
• Dependent on concentration, protofibrillar Ab1-42 altered Cav1 a1 mRNA expression in differentiated 
SH-SY5Y cells. 
• Protofibrillar Ab1-42 at 1µM caused a significant increase in Cav1.2 mRNA expression, whereas a 
significant reduction in Cav1.3 mRNA expression was seen with 100nM Ab1-42. 
• Use of a global and selective CCBs were unable to prevent Ab1-42 -mediated changes in SH-SY5Y cell 
activity. 
 
The current study has shown that protofibrillar Ab1-42, dependent on 
concentration, impairs calcium homeostasis through selective changes in differentiated 
SH-SY5Y Cav1 mRNA expression. The use of selective CCBs demonstrated that they were 
unable to suppress Ab1-42 -mediated neurotoxicity. Ab is known to modulate VGCC-
dependent intracellular Ca2+ levels in distinct ways; (i) changing the kinetics of calcium 
currents, (ii) changing the expression of  specific VGCC subunits, and (iii) altering channel 
trafficking to the cell membrane (Chiou, 2006; Anekonda et al., 2011; Gholamipour-
Badie et al., 2013). 
Findings from this study indicate a significant increase in transcript expression 
for Cav1.2 with 1µM protofibrillar Ab1-42 treatment. Although in the current study we 
were unable to investigate whether this change in gene expression translates to a 
changes a protein level due to issues with the Cav-antibodies available (antibody 
specificity, no robust signal), work from previous studies indicate Ab-mediated changes 
in VGCC expression at protein level as well. Coon et al. revealed an upregulation in 
hippocampal Cav1 channel expression in brains from individuals diagnosed with AD 
(Coon et al., 1999). As this change in Cav1 expression was localised in areas of extensive 
neuronal loss, it was suggested that Cav1 channels are important in maintaining 
neuronal survival and that altered expression of VGCCs seen in AD could be responsible 
for activating pathways that induce neuronal apoptosis. In contrast to Cav1.2 
upregulation at transcript level, the current study revealed that lower concentrations of 
protofibrillar Ab1-42 (100nM), which more closely represent Ab physiological levels, 
caused a significant downregulation in Cav1.3 transcript expression. This is the first 
study to suggest differential effects of protofibrillar Ab1-42 on Cav1 expression 
dependent on the Ab concentration. Although Coon et al. findings suggest an increase 
in global Cav1 expression in AD brains through CCB-autoradiography binding 
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experiments, it failed to address which Cav1 subfamily members Ab causes an 
upregulation of.  
Cav1 channels have been linked to neuronal survival and apoptosis. One manner 
by which changes in Cav1 activity can cause neuronal death is through activation of 
CAMKKII and phosphorylation of AMPK leading to caspase activation (Hettiarachchi et 
al., 2014). Work done by Hettiarachchi et al. (2014) revealed that this apoptotic 
mechanism can be blocked by nifedipine, hence proving that protofibrillar Ab1-42 
increases Cav1 activity and consequently Ca2+ influx, which may occur through changes 
in the expression of Cav1 channels. Release of ROS which then activates NF-kB, 
consequently causing an upregulation in Cav1 a1 subunit expression and subsequent 
increase in Cav1 conductance has been proposed as a pathway that aggregated Ab  can 
cause increase in Ca2+ influx (Green and Peers, 2002; Chiou, 2006). In contrast to the 
current study, work done by Chiou (2006) suggests that aggregated 20µM Ab25-35 not 
only causes an upregulation in both gene and protein expression of the a1 subunit of 
Cav1.2, but also of Cav2.1 and Cav2.2. Contradictory findings in regards to changes in 
Cav1.3 and Cav2 expression between the current study and Chiou (2006) could be due 
to a number of differences in the methodologies, for example the species, assembly and 
the concentration of Ab used. Additionally, within the present study, changes in mRNA 
expression of Cav1 channels where only noted in RTA-differentiated SH-SY5Y cells, 
whereas Chiou investigated changes in VGCC expression in only undifferentiated SH-
SY5Y cells which represent a pre-mature neuronal phenotype. It has been suggested 
that APP can form a direct protein-protein interaction with Cav1.2, consequently 
reducing Cav1.2 trafficking to the membrane (Yang et al., 2009). This suggests that 
reduction in APP, due to increased APP processing into Ab, may be responsible for the 
noted increase in Cav1.2 expression at the functional level, and not gene level, seen in 
some studies. In addition, Kim and Rhim (2011) revealed that 25nM Ab25-35 treatment 
led to an increase in the presence of functional Cav1.2 and Cav1.3 channels at 
hippocampal cell membranes. Moreover, the increase in Cav1.2 expression could also 
be linked to an increase at gene level. This suggests, that Ab may not only alter the 
expression of the a1 pore-forming subunits, which were investigated in the current 
study, but may also act through changing the expression or direct interaction with the 
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VGCC accessory subunits which are responsible for the transport of the channels to the 
membrane, and hence changing the number of Cav functional channels present at the 
membrane. In support of this, evidence from co-immunoprecipitation experiments 
revealed that treatment of Cav1.3 (containing a1D and b3 subunits) transfected HEK293 
cells with Ab25-35 caused a marked increase in both Cav1.3 amplitude and conductance, 
achieved through direct interaction with the b3 subunit (Kim and Rhim, 2011).  
Although work done in this study clearly suggest Ab-mediated calcium 
dyshomeostasis through changes in Cav1 expression at transcript level, the impact of 
such changes on neuronal function are yet to be resolved. Both Cav1.2 and Cav1.3 are 
known to have roles in neuronal excitability and neuronal firing (McKinney et al., 2009; 
Liu et al., 2014). Therefore, the noted increase in Cav1.2 expression at a gene level in 
this study, if translated to an upregulation at protein level, may suggest an increase in 
neuronal excitability and firing. Although a number of studies have linked AD to a 
reduction in neuronal and overall synaptic function, pre-clinical and early-stages AD 
reveal neuronal hyperexcitability (Busche et al., 2008, 2012; Busche and Konnerth, 
2015; Kazim et al., 2017). Thus, this suggests a critical role for Cav1.2 at early stages of 
the disease. Additionally, Cav1.2-dependent Ca2+ influx has also been linked to CREB-
dependent gene transcription of genes with roles in synaptic function, neuronal 
proliferation, differentiation, and neuronal survival (Moosmang et al., 2005; 
Marschallinger et al., 2015). Therefore, in further support of an upregulation of Cav1.2 
at early-stages of the disease, increase in CREB-dependent activation of genes linked to 
synaptic activity and plasticity may cause the reported neuronal hyperactivity. Cav1.3 
has also been shown to have a role in dentritic spine morphology and stability (Stanika, 
Flucher and Obermair, 2015; Stanika et al., 2016). A reduction in Cav1.3 in this study 
may suggest structural changes in dendrites which could impair long-term potentiation 
and overall synaptic activity (McKinney et al., 2009). In addition, adult neurogenesis, a 
process important in learning and memory, has also been shown to be regulated by Ca2+ 
influx through Cav1.3 (Marschallinger et al., 2015). The reduction in Cav1.3 expression 
shown by treatment with protofibrillar Ab1-42 in this study may explain the cognitive 
deficits due to impaired neurogenesis seen at early stages of Alzheimer’s disease (Scopa 
et al., 2020). 
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It is widely accepted that not only pathological conditions, but also normal 
ageing can alter the expression of Cav1 channels, seen in studies on animal models and 
post-mortem tissue (Blalock et al., 2003; Thibault et al., 2012; Nunez-Santana et al., 
2014). Consequently, there is a considerable interest in investigating whether 
pathological conditions such as AD may induce changes in VGCC expression different 
than those seen during normal ageing. Work done by Nunez-Santana demonstrated an 
increase in the presence of both Cav1.2 and Cav1.3 on the cell surface of hippocampal 
neurons (Nunez-Santana et al., 2014). Although an increase in functional Cav1 channels 
was observed, this was not due an upregulation at transcript level (Nunez-Santana et 
al., 2014). Despite Nunez-Santana et al. not observing any changes in the mRNA 
expression of specific Cav1 members, their study focused on identifying changes in 
VGCC expression during normal ageing. Therefore, this suggests that during normal 
ageing, compared to pathological conditions such as AD, other factors may be 
responsible for changes in VGCC expression at the functional level such as post-
translational modifications, or changes in neuronal excitability. 
In further support of an important role for Cav1 channels at early-stages of AD 
pathology, Gholamipour-Badie and colleagues, through behavioural experiments 
revealed that the Cav1 CCBs nimodipine and isradipine were beneficial in reducing the 
decline of learning and memory in Wistar rats which were induced by Ab1-42 injections 
in the endorhinal cortex (Gholamipour-Badie et al., 2013). Block of  Cav1 channels by 
these CCBs led to a downregulation of calpain-2 at protein level, and subsequent 
reduction in caspase-12 and -3 protein expression, therefore reducing synaptic loss and 
neuronal apoptosis (Gholamipour-Badie et al., 2013). In further support of Cav1 
channels role in neuronal survival, Anekonda et al. (2011) revealed that isradipine, 
reduced oligomeric Ab1-42 -mediated neurotoxicity in APP-stably transfected MC65 
neuroblastoma cells, although this occurred through a caspase-3 independent pathway. 
Similar to our study, oligomeric Ab1-42 was found to increase Cav1-dependent Ca2+ influx 
via a 2-fold upregulation of Cav1.2 mRNA expression, with a delayed increase in protein 
level seen by 72hr (Anekonda et al., 2011). Ueda and colleagues revealed that 
incubation of both cortical and hippocampal neurons with protofibrillar 10µM Ab25-35 
increased Ca2+ influx, possibly through an upregulation in VGCC expression, which in 
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turn induced cell apoptosis through a ROS manner (Ueda et al., 1997). Agreeing with 
findings from the present study where no change in the Cav2.2 expression, and also use 
of Cav2 CCBs did not alter Ab-mediated changes in cell activity, Ueda et al. shown that 
3µM nimodipine significantly reduced both Ca2+ influx and cell death mediated by Ab25-
35, whereas blockers of Cav2.1 and Cav2.2 channels, at the concentrations tested, were 
largely non-effective against Ab-induced cell death (Ueda et al., 1997). In contrast to 
Ueda’s study, Brown et al. 2005, suggested that mitochondrial dysfunction and release 
of ROS precedes Ab-mediated changes in VGCC activity. This in turn, induces 
aggregation of Ab1-40 which then causes an increasing in Cav1.2 a1 subunit trafficking, 
increasing the number of functional channels present at the membrane and increasing 
overall Ca2+ influx (Brown et al., 2005). Differences in findings could be due to studying 
the effect of aggregated Ab in transfected- HEK293 cell line, compared to primary 
neurons which natively express VGCCs. Contradictory to other studies, Thibault et al., 
revealed that in hippocampal neurons of APP/PS1 mouse models of AD, a reduction in 
the activity of Cav1 currents is observed as compared to hippocampal neurons from 
control animals (Thibault et al., 2012).  Yagami et al. (2004), revealed that incubation of 
primary cortical neurons with 10µM aggregated Ab25-35 caused noted morphological 
changes and DNA damage, leading to 70% cell death by 48hr.  Whereas adding Ab25-35 
in combination with Cav1 CCBs S-312-d or nimodipine, significantly reduced the noted 
cell death (Yagami et al., 2004). These results further prove that Cav1 channels have a 
critical role in Ab-mediated neuronal death. On the other hand, similar to our study 
conducted on both undifferentiated and differentiated SH-SY5Y cells, treating primary 
cortical neurons with Ab25-35 and the Cav2 CCBs w-conotoxin-MVIIC/w-agatoxin-IVA 
(P/Q-type blockers) or w-conotoxin-GVIA (N-type blocker) did not reduce Ab25-35 -
mediated neurotoxicity (Yagami et al., 2004). This suggests that neuronal cell apoptosis 
induced by aggregated Ab occurs through a Cav1, but Cav2-independent pathway. In 
further support of Cav1 role in neuronal survival, use of the Cav1 CCB nimopridine can 
prevent Ab-mediated neuronal loss further proving that part of Ab’s mechanism of 
action involves Cav1 channels, possibly through inducing their activation (Ho, Ortiz and 
Shea, 2001). 
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Overall, evidence from the present study and the literature, points to an 
important role for Cav1 channels in AD pathology through changes in neuronal survival. 
Although in this study, changes in the mRNA expression of Cav1 channels were noted 
with protofibrillar Ab1-42 treatment, the effect of the peptide on Cav1 channels at the 
functional level was not investigated. Likewise, although protofibrillar Ab1-42 did not 
alter transcript expression of Cav2 and Cav3 channels, the effect of the peptide on 
channel conductance, or through direct interaction and changes in the expression of 
accessory subunits cannot be excluded. Differences in results obtained in this study 
compared to the literature could be due to variations in methodology, such as the Ab 
peptide concentration and species used, degree of aggregation, cell type investigated 































Effect of CO on Ab-mediated neurotoxicity 
 
• Treating SH-SY5Y cells with either Ab1-42 left to aggregate in the presence of CORM2, or with a 
combination of protofibrillar Ab1-42 and CORM2 did not alter Ab-mediated changes in cell activity. 
 
The current study demonstrates that allowing Ab1-42 to aggregate in the 
presence of CORM2, did not reduce Ab-mediated changes in undifferentiated SH-SY5Y 
cell (metabolic) activity. In addition, treating both undifferentiated and differentiated 
SH-SY5Y cells with a combination of protofibrillar Ab1-42 and CORM2, also did not alter 
Ab-mediated changes in cell activity.  
CORM molecules can directly interact with Ab through modification of specific 
amino acid residues. For example, Valensin et al. (2010) suggested a direct interaction 
of CORM3 with histidine (His) residues on the Ab1-28 peptide (His13 & His14), 
significantly reducing degree of cytotoxicity (Valensin et al., 2010). In support of this, 
Santos-Silva and colleagues also demonstrated that CORM3 is able to form protein 
adducts by direct interaction of the ruthenium (Ru) structure with His residues on the 
Ab peptide (Santos-Silva et al., 2011). Arispe et al., discovered that modulation of His 
residues of the Ab peptide, such as through the use of His-related compounds, 
prevented Ab pore formation on the membrane and subsequent calcium 
dyshomeostasis and cell death (Arispe, Diaz and Flora, 2008). Due to this, there has been 
considerable interest in identifying whether a potential Ru-Ab complex could potentially 
reduce some of the toxic effects of the peptide in vivo.  Building on these studies, De 
Simone et al. (2019) revealed that CORM3 can act as an anti-aggregator molecule 
through direct interaction of the CORM3 Ru structure with His residues of the peptide 
when Ab1-42 was left to aggregate in the presence of high non-physiological 
concentrations of CORM3 (250-500µM). Similarly, CORM2, which contains two Ru 
structures, was also shown to form CORM2/Ab1-42 stable adducts at a much lower 
CORM2/Ab1-42 molar ratio. ESI-mass spectrometry and ThT analysis revealed that in 
peptide preparations that contain CORM3 (1:1 ratio; 50µM), monomeric structures 
could still be detected by 48hr, whereas in the absence of CORM3 complete removal of 
monomeric structures is observed by 48hr  (De Simone et al., 2019). In our study, using 
the same methodology as the one used by De Simone et al. to let Ab1-42 aggregate in 
the presence of CORM2, did not protect SH-SY5Y cells from Ab1-42 -mediated changes in 
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cell activity. Although no changes in cytotoxicity were noted, direct interaction of 
CORM2 with the peptide could not be excluded. Differences in observations within our 
study and other studies could be due to differences in methodology such as the type 
and concentration of CORM, and also Ab concentration, species and assembly used. For 
example, De Simone et al., used Ab1-42 at concentrations as high as 50µM which do not 
correspond to physiological concentrations seen in vivo. Additionally, pre-treatment of 
Ab1-42 was carried out in HFIP, in contrast to NH4OH which was used in our study. 
Moreover, concentrations above 100µM of CORM2 tested by De Simone and colleagues 
do not correspond to physiological levels of CO. 
In addition to CORM2 (via its ruthenium structure) interfering with the 
aggregation process of Ab, Kim et al. (2019) was able to prove that CO is able to interfere 
with Ab production. Injection of CORM3 to 3xTg-AD animal models, significantly 
reduced the expression of BACE1 (b-secretase) at both mRNA and protein level through 
NF-kB binding BACE1, causing a reduction in  Ab production (Kim et al., 2019).  
In addition to CO demonstrating anti-aggregating properties, evidence suggests 
that CO may also exert anti-apoptotic effects. In the current study, CORM2 was unable 
to prevent Ab1-42 -mediated neurotoxicity. A number of pre-clinical studies conducted 
on animal models revealed that inhalation of physiological levels of CO, was able to 
protect further tissue damage by reducing neuronal loss in the hippocampus and the 
cortex, during times of restoration of oxygen flow following an ischemic stroke, possibly 
through an ion channel-dependent mechanism (Zeynalov and Doré, 2009; Mahan et al., 
2012). One pathway by which it may confer these anti-apoptotic effects, could be 
through increasing sGC activity, increasing NOS activity and NO production through an 
ion-channel manner (Vieira, Queiroga and Alves, 2008). As treatment with nM 
concentrations of oligomeric Ab1-42 have been linked to changes in the activity of sGC 
and subsequent expression of cGMP and phosphorylation of CREB, with can have 
detrimental effect in neuronal plasticity (Puzzo et al., 2005), CO’s effect on this pathway 
may prevent neuronal dysfunction and subsequent neuronal death seen in AD. 
Zuckerbraun et al. (2007) proposed a different pathway that CO may confer anti-
apoptotic effects via a mechanism involving mitochondria targeting. CO cytoprotection 
included inhibition of cytochrome c oxidase, release of ROS from mitochondria, and 
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lastly activation of p38, similar to the mode of action seen by the gasotransmitter nitric 
oxide (Zuckerbraun et al., 2007). Hettiarachchi et al. revealed that use of a selective and 
a pan-caspase blocker reduced protofibrillar Ab1-42 cytotoxicity, suggesting that 
activating pro-apoptotic pathways via caspases is part of the manner by which 
protofibrillar Ab1-42 causes cell dysfunction. Hettiarachchi et al. also revealed that part 
of the peptide’s mode of action involves increasing Cav1 channel activity, which in turn 
can cause activation of CAMKKII and subsequent phosphorylation and activation of 
AMPK. Phosphorylation and subsequent activation of AMPK could be blocked with 
CORM2 treatment (Hettiarachchi et al., 2014). In contrast to Hettiarachchi et al., 
research done by Duckles proposed that CO can reduce Cav3 channel conductance, and 
therefore exhibit anti-proliferative properties (Duckles et al., 2015). In contrast to 
Hettiarachchi et al. where CORM2 was shown to prevent Ab-mediated cell death of both 
SH-SY5Y and hippocampal neurons through direct evaluation of cell apoptosis via 
measuring activation of caspase-3 and propidium iodine staining, our data suggest that 
CORM2 was unable to reduce Ab1-42 -mediated change in cell activity in both 
undifferentiated and differentiated SH-SY5Y cells. Although our study suggests that 
CORM2 is unable to prevent Ab1-42 induced cytotoxicity, differences in findings could be 
due to differences in methodology. For example, in our study a higher concentration of 
Ab1-42 (3µM) was tested, whereas Hettiarachchi tested lower concentrations that better 
represent in vivo Ab1-42 levels (100 and 500nM). Additionally Hettiarachchi et al. 
reported CORM2 anti-apoptotic effects using a higher molar ratio (1:100) than the ones 
tested in the current study.  Moreover, Hettiarachchi used techniques that directly 
measure degree of cell apoptosis (caspase-3 and propidium iodine staining), whereas in 
this study metabolic activity was evaluated which although can give indication of cell 
dysfunction, it does not directly investigate cell death. Lastly, although previous studies 
have suggested that CO can exhibit anti-apoptotic effects through increasing sGC and 
preventing the phosphorylation of CAMKII and AMPK, lack of anti-apoptotic effects seen 
in the current study by CORM2 may suggest that µM concentrations of Ab1-42 may 
induce apoptosis through independent pathways than those seen with more 
physiological concentrations of Ab1-42. 
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To recap, although CORMs via their ruthenium structure, and CO specifically 
have been shown by previous studies to act cytoprotectively, in the current study, 
CORM2 was unable to prevent Ab-mediated changes in SH-SY5Y cell activity. Although 
direct interaction of CORM2 with Ab1-42 cannot be excluded, the findings suggest that 































This study has demonstrated that NH4OH pre-treatment of Ab1-42 leads to time-
dependent protofibril formation that structurally and functionally resembles 
aggregated Ab1-42 cytotoxicity in vivo. In addition, this is the first study to compare Ab1-
42 aggregation in the presence or absence of SDS. In support of the hypothesis that SDS 
can mimic the cell microenvironment, low levels of SDS were proven to aid protofibril 
formation. 
Overall, findings from the current study, agreeing with the hypotheses, have proven 
that protofibrillar Ab1-42 does indeed impair neuronal function, through pathways 
including changes in voltage-gated calcium channel mRNA expression. Changes in 
Cav1.2 and Cav1.3 gene expression seen in this study may suggest a role for Cav1 
channels at early stages of AD. Although CORM2 has been shown to act 
cytoprotectively, and although cell metabolic activity assays carried in this study cannot 
exclude a direct interaction of CORM2 with the peptide, in the current study CORM2 
was unable to prevent Ab-mediated cell dysfunction. Further experiments aim to 
investigate and identify the effect of protofibrillar Ab1-42 and CORM2 on Cav2.2 at the 
functional level, due to its high expression in the CNS and important role in synaptic 
function. This will further our understanding of protofibrillar Ab1-42 and CO role on 









































Chapter 5: Modulation of Cav2.2 channels by 
























Oxidative stress forms part of the pathogenesis of many diseases, including AD  
(Subbarao et al., 1990; Schipper et al., 1995; Dallas et al., 2011; Wojsiat et al., 2018). 
Reduction in antioxidants, increase in lipid peroxidation products and redox active iron 
which induces ROS release, identified via post-mortem studies, have been reported in 
AD (Subbarao et al., 1990; Schipper et al., 1995). Oxidative stress has been linked to 
neuronal dysfunction and ultimately cell death seen in AD (Schipper et al., 1995; 
Pappolla et al., 1998; Schipper, 2004). In AD, oxidative stress and increase in heme levels 
have been linked to an upregulation in HO-1 expression, seen in neurons and astrocytes, 
which is believed to occur as a defence mechanism against free radicals (Schipper, Cissé 
and Stopa, 1995; Hettiarachchi et al., 2014). As CO is one of the products of HO-
dependent heme catabolism, recently there has been considerable interest in 
identifying whether CO can exert antioxidant properties and be effective against AD 
pathology. 
It is widely accepted that post-translational modifications, such as redox 
modulation, can modulate the activity of ion channels including VGCCs (Li et al., 1998; 
Lazniewska and Weiss, 2017; Qian et al., 2017). Numerous studies have proposed that 
CO may modulate ion channels through a number of different mechanisms. In voltage-
gated potassium channels, such as Kv2.1, which have been implicated with cell death, 
CO was shown to prevent oxidant-dependent neuronal death (Dallas et al., 2011). In 
contrast, in Kv1.5 inhibition by CO was shown to occur through an oxidant-dependent 
manner via a pathway possibly involving release of ROS from mitochondria (Al-Owais et 
al., 2017). In cardiac KATP channels findings revealed that CO can activate these channels 
through a heme binding domain (Kapetanaki et al., 2018). CO requires heme to bind to 
KATP, forming a complex which CO can then interact with, and modulate these channels 
(Kapetanaki et al., 2018). In VGCCs, specifically Cav1 and Cav3 channels, CO was also 
shown to change channel kinetics through an oxidation mechanism (Scragg et al., 2008; 
Boycott et al., 2013). Release of ROS from mitochondria and direct modulation of 
cysteine residues at specific sites on the a1 pore-forming subunit have been implicated 
as some of the mechanisms by which CO may modulate Cav channel kinetics, and 
consequently channel activity (Scragg et al., 2008; Boycott et al., 2013).   
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As AD has been linked to altered VGCC expression and activity (Nimmrich et al., 
2008; Mezler et al., 2012; Hermann et al., 2013), investigating the effect of protofibrillar 
Ab1-42 on calcium currents, and redox-dependent VGCC modulation may help us better 
understand AD pathology and the role of VGCCs in AD pathogenesis. Additionally, 
identifying novel mechanisms by which oxidative stress or its downstream effects can 
be targeted may have clinical significance in treating AD. Although a number of studies 
have proven that CO can modulate ion channels via a redox-dependent pathway, the 
effect of CO on Cav2.2 channels has not been investigated.  
Cav2.2 channels merit further investigation given their prominent role in 
mediating presynaptic Ca2+ influx. The effect of CO on channel kinetics, through CORM2 
treatment, was investigated in Cav2.2-stably transfected HEK293 cells. Moreover, the 





The aim of the study was to identify the effects of protofibrillar Ab1-42 on Cav2.2 
at the functional level. Additionally, the effect of CO on Cav2.2 was also investigated, 





• To identify the effect of protofibrillar Ab1-42 on Cav2.2 channels at the functional 
level using Cav2.2 (a1B (Cav2.2), b1b, and a2d subunits) stably-transfected HEK293 
cells. 
• To investigate CO-dependent changes in Cav2.2 channel properties, using CORM2 
treatment of Cav2.2 (a1B (Cav2.2), b1b, and a2d subunits) channels in stably-
transfected HEK293 cells. 
• To examine whether CO modulates Cav2.2 channels via a redox mechanism through 






• Due to the important role(s) of Cav2.2 in neuronal cells, it is expected that 
protofibrillar Ab1-42 may change channel kinetics. 
• As CO has shown to modulate a number of ion channels, it is expected that 










































5.2.1. Effect of protofibrillar Ab1-42 on Cav2.2. channels 
 
Prior to investigating the effect of protofibrillar Ab1-42 on Cav2.2 kinetics, the 
presence of functional Cav2.2 (a1B (Cav2.2), b1b, and a2d subunits) in stably transfected 
HEK293 cells was verified via whole cell patch clamp. Treatment of cells with the Cav2.2 
blocker w-conotoxin-GVIA confirmed the presence of functional Cav2.2 channels (n=5) 
(Fig. 5.2.1.1A and B). Cells displayed maximum current at +10mV. Boltzmann fit analysis 
to current voltage (I/V) relationship was used to investigate changes in biophysical 
properties. Reversal potential (Rp), maximal conductance (Gmax), Vhalf, and slope (k) 
remained unaltered following exposure to 10nM w-conotoxin-GVIA (Fig. 5.2.1.2A-D). 
Cells were also subjected to a single-step protocol (+10mV) for investigating changes in 
current density over time (Fig. 5.2.1.3A and B). The CCB w-conotoxin-GVIA (~10mins) 
caused a significant reduction in Cav2.2 current density by 21.0 ± 7.4 pA/pF (P<0.05) 
compared to untreated cells. Time-dependent reduction in Cav2.2 current amplitude 
can be seen in Fig. 5.2.1.3C. 
Once the presence of functional Cav2.2 channels was verified, the effect of 
protofibrillar Ab1-42 on Cav2.2 currents was investigated via population experiments 
using whole cell patch clamp (n=15). A multi-step protocol was applied to Cav2.2 stably-
transfected HEK293 cells treated with 100nM protofibrillar Ab1-42 for 24hr (Fig. 
5.2.1.4A). Rp, Gmax, Vhalf and current density remained unaffected (Fig. 5.2.1.4A-C and 
F). In contrast, 100nM protofibrillar Ab1-42 caused a significant change in Cav2.2 slope 
factor by 6.8 ± 3.0 mV (P<0.05) compared to vehicle control (PBS) treated cells (Fig. 
5.2.1.4D). 
In contrast, Cav2.2 currents treated with a higher concentrations of protofibrillar 
Ab1-42 (24hr; 1µM) revealed a significant reduction in both Gmax (Fig. 5.2.1.5A and C) 
and current density (Fig. 5.2.1.5F) by 0.5 ± 0.2 ns/pF (P<0.05) and 20.1 ± 11.0 pA/pF 
(P<0.05) respectively. Other channel properties such as Rp (Fig. 5.2.1.5B), Vhalf (Fig. 










































Figure 5.2.1.1: Effect of w-Conotoxin-GVIA on Cav2.2 currents. The effect of w-conotoxin-GVIA on Cav2.2 channels of stably-
transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example current-voltage traces (-70 to +50mV) prior 
(left) and after (right) 10nM w-conotoxin-GVIA treatment. (B) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels 
(mean ± SEM) of HEK293 cells prior and after 10nM w-conotoxin-GVIA treatment, fitted with the Boltzmann fit equation (n=5). 










































Figure 5.2.1.2: Effect of w-conotoxin-GVIA on Cav2.2 kinetics. The effect of w-conotoxin-GVIA on Cav2.2 channel 
kinetics of stably transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Reversal potential of 
Cav2.2 channels (mean ± SEM) prior (untreated) and after 10nM w-conotoxin-GVIA treatment (n=5). (B) Maximal 
conductance of Cav2.2 channels (mean ± SEM) prior (untreated) and after 10nM w-conotoxin-GVIA treatment (n=5). 
(C) Half-activation voltage of Cav2.2 channels (mean ± SEM) prior (untreated) and after 10nM w-conotoxin-GVIA 
treatment (n=5). (D) Slope of Cav2.2 channels (mean ± SEM) prior (untreated) and after 10nM w-conotoxin-GVIA 
treatment (n=5). Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes in channel kinetics 










































Figure 5.2.1.3: Effect of w-conotoxin-GVIA on Cav2.2 current amplitude. The effect of w-conotoxin-GVIA on Cav2.2 
current amplitude of Cav2.2-stably transfected HEK293 cells was investigated via whole-cell patch clamp. (A) 
Example trace of a single-step (+10mV) recording of Cav2.2 current prior (black) and after (purple) 10nM w-
conotoxin-GVIA treatment. (B) Reduction in Cav2.2 current amplitude (mean ± SEM) with w-conotoxin-GVIA 
treatment (n=5). (C) Representative example of time-dependent changes in Cav2.2 current amplitude (+10mV) with 
w-conotoxin-GVIA (purple) treatment. Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes 













































































Figure 5.2.1.4: Effect of protofibrillar 100nM Ab1-42 on Cav2.2 kinetics. Whole-cell patch clamp population 
experiments investigating the effect of protofibrillar 100nM Ab1-42 on Cav2.2 channel kinetics of Cav2.2-stably 
transfected HEK293 cells. (A) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ± SEM) treated 
with the vehicle control (PBS) compared to protofibrillar 100nM Ab1-42 treatment (n=15). (B) Reversal potential of 
Cav2.2 channels (mean ± SEM) treated with the vehicle control(PBS) compared to protofibrillar 100nM Ab1-42 (n=15). 
(C) Maximal conductance of Cav2.2 channels (mean ± SEM) treated with the vehicle control (PBS) compared to 
protofibrillar 100nM Ab1-42 (n=15). (D) Half-activation voltage of Cav2.2 channels (mean ± SEM) treated with the 
vehicle control (PBS) compared to protofibrillar 100nM Ab1-42 (n=15). (E) Changes in the slope of Cav2.2 channels 
(mean ± SEM) treated with protofibrillar 100nM Ab1-42 (n=15). (F) Current density of Cav2.2 channels (mean ± SEM) 
of HEK293 cells treated with vehicle control (PBS) compared to protofibrillar 100nM Ab1-42 treatment (n=15). Clampfit 
10.3 was used for trace analysis. GraphPad was used for plotting current-voltage relationship and carrying out 






































































Figure 5.2.1.5: Effect of protofibrillar 1µM Ab1-42 on Cav2.2 kinetics. Whole-cell patch clamp population experiments 
investigating the effect of protofibrillar 1µM Ab1-42 on Cav2.2 channel kinetics of Cav2.2-stably transfected HEK293 
cells. (A) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ± SEM) treated with vehicle control 
(PBS) compared to protofibrillar 1µM Ab1-42 treatment (n=15). (B) Reversal potential of Cav2.2 channels (mean ± SEM) 
treated with the vehicle control (PBS)  compared to protofibrillar 1µM Ab1-42 (n=15). (C) Reduction in maximal 
conductance of Cav2.2 channels (mean ±SEM) treated with protofibrillar 1µM Ab1-42 (n=15). (D) Half-activation 
voltage of Cav2.2 channels (mean ± SEM) treated with the vehicle control (PBS) compared to protofibrillar 1µM Ab1-
42 (n=15). (E) Slope of Cav2.2 channels (mean ± SEM) treated with the vehicle control (PBS) compared to protofibrillar 
1µM Ab1-42 (n=15). (F) Reduction in Cav2.2 current density (mean ± SEM) with protofibrillar 1µM Ab1-42 treatment 
(n=15). Clampfit 10.3 was used for trace analysis. GraphPad was used for plotting current-voltage relationship and 




5.2.2. Effect of CO on Cav2.2 channels 
 
Prior to investigating the effect of CORM2 on Cav2.2 channels of HEK293 cells, 
the effect of DMSO (vehicle control) was investigated (Fig. 5.2.2.1A-B). DMSO (1/1000 
dilution) alone had no significant effect on the Cav2.2 channel properties measured (Rp, 
Gmax, Vhalf and k) (Fig. 5.2.2.2A-D). In addition, DMSO also had no effect on Cav2.2 
current density over time (Fig. 5.2.2.3A and B).  
Following DMSO control experiments, the effect of CORM2 on Cav2.2 channel 
kinetics, was then investigated via whole-cell patch clamp. Analysis of Cav2.2 channel 
properties, revealed that 100nM (n=6) and 500nM (n=8) CORM2 had no effect on all 
measured Cav2.2 channel properties (Fig. 5.2.2.4A-F and Fig. 5.2.2.5A-F respectively). 
In contrast, Cav2.2 currents (Fig. 5.2.2.6A and B) exposed to a higher concentration of 
CORM2 (10µM; n=6) revealed a significant reduction in Gmax by 0.4 ± 0.1 ns/pF (P<0.05), 
an increase in the Vhalf by 7.1 ± 2.8 mV (P<0.05) and a significant change in the slope 
factor of Cav2.2 currents by 15.8 ± 6.7 mV (P<0.05) (Fig. 5.2.2.7B,C and D). Rp of Cav2.2 
currents remained unchanged following 10µM application (Fig. 5.2.2.7A). 10µM 
CORM2 (~10mins) led to a time-dependent reduction in Cav2.2 current density by 15.9 
± 2.9 pA/pF (P<0.01) (Fig. 5.2.2.8A-C).  
In order to verify that changes in channel properties seen by CORM2 treatment 
are indeed due to CO release, whole cell patch clamp experiments were also repeated 
in the presence of 10µM iCORM2 (n=9). Similarly to CORM2, plotting Cav2.2 current-
voltage relationship (Fig. 5.2.2.9A and B) revealed that iCORM2 also caused a significant 
change in Gmax by 0.5 ± 0.1 ns/pF (P<0.01), Vhalf by 1.5 ± 0.3 mV (P<0.01)  and slope 
factor by 0.5 ± 0.2 mV (P<0.05) (Fig. 5.2.2.10B-D). Rp remained unaltered (Fig. 
5.2.2.10A). Applying a single-step protocol to identify changes in Cav2.2 current density 
revealed a reduction in Cav2.2 amplitude by 10.7 ± 22.6 pA/pF (P<0.001) with 10µM 
iCORM2 treatment (Fig. 5.2.2.11A and B). Time-dependent changes in Cav2.2 current 
amplitude with 10µM iCORM2 treatment (~10mins) can be seen in Fig. 5.2.2.11C.  
As both CORM2 and iCORM2 were shown to have an effect on Cav2.2 channel 
kinetics, stably-transfected HEK293 cells were also subjected to treatment with iCORM2 
followed by CORM2 at 10µM concentration (n=6). Plotting Cav2.2 current-voltage 
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relationship (Fig. 5.2.2.12A and B) revealed that treating cells with 10µM iCORM2 
followed by CORM2 caused a further significant reduction in Gmax by 0.9 ± 0.2 ns/pF 
(P<0.01), whereas no change in the Rp, Vhalf  or slope factor was noticed (Fig. 5.2.2.13A-
D). Interestingly, when cells where subjected to a single-step protocol 10µM iCORM2 
caused a 5.4 ± 1.6 pA/pF (P<0.05) reduction in current density, whereas iCORM2 
followed by 10µM CORM2 treatment caused an additional 9.3 ± 2.4 pA/pF (P<0.01) 
reduction in current density (Fig. 5.2.2.14A and B). Time-dependent reduction in Cav2.2 




























































Figure 5.2.2.1: Effect of vehicle control (DMSO) on Cav2.2 currents. The effect of the vehicle control (DMSO) on Cav2.2 
channels of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example current-voltage traces 
(-70 to +50mV) prior (left) and after (right) vehicle control (DMSO) treatment. (B) Current-voltage (-70 to +50mV) relationship 
of Cav2.2 channels (mean ± SEM) of HEK293 cells prior (untreated) and after vehicle control (DMSO) treatment, fitted with 
the Boltzmann fit equation (n=6). Clampfit 10.3 was used for trace analysis, and GraphPad for plotting current-voltage 








































Figure 5.2.2.2: Effect of the vehicle control (DMSO) on Cav2.2 kinetics. The effect of the vehicle control (DMSO) on 
Cav2.2 channel kinetics of stably transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Reversal 
potential of Cav2.2 channels (mean ± SEM) prior (untreated) and after vehicle control (DMSO) treatment (n=6). (B) 
Maximal conductance of Cav2.2 channels (mean ± SEM) prior (untreated) and after vehicle control (DMSO) treatment 
(n=6). (C) Half-activation voltage of Cav2.2 channels (mean ± SEM) prior (untreated) and after vehicle control (DMSO) 
treatment (n=6). (D) Slope of Cav2.2 channels (mean ± SEM) prior (untreated) and after vehicle control (DMSO) 
treatment (n=6). Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes in channel kinetics 











































Figure 5.2.2.3: Effect of vehicle control (DMSO) on Cav2.2 current amplitude. The effect of the vehicle control 
(DMSO) on Cav2.2 current amplitude of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. 
(A) Example trace of single-step (+10mV) recording of Cav2.2 current prior (black) and after (maroon) vehicle control 
treatment (DMSO). (B) Current density of Cav2.2 channels (mean ± SEM) with vehicle control (DMSO) treatment 
(n=6). Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes in current amplitude. Statistical 


























































































Figure 5.2.2.4: Effect of 100nM CORM2 on Cav2.2 kinetics. The effect of 100nM CORM2 on Cav2.2 channel kinetics 
of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Current-voltage (-70 to +50mV) 
relationship of Cav2.2 channels (mean ± SEM) of HEK293 cells prior (untreated) and after 100nM CORM2 treatment 
(n=6). (B) Reversal potential of Cav2.2 channels (mean ± SEM) prior (untreated) and after 100nM CORM2 treatment 
(n=6). (C) Maximal conductance of Cav2.2 channels (mean ± SEM) prior (untreated) and after 100nM CORM2 
treatment (n=6). (D) Half-activation voltage of Cav2.2 channels (mean ± SEM) prior (untreated) and after 100nM 
CORM2 treatment (n=6). (E) Slope of Cav2.2 channels (mean ± SEM) prior (untreated) and after 100nM CORM2 
treatment (n=6). (F) Cav2.2 current density (mean ± SEM) prior (untreated) and after 100nM CORM2 treatment (n=6). 
Clampfit 10.3 was used for trace analysis. GraphPad was used for plotting current-voltage relationship and carrying 


















































































Figure 5.2.2.5: Effect of 500nM CORM2 on Cav2.2 kinetics. The effect of 500nM CORM2 on Cav2.2 channel kinetics 
of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Current-voltage (-70 to +50mV) 
relationship of Cav2.2 channels (mean ± SEM) prior (untreated) and after 500nM CORM2 treatment, fitted with the 
Boltzmann fit equation (n=8). (B) Reversal potential of Cav2.2 channels (mean ± SEM) prior (untreated) and after 
500nM CORM2 treatment (n=8). (C) Maximal conductance of Cav2.2 channels (mean ± SEM) prior (untreated) and 
after 500nM CORM2 treatment (n=8). (D) Half-activation voltage of Cav2.2 channels (mean ± SEM) prior (untreated) 
and after 500nM CORM2 treatment (n=8). (E) Slope of Cav2.2 channels (mean ± SEM) prior (untreated) and after 
500nM CORM2 treatment (n=8). (F) Cav2.2 current density (mean ± SEM) prior (untreated) and after 500nM CORM2 
treatment (n=8). Clampfit 10.3 was used for trace analysis. GraphPad was used for plotting current-voltage 



































Figure 5.2.2.6: Effect of 10µM CORM2 on Cav2.2 currents. The effect of 10µM CORM2 on Cav2.2 channels of stably-
transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example current-voltage traces (-70 to +50mV) 
prior (left) and after (right) 10µM CORM2 treatment. (B) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels 
(mean ± SEM) of HEK293 cells prior (untreated) and after 10µM CORM2 treatment, fitted with the Boltzmann fit equation 











































Figure 5.2.2.7: Effect of the 10µM CORM2 on Cav2.2 kinetics. The effect of 10µM CORM2 on Cav2.2 channel kinetics 
of stably transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Reversal potential of Cav2.2 
channels (mean ± SEM) prior (untreated) and after 10µM CORM2 treatment (n=6). (B) Reduction in maximal 
conductance of Cav2.2 channels (mean ± SEM) with 10µM CORM2 treatment (n=6). (C) Increase in half-activation 
voltage of Cav2.2 channels (mean ± SEM) with 10µM CORM2 treatment (n=6). (D) Change in the slope of Cav2.2 
channels (mean ± SEM) with 10µM CORM2 treatment (n=6). Clampfit 10.3 was used for trace analysis, and GraphPad 
for analysing changes in channel kinetics obtained from Boltzmann fit analysis. Statistical analysis was carried out via 











































Figure 5.2.2.8: Effect of 10µM CORM2 on Cav2.2 current amplitude. The effect of 10µM CORM2 on Cav2.2 current 
amplitude of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example trace of 
single-step (+10mV) recording of Cav2.2 current prior (black) and after (blue) 10µM CORM2 treatment. (B) 
Reduction in Cav2.2 current density (mean ± SEM) with 10µM CORM2 treatment (n=6). (C) Representative example 
of time-dependent changes in Cav2.2 current (+10mV) with 10µM CORM2 (blue) treatment. Clampfit 10.3 was used 
for trace analysis, and GraphPad for analysing changes in current amplitude. Statistical analysis was carried out via 







































Figure 5.2.2.9: Effect of 10µM iCORM2 on Cav2.2 currents. The effect of 10µM iCORM2 on Cav2.2 channels of stably-transfected 
HEK293 cells was investigated via whole-cell patch clamp. (A) Example current-voltage traces (-70 to +50mV) prior (left) and after 
(right) 10µM iCORM2 treatment. (B) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ± SEM) of HEK293 
cells prior (untreated) and after 10µM iCORM2 treatment, fitted with the Boltzmann fit equation (n=9). Clampfit 10.3 was used 










































Figure 5.2.2.10: Effect of 10µM iCORM2 on Cav2.2 kinetics. The effect of 10µM iCORM2 on Cav2.2 channel kinetics 
of stably transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Reversal potential of Cav2.2 
channels (mean ± SEM) prior (untreated) and after 10µM iCORM2 treatment (n=9). (B) Reduction in maximal 
conductance of Cav2.2 channels (mean ± SEM) with 10µM iCORM2 treatment (n=9). (C) Increase in half-activation 
voltage of Cav2.2 channels (mean ± SEM) with 10µM iCORM2 treatment (n=9). (D) Change in slope of Cav2.2 channels 
(mean ± SEM) with 10µM iCORM2 treatment (n=9). Clampfit 10.3 was used for trace analysis, and GraphPad for 
analysing changes in channel kinetics obtained from Boltzmann fit analysis.  Statistical analysis was carried out via 















Figure 5.2.2.11: Effect of 10µM iCORM2 on Cav2.2 current amplitude. The effect of 10µM iCORM2 on Cav2.2 
current amplitude of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example trace 
of single-step (+10mV) recording of Cav2.2 current prior (black) and after (blue) 10µM iCORM2 treatment. (B) 
Reduction in Cav2.2 current density (mean ± SEM) with 10µM iCORM2 treatment (n=9). (C) Representative example 
of time-dependent changes in Cav2.2 current (+10mV) with 10µM iCORM2 (blue) treatment. Clampfit 10.3 was used 
for trace analysis, and GraphPad for analysing changes in current amplitude. Statistical analysis was carried out via 



































Figure 5.2.2.12: Effect of CORM2 on Cav2.2 currents. The effect of CO, through iCORM2 followed by CORM2 treatment, on 
Cav2.2 channels of stably-transfected HEK293 cells was investigated via whole-cell patch clamp through treatment. (A) 
Example current-voltage traces (-70 to +50mV) prior (left) and after (right) 10µM iCORM2 followed by CORM2 treatment. 
(B) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ±SEM) prior (untreated) and after 10µM iCORM2 
followed by CORM2 treatment, fitted with the Boltzmann fit equation (n=6). Clampfit 10.3 was used for trace analysis, and 









































Figure 5.2.2.13: Effect of CO on Cav2.2 kinetics. The effect of CO, through iCORM2 followed by CORM2 treatment on 
Cav2.2 channel kinetics of stably-transfected HEK293 cells investigated via whole-cell patch clamp. (A) Reversal 
potential of Cav2.2 channels (mean ±SEM) prior (untreated) and after 10µM iCORM2 followed by CORM2 treatment 
(n=6). (B) Reduction in maximal conductance of Cav2.2 channels (mean ±SEM) with 10µM iCORM2 followed by 
CORM2 treatment (n=6). (C) Half-activation voltage of Cav2.2 channels (mean ±SEM) prior (untreated) and after 
10µM iCORM2 followed by CORM2 treatment (n=6). (D) Slope of Cav2.2 channels (mean ±SEM) prior (untreated) and 
after 10µM iCORM2 followed by CORM2 treatment (n=6). Clampfit 10.3 was used for trace analysis, and GraphPad 
for analysing changes in channel kinetics obtained from Boltzmann fit analysis. Statistical analysis was carried out via 











































Figure 5.2.2.14: Effect of CO on Cav2.2 current amplitude. The effect of CO, through iCORM2 followed by CORM2 
treatment, on Cav2.2 current amplitude of stably-transfected HEK293 cells was investigated via whole-cell patch 
clamp. (A) Example trace of single-step (+10mV) recording of Cav2.2 current prior (black), followed by 10µM 
iCORM2 (light blue) and 10µM CORM2 (dark blue) treatment. (B) Reduction in Cav2.2 current amplitude (mean 
±SEM) with 10µM iCORM2 followed by CORM2 treatment (n=6). (C) Representative example of time-dependent 
changes in Cav2.2 current (+10mV) with 10µM iCORM2 (light blue) followed by CORM2 (dark blue) treatment. 
Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes in current amplitude. Statistical 
analysis was carried out via one-tailed paired T-test. (*=P<0.05; **=P<0.01) 
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5.2.3. Redox modulation of Cav2.2 channels by CO 
 
Once CORM2 was verified to have an effect on Cav2.2 channel kinetics, the 
hypothesis that CORM2 may modulate Cav2.2 channels through a redox manner was 
then investigated via whole-cell patch clamp.  
Plotting Cav2.2 current-voltage relationship (Fig. 5.2.3.1A) of HEK293 cells 
treated with the oxidising agent DTDP (2,2-dithiodipyridine) revealed that 1µM DTDP 
(n=6) has no significant effect on any of the Cav2.2 channel kinetics (Fig. 5.2.3.1B-F). In 
contrast, plotting the Cav2.2 current-voltage relationship (Fig. 5.2.3.2A and B) of cells 
treated with 10µM DTDP (n=5) although did not have any effect on Rp, Gmax, Vhalf and 
slope factor (Fig 5.2.3.3A-D), 10µM DTDP caused a significant reduction in current 
density by 7.7 ± 1.7 pA/pF (P<0.001) (Fig. 5.2.3.4A and B). Time-dependent changes in 
Cav2.2 current amplitude with 10µM DTDP treatment (~10mins) can be seen in Fig. 
5.2.3.4C. 
As the oxidising agent DTDP caused a significant reduction in current density 
similar to treatment with CORM2, CORM2 modulation of Cav2.2 channels through an 
oxidising manner was also investigated via whole-cell patch clamp. Plotting Cav2.2 
current-voltage relationship (Fig. 5.2.3.5A-B) of HEK293 cells treated with 10µM DTDP 
followed by 10µM CORM2 (n=7) revealed a significant reduction in Gmax by 0.4 ± 0.2 
ns/pF (P<0.05) and 9.3 ± 4.4 mV (P<0.05) in slope factor (Fig. 5.2.3.6B and D). Whereas 
no change in the Rp and Vhalf of Cav2.2 channels was noted (Fig. 5.2.3.6A and C). When 
cells where subjected to a single-step protocol 10µM DTDP caused a 7.4 ± 2.2 pA/pF 
(P<0.01) reduction in current density, whereas 10µM DTDP followed by 10µM CORM2 
treatment caused an additional 4.7 ± 0.7 pA/pF (P<0.01) reduction in current density, 
suggesting CORM2 may act similarly to an oxidising agent (Fig. 5.2.3.7A). Time-
dependent reduction in Cav2.2 current amplitude with DTDP followed by CORM2 can 
be seen in Fig. 5.2.3.7B. 
In order to verify that CORM2 acts as a redox modulator of Cav2.2 channel by 
acting as an oxidizing agent, the effect of the reducing agent DTT (dithiothreitol) on 
CORM2-dependent changes in Cav2.2 channel kinetics was also investigated (n=6). 
Plotting Cav2.2 current-voltage relationship (Fig. 5.2.3.8A and B) revealed that 1mM 
 183 
DTT had no effect on the Rp, Gmax and slope factor of Cav2.2 currents (Fig. 5.2.3.9A, B 
and D). Whereas, 1mM treatment caused a significant change in Vhalf of Cav2.2 currents 
by 3.0 ± 1.4 mV (P<0.05) (Fig. 5.2.3.9C). Applying a single-step protocol to study changes 
in current density revealed that 1mM DTT (~10mins) had no effect on Cav2.2 current 
density (Fig. 5.2.3.10A and B).   
As a last-step, in order to verify that CORM2 modulates Cav2.2 through an 
oxidising mechanism, Cav2.2 stably-transfected HEK293 cells were also treated with 
10µM CORM2 followed by 1mM DTT (n=5).  Plotting Cav2.2 current-voltage relationship 
(Fig. 5.2.3.11A and B) revealed that although CORM2 alone treatment did not cause any 
change in Rp or Vhalf, treating cells with 10µM CORM2 followed by 1mM DTT caused a 
10.39 ± 2.9 mV (P<0.01) and 6.2 ± 1.0 mV (P<0.01) change respectively (Fig. 5.2.3.12A 
and C). Treating cells with 10µM CORM2 alone caused a 0.9 ± 0.3 ns/pF (P<0.05) 
reduction in Gmax. Whereas, treating cells with 10µM CORM2 followed by 1mM DTT 
caused complete restoration in Gmax (0.3 ± 0.3 ns/pF) (Fig. 5.2.3.12B). In contrast, 
treating cells with 10µM CORM2 followed by 1mM DTT had no effect on Cav2.2 slope 
factor (Fig. 5.2.3.12D).  Applying a single-step protocol to study changes in current 
density revealed that 10µM CORM2 reduces Cav2.2 current density by 25.2 ± 7.7 pA/pF 
(P<0.05). Whereas treating cells with 10µM CORM2 followed by 1mM DTT caused 
complete restoration in Cav2.2 current density (12.8 ± 10.1 pA/pF) (Fig. 5.2.3.13A).  
Time-dependent changes in current amplitude of Cav2.2 channels of HEK293 cells 





























































































Figure 5.2.3.1: Effect of 1µM DTDP on Cav2.2 kinetics. The effect of 1µM DTDP on Cav2.2 channel kinetics of stably-
transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Current-voltage (-70 to +50mV) relationship 
of Cav2.2 channels (mean ± SEM) of HEK293 cells prior (untreated) and after 1µM DTDP treatment (n=6). (B) Reversal 
potential of Cav2.2 channels (mean ± SEM) prior (untreated) and after 1µM DTDP treatment (n=6). (C) Maximal 
conductance of Cav2.2 channels (mean ± SEM) prior (untreated) and after 1µM DTDP treatment (n=6). (D) Half-
activation voltage of Cav2.2 channels (mean ± SEM) prior (untreated) and after 1µM DTDP treatment (n=6). (E) Slope 
of Cav2.2 channels (mean ± SEM) prior (untreated) and after 1µM DTDP treatment (n=6). (F) Amplitude of Cav2.2 
channels (mean ± SEM) prior (untreated) and after 1µM DTDP treatment (n=6). Clampfit 10.3 was used for trace 
analysis. GraphPad was used for plotting current-voltage relationship and carrying out Boltzmann fit analysis. 








































Figure 5.2.3.2: Effect of 10µM DTDP on Cav2.2 currents. The effect of 10µM DTDP on Cav2.2 channels of stably-transfected 
HEK293 cells was investigated via whole-cell patch clamp. (A) Example current-voltage traces (-70 to +50mV) prior (left) and 
after (right) 10µM DTDP treatment. (B) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ± SEM) of 
HEK293 cells prior and after 10µM DTDP treatment, fitted with the Boltzmann fit equation (n=5). Clampfit 10.3 was used for 










































Figure 5.2.3.3: Effect of 10µM DTDP on Cav2.2 kinetics. The effect of 10µM DTDP on Cav2.2 channel kinetics of stably 
transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Reversal potential of Cav2.2 channels (mean 
± SEM) prior (untreated) and after 10µM DTDP treatment (n=5). (B) Maximal conductance of Cav2.2 channels (mean 
± SEM) prior (untreated) and after 10µM DTDP treatment (n=5). (C) Half-activation voltage of Cav2.2 channels (mean 
± SEM) prior (untreated) and after 10µM DTDP treatment (n=5). (D) Slope of Cav2.2 channels (mean ± SEM) prior 
(untreated) and after 10µM DTDP treatment (n=5). Clampfit 10.3 was used for trace analysis, and GraphPad for 
analysing changes in channel kinetics obtained from Boltzmann fit analysis. Statistical analysis was carried out via 











































Figure 5.2.3.4: Effect of 10µM DTDP on Cav2.2 current amplitude. The effect of 10µM DTDP on Cav2.2 current 
amplitude of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example trace of 
single-step (+10mV) recording of Cav2.2 current prior (black) and after (red) 10µM DTDP treatment. (B) Reduction 
in Cav2.2 current amplitude (mean ± SEM) with 10µM DTDP treatment (n=5). (C) Representative example of time-
dependent changes in Cav2.2 current (+10mV) with 10µM DTT (red) treatment. Clampfit 10.3 was used for trace 
analysis, and GraphPad for analysing changes in current amplitude. Statistical analysis was carried out via one-







































Figure 5.2.3.5: Redox modulation of CO on Cav2.2 currents. The effect of CO, through 10µM DTDP followed by CORM2 
treatment, on Cav2.2 channels of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example 
current-voltage traces (-70 to +50mV) prior (left) and after (right) 10µM DTDP followed by CORM2 treatment. (B) Current-
voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ±SEM) prior (untreated) and after 10µM DTDP followed by 
CORM2 treatment, fitted with the Boltzmann fit equation (n=7). Clampfit 10.3 was used for trace analysis, and GraphPad for 









































Figure 5.2.3.6: Redox-dependent effect of CO on Cav2.2 kinetics. The effect of CO, through 10µM DTDP followed by 
CORM2 treatment on Cav2.2 channel kinetics of stably-transfected HEK293 cells investigated via whole-cell patch 
clamp. (A) Reversal potential of Cav2.2 channels (mean ±SEM) prior (untreated) and after 10µM DTDP followed by 
CORM2 treatment (n=7). (B) Reduction in maximal conductance of Cav2.2 channels (mean ±SEM) treated with 10µM 
DTDP followed by CORM2 (n=7). (C) Half-activation voltage of Cav2.2 channels (mean ±SEM) prior (untreated) and 
after 10µM DTDP followed by CORM2 treatment (n=7). (D) Change in slope of Cav2.2 channels (mean ±SEM) treated 
with 10µM DTDP followed by CORM2 (n=7). Clampfit 10.3 was used for trace analysis, and GraphPad for analysing 
changes in channel kinetics obtained from Boltzmann fit analysis. Statistical analysis was carried out via one-tailed 











































Figure 5.2.3.7: Redox-dependent effect of CO on Cav2.2 current amplitude. The effect of CO, through 10µM DTDP 
followed by CORM2 treatment on Cav2.2 current amplitude of stably-transfected HEK293 cells was investigated via 
whole-cell patch clamp. (A) Reduction in Cav2.2 current amplitude (mean ± SEM) with 10µM DTDP followed by 
CORM2 treatment (n=7). (B) Representative example of time-dependent changes in Cav2.2 current (+10mV) with 
10µM CORM2 (light red) followed by CORM2 (dark red) treatment. Clampfit 10.3 was used for trace analysis, and 










































Figure 5.2.3.8: Effect of 1mM DTT on Cav2.2 currents. The effect of 10µM DTDP on Cav2.2 channels of stably-transfected 
HEK293 cells was investigated via whole-cell patch clamp. (A) Example current-voltage traces (-70 to +50mV) prior (left) and 
after (right) 1mM DTT treatment. (B) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ± SEM) of 
HEK293 cells prior and after 1mM DTT treatment, fitted with the Boltzmann fit equation (n=6). Clampfit 10.3 was used for 











































Figure 5.2.3.9: Effect of 1mM DTT on Cav2.2 kinetics. The effect of 1mM DTT on Cav2.2 channel kinetics of stably 
transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Reversal potential of Cav2.2 channels (mean 
± SEM) prior (untreated) and after 1mM DTT treatment (n=6). (B) Maximal conductance of Cav2.2 channels (mean ± 
SEM) prior (untreated) and after 1mM DTT treatment (n=6). (C) Increase in half-activation voltage of Cav2.2 channels 
(mean ± SEM) treated with 1mM DTT treatment (n=6). (D) Slope of Cav2.2 channels (mean ± SEM) prior (untreated) 
and after 1mM DTT treatment (n=6). Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes 















































Figure 5.2.3.10: Effect of 1mM DTT on Cav2.2 current amplitude. The effect of 10µM DTDP on Cav2.2 current 
amplitude of stably-transfected HEK293 cells was investigated via whole-cell patch clamp. (A) Example trace of single-
step (+10mV) recording of Cav2.2 current prior (black) and after (brown) 1mM DTT treatment. (B) Amplitude of 
Cav2.2 channels (mean ± SEM) with 1mM DTT treatment (n=6). Clampfit 10.3 was used for trace analysis, and 






































Figure 5.2.3.11: Modulation of Cav2.2 channels by CO through a redox manner. The effect of CO, through 10µM CORM2 
followed by 1mM DTT treatment, on Cav2.2 channels of stably-transfected HEK293 cells was investigated via whole-cell patch 
clamp through treatment. (A) Example current-voltage traces (-70 to +50mV) prior (left) and after (right) 10µM CORM2 
followed by 1mM DTT treatment. (B) Current-voltage (-70 to +50mV) relationship of Cav2.2 channels (mean ±SEM) prior 
(untreated) and after 10µM CORM2 followed by 1mM DTT treatment, fitted with the Boltzmann fit equation (n=5). Clampfit 









































Figure 5.2.3.12: Redox-dependent effect of CO on Cav2.2 kinetics. The effect of CO, through 10µM CORM2 followed 
by 1mM DTT treatment on Cav2.2 channel kinetics of stably-transfected HEK293 cells investigated via whole-cell patch 
clamp. (A) Increase in reversal potential of Cav2.2 channels (mean ±SEM) treated with 10µM CORM2 followed by 
1mM DTT (n=5). (B) Reduction in maximal conductance of Cav2.2 channels (mean ±SEM) treated with 10µM CORM2. 
Complete reversal in conductance was noted with 10µM CORM2 followed by 1mM DTT treatment (n=5). (C) Increase 
in half-activation voltage of Cav2.2 channels (mean ±SEM) treated with 10µM CORM2 followed by 1mM DTT (n=5). 
(D) Slope of Cav2.2 channels (mean ±SEM) prior (untreated) and after 10µM CORM2 followed by 1mM DTT treatment 
(n=5). Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes in channel kinetics obtained 










































Figure 5.2.3.13: Redox-dependent effect of CO on Cav2.2 current amplitude. The effect of CO, through 10µM 
CORM2 followed by DTT treatment on Cav2.2 current amplitude of stably-transfected HEK293 cells was investigated 
via whole-cell patch clamp. (A) Reduction in Cav2.2 current amplitude (mean ± SEM) with 10µM CORM2. Complete 
reversal in current amplitude with 10µM CORM2 followed by DTT treatment (n=5). (B) Representative example of 
time-dependent changes in Cav2.2 current (+10mV) with 10µM CORM2 (light brown) followed by 1mM DTT (dark 
brown) treatment. Clampfit 10.3 was used for trace analysis, and GraphPad for analysing changes in current 





Effect of protofibrillar Ab1-42 on Cav2.2 channels 
 
• Protofibrillar Ab1-42  at 100nM significantly changed the slope factor of Cav2.2 currents in stably-
transfected HEK293 cells. 
• Protofibrillar Ab1-42  at 1µM reduces Cav2.2 currents in stably-transfected HEK293 cells. 
As a first step in investigating the effects of protofibrillar Ab1-42  on VGCCs, functional 
Cav2.2 (a1B (Cav2.2), b1b, and a2d subunits) channels expression in stably-transfected 
HEK293 cells was verified via the use of w-conotoxin-GVIA. Treatment with 100nM 
protofibrillar Ab1-42 although it significantly changed the slope factor, it did not change 
Cav2.2 conductance or other channel properties. In contrast, higher concentration 
(1µM) of protofibrillar Ab1-42 caused a significant reduction in both Cav2.2 conductance 
and amplitude. While it has been proven by a number of studies that aggregated Ab1-42 
can alter the activity of VGCCs, contradictory evidence exist in relation to the effect of 
Ab1-42 on these channels (Nimmrich et al., 2008; Mezler et al., 2012; Hermann et al., 
2013). Previous studies have shown that exposure to high (200-830) nM concentrations 
of human synthetic oligomeric Ab1-42 caused a significant increase in both Cav2.1 and 
Cav2.2 amplitude, and additionally a leftward shift of Vhalf towards more 
hyperpolarised values (Mezler et al., 2012; Hermann et al., 2013). The changes in Cav2.1 
kinetics was found to occur due to a physical interaction of globulomer Ab1-42 with the 
a1 subunit of the channel (Mezler et al., 2012). Although Mezler et al. revealed a direct 
interaction for globulomer Ab1-42 with the a1 subunit of Cav2.1, the mechanism by 
which Ab1-42 interacts with the peptide, such as modulation of specific residues, was not 
investigated. In contrast, a study conducted in 2002 by Ramsden and colleagues, 
agreeing with the results in the current study revealed that  aggregated Ab1-40 (1µM) 
reduces Cav2.2 currents, whereas unaggregated Ab1-40 increases Ca2+ currents 
(Ramsden, Henderson and Pearson, 2002). Differences in findings within the literature 
and the current study could be explained due to differential effects of Ab on Cav2 
channels dependent on Cav2 subtype, and also differential effects dependent on the Ab  
species, aggregation status and concentration used. Moreover, the current study 
investigated the effect of Ab1-42 on cells exposed to the amyloid peptide over 24hr, 
whereas Hermann et al. (2013) and Mezler et al. (2012) investigated the effect of acute 
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treatment (10mins) with Ab1-42. This suggests that short term exposure to Ab may cause 
an initial increase in channel conductance and therefore synaptic activity, whereas 
prolonged exposure and exposure to higher levels of Ab, can ultimately lead to changes 
in the synapses and synaptic decline, possibly through a pathway involving a reduction 
in VGCC conductance (Sheng et al., 1996; Koppensteiner et al., 2016; Arbel-Ornath et 
al., 2017). In line with this, studies have revealed that pre-clinical and early-stages of AD 
are characterised by neuronal hyperactivity, possibly as a compensatory mechanism, 
that can eventually lead to synaptic loss which is especially noted at later stages of AD 
(Miller et al., 2008; Yassa et al., 2010; Putcha et al., 2011; Busche et al., 2012; Busche 
and Konnerth, 2015). Thus, reduction in Cav2.2 currents noted in the current study may 
be representative of synaptic dysfunction seen at later stages of AD rather than pre-
clinical or early-stages. Although Nimmrich et al. used primary neurons in contrast to 
SH-SY5Y neuronal line used in the current study, Nimmrich et al.  (2008) demonstrated 
that one manner by which treatment with low nM Ab1-42 globulomers caused a marked 
downregulation in synaptic activity of hippocampal neurons was through a reduction in 
Cav2.1 channel conductance. A reduction in Ca2+ influx due to Ab-mediated changes in 
VGCC currents can have detrimental effects in neuronal function, for example through 
interfering with neurotransmission. For example, oligomeric Ab has been implicated 
with neuronal morphological changes, such as reduction in spine density and in overall 
dendritic spine number which can subsequently influence synaptic activity (Arbel-
Ornath et al., 2017). Another manner by which VGCC dysfunction may lead to reduction 
in neurotransmission is through less Ca2+ binding to the Ca2+ sensor synaptotagmin 
which is known to interact with the SNARE complex, facilitating vesicular fusion and 
subsequent neurotransmitter release (Bennett et al., 1992; Pang et al., 2006; Xu et al., 
2009; Südhof, 2013).    
Taken together, the current study, supported by previous research, proves that 








Effect of CO on Cav2.2 channels  
 
• CO, through CORM2 reduces Cav2.2 currents of stably-transfected HEK293 cells in a concentration-
dependent manner. 
• The mechanism by which CO reduces Cav2.2 currents involves redox modulation. 
 
A growing number of ion channels have been reported to be modulated by CO 
(Scragg et al., 2008; Dallas et al., 2011; Mezler et al., 2012; Boycott et al., 2013; Al-Owais 
et al., 2017; Kapetanaki et al., 2018). The current study is the first study to prove that 
CO, through CORM2 treatment, can modulate Cav2.2 channels through a reduction in 
the conductance and also changes in other channel properties.  
Similarly to the current study, previous evidence, although conducted on Cav1 
rather than Cav2 channels, has revealed that in both rodent native and human and 
rodent recombinant Cav1.2 channels 30µM CORM2 inhibits Cav1 currents, whereas 
iCORM2 has no effect on Ca2+ currents (Scragg et al., 2008). Similarly, Boycott et al. 
(2013) proposed that CORM2 also inhibits LVA Cav3 channels. Although in the current 
study, iCORM2 was shown to also reduce Cav2.2 conductance, a larger reduction in 
conductance and amplitude was seen with CORM2 suggesting that the effect of CORM2 
on these channels is at least partly due to the release of CO.  
In addition to revealing that CO through CORM2 treatment modulates Cav2.2 
channels and reduces Ca2+ influx through these channels, use of the oxidant DTDP and 
the reducing agent DTT revealed that the mode of action of CO involves redox 
modulation of these channels. The current study is the first study to suggest redox 
modulation of Cav2 channels by CO. In the current study both CORM2 and the oxidant 
DTDP caused a significant reduction in Cav2.2 currents. Treating cells with DTDP alone 
caused a small reduction in Cav2.2 currents, whereas treating cells with DTDP followed 
by CORM2 caused a larger degree of reduction. This suggests that CORM2 may act in a 
similar manner to DTDP. As iCORM2 did not cause the same degree of changes in Cav2.2 
kinetics as with treatment with CORM2, it is believed that at least partly, the inhibitory 
effects seen by CORM2 are due to release of CO. In further support of a redox role for 
CO, treating cells with CORM2 followed by DTT, an antioxidant, partly prevented CO-
mediated Cav2.2 inhibition.  
Numerous studies have proven that redox modulation of VGCCs, through either 
indirect modulation such as lipid peroxidation, or direct redox modulation of specific 
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residues on these channels can have an impact on their overall function, with clinical 
significance in diseases such as AD (Li et al., 1998). For example, treatment of neuronal 
Cav2.1 channels with H2O2 has been shown to increase Cav2.1 current amplitude by 
causing the channels to open at more hyperpolarised values (Li et al., 1998). Although 
the manner by which oxidation with H2O2 modulates these channels was not 
investigated, direct interaction with the a2d subunit was excluded (Li et al., 1998). In 
contrast, work done on cardiac Cav1.2 revealed that oxidation with DTDP causes a 
decrease in Cav1.2 currents through directly modulating specific cysteine residues 
found on the a1 pore-forming subunit (Chiamvimonvat et al., 1995; Scragg et al., 2008). 
A number of studies have proven that CO may also modulate ion channels 
through a redox manner (Scragg et al., 2008; Dallas et al., 2011; Al-Owais et al., 2017). 
Even though redox modulation has been proposed as one manner by which CO may 
modulate VGCCs, some studies suggest that it works similar to an oxidising, where other 
studies suggest it may act similar to a reducing agent. In agreement to findings from the 
current study, where CORM2 was shown to reduce Cav2.2 currents, Scragg et al. (2008) 
and Boycott et al. (2013) have proven that the use of the reducing agent DTT (low mM 
concentrations) can partly or completely reverse the inhibitory effects of CORM2 on 
VGCCs. This suggests that CO, through CORM2 treatment, may act as an oxidant and 
therefore may change channel properties in a redox-dependent manner. Although 
these studies agree with the current study, these studies focused on Cav1 and Cav3 
channels. The current study is the first study to suggest redox modulation of Cav2 
channels by CO. In contrast, Dallas et al. (2011) although agreeing that CO may act as a 
redox modulator, in neuronal Kv2.1 channels was shown to act as a reducing agent 
rather than an oxidant.  
A number of mechanisms have been proposed as to how CO modulate ion 
channels such as VGCCs through a redox manner, with a number of studies implicating 
specific cysteine residues as the ion-channel site required for CO-channel sensitivity. For 
example, in KATP channels findings revealed that CO can activate these channels through 
a change in conformational structure via a mechanism that requires heme binding onto 
the channel forming a heme-SUR2A complex. Following the formation of the complex, 
CO can then displace a cysteine residue in order to interact and bind to the heme-SUR2A 
complex. This change in conformational structure can then induce KATP activation 
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(Kapetanaki et al., 2018). In VGCCs, specifically Cav1 channels, it was revealed that 
specific cysteine residues within the a1 subunit cytoplasmic C-terminus of the channels 
were required for CO binding, identified through site-mutagenesis (Scragg et al., 2008). 
CO-dependent redox modulation of Cav1 channels involved release of ROS from ETC 
mitochondrial complex III, where similar to the current study, use of the reducing agent 
DTT prevented the effect of CO on the Cav1 channels (Scragg et al., 2008). Whereas in 
LVA VGCCs, specifically Cav3.2 channels, CORM2 (µM concentrations) significantly 
reduces VGCC current amplitude through targeting cysteines present at an extracellular 
site of the a1 subunit (cysteines linking region S5 and S6 in domain I) (Boycott et al., 
2013). Some of these cysteine residues are conserved between all Cav families 
(Karmazinova et al., 2010). Substitution of these cysteine residues with alanine residues 
can either change channel kinetics, reduce channel conductance or result in a non-
functional channel, proving that these residues have an important role in the gating 
properties of the channel (Karmazinova et al., 2010). Use of DTT has shown to cause an 
increase in reduced channel conductance seen with substitution of these cysteine 
residues (Karmazinova et al., 2010).  It has been suggested that compounds containing 
metals such as CORM2 which contains ruthenium, may work by interacting with these 
cysteine residues, therefore disrupting the stability of the VGCC structure, and 
consequently blocking Cav currents. Whereas DTT is believed to work by either 
disrupting disulphide bonds or as a scavenger by removing the metal interacting with 
the channel (Chiamvimonvat et al., 1995; Karmazinova et al., 2010). Boycott et al. (2013) 
revealed that AuF, an agent that blocks the reduction of Trx (thioredoxin), with known 
ion-channel redox modulator roles, reduced Cav3.2 currents similarly to CORM2 
treatment, whereas DTT restored currents. Similarly to our findings, Boycott et al. 
(2013) revealed that treatment of Cav3 channels with DTT alone only caused a marginal 
change in the size of the current, whereas treatment with CORM2, followed by DTT 
caused a significant increase in current, and therefore partially reversed the inhibitory 
effect of CORM2. Therefore, it is believed that CO may modulate Cav3.2 channels 
through a Trx-manner (Boycott et al., 2013). Although CO-dependent modulation of 
Cav3.2 channels was shown to involve Trx, CORM2 was not shown to influence Cav3.1 
and Cav3.3 channels using the same mechanism  (Boycott et al., 2013).  
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Taken together, CORM2 was shown to reduce Cav2.2 currents through a redox-
dependent manner. Although iCORM2 was also shown to reduce Cav2.2 currents, a 
higher degree of reduction was seen with CORM2. This suggests that although some of 
these inhibitory effects seen by CORM2 could be due to the presence of the metal 
ruthenium structure, part of the changes in channel kinetics seen by CORM2 are due to 
CO. The effect of CORM2 on Cav2.2 is reversed with treatment with the reducing agent 
DTT, suggesting that CORM2 acts as an oxidant. Although previous work done by other 
groups reveal differential redox effects of CO on ion channels, CO may act differently 
dependent on the ion channel type and the ion channel subunit composition.   Similar 
mechanisms to Cav1 and Cav3 channels noted from previous studies, such as indirect 
modulation via release of ROS from mitochondria, or direct interaction with cysteine 
residues at specific sites on the a1 pore-forming subunit may also underlie the 






























In support of the hypothesis protofibrillar Ab1-42 induced concentration-
dependent changes in Cav2.2 channel properties. The reduction in channel conductance 
seen with 1µM Ab1-42 may reflect late-stages of AD where a high degree of synaptic 
dysfunction is reported.  
 Parallel studies, in support of the hypothesis that CO modulates ion channels, 
revealed that CORM2 inhibits Cav2.2 channels. Although a role for the ruthenium dimer 
present in CORM2 cannot be excluded, this redox-dependent inhibitory effect is 
















































































6.1. Overall discussion 
 
Calcium dysregulation comprises a main feature of numerous 
neurodegenerative diseases. In AD, Ab misfolding, accumulation and aggregation has 
been linked to changes in VGCCs and neuronal dysfunction (e.g. synaptic loss) and 
eventually even neuronal death (Ueda et al., 1997; Arbel-Ornath et al., 2017). Similarly, 
in ALS (amyotrophic lateral sclerosis), a motor neuron disease, through both molecular 
and electrophysiology approaches an increase in HVA VGCC, particularly Cav1 activity 
has been proposed as part of the mechanism accounting for the noted protein 
misfolding and accumulation, which drives the noted neurodegeneration (Mosier et al., 
1995; Pullen et al., 2004; Pambo-Pambo, Durand and Gueritaud, 2009; Leal et al., 2013; 
Chang and Martin, 2016). Epilepsy, Parkinson’s disease (PD) and psychiatric disorders 
are some other conditions where Ca2+ dysregulation has also been reported 
(Nedergaard, Flatman and Engberg, 1993; Talley et al., 2000; Zhang et al., 2002; Chan et 
al., 2007; Miki et al., 2008; Hurley et al., 2013; Ripke et al., 2013; Ostacher et al., 2014). 
The current study focuses on the effect of protofibrillar Ab1-42 on VGCCs and 
modulation of these channels by CO. It provides evidence that different VGCCs, 
specifically Cav1.2, Cav1.3 and Cav2.2 may be modulated by Ab during AD. Moreover 
CORM2, either through CO release or/and due to the presence of the metal ruthenium, 
was shown to have a redox-dependent inhibitory effect on Cav2.2. 
AD has been linked to changes in both the expression and activity of Cav1 
channels (Coon et al., 1999; Chiou, 2006; Kim and Rhim, 2011; Hettiarachchi et al., 
2014). The current study has shown that protofibrillar Ab1-42, dependent on 
concentration, impairs calcium homeostasis through selective changes in differentiated 
SH-SY5Y Cav1 mRNA expression. Findings from this study indicate a significant increase 
in transcript expression for Cav1.2 with 1µM protofibrillar Ab1-42 treatment, whereas a 
significant reduction in Cav1.3 expression with 100nM protofibrillar Ab1-42 was seen. 
Similar to AD, where changes in Cav1 expression are seen, in PD where extensive 
dopaminergic neuronal loss is seen, changes in Cav1.2 and Cav1.3 expression and 
activity have been linked to neuronal hyperexcitability (Nedergaard, Flatman and 
Engberg, 1993; Chan et al., 2007; Hurley et al., 2013). Changes in VGCC activity are also 
seen in ALS at early stages of the disease, during stages of hyperexcitability and 
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excitotoxicity (Bories et al., 2007; Pambo-Pambo, Durand and Gueritaud, 2009). As 
changes in Cav1 expression and activity has been shown to be part of the pathological 
mechanisms of numerous neurodegenerative diseases, including AD, a number of 
cohort studies have suggested that the use of dihydropyridines may provide 
neuroprotection. In hypertensive patients use of dihydropyridines revealed that it may 
confer some neuroprotection against risk in developing PD, shown through a reduction 
in the incidence of PD (Ritz et al., 2010; Lee et al., 2014). Although this may suggest that 
use of dihydropyridines would also be effective against AD, clinical trials have revealed 
mixed findings. Potential reasons for clinical trials failing to exhibit significant effects in 
interrupting or delaying AD pathology could be due to low brain bioavailability of the 
CCB tested, the disease stage at which the drug was tested and also selectivity issues 
could also affect findings, such as nimodipine which targets all Cav1 isoforms (Birks and 
López-Arrieta, 2002; Anekonda et al., 2011; Gholamipour-Badie et al., 2013; Zamponi, 
2016). Neuronal hyperexcitability is a feature of both pre-clinical AD and early-stage AD 
(Busche et al., 2008; Busche and Konnerth, 2015; Kazim et al., 2017). As in the CNS Cav1 
channels have shown to be vital for neuronal excitability and firing, changes in the 
expression of Cav1 channels highlighted in the current study may be indicative of early 
stages of AD (McKinney et al., 2009; Liu et al., 2014). In addition to neuronal excitability 
and firing, Cav1.2 has also been implicated in regulating CREB-dependent gene 
expression of genes linked to synaptic function, cell proliferation, development and 
apoptosis, whereas Cav1.3 has a role in dendritic spine morphology, stability and adult 
neurogenesis which is a vital process for learning and memory (Moosmang et al., 2005; 
McKinney et al., 2009; Liu et al., 2014; Marschallinger et al., 2015; Stanika, Flucher and 
Obermair, 2015; Stanika et al., 2016). Neuronal hyperactivity which can occur due to 
impairments in neuronal morphology, synaptic activity and overall synaptic plasticity, 
as well as deficits in adult neurogenesis, are both known as features of early-stage AD 
(Busche et al., 2008; Busche and Konnerth, 2015; Kazim et al., 2017; Scopa et al., 2020). 
As Cav1 channels have been shown to have important roles in all these processes, 
changes in their expression and activity may be part of the pathogenic mechanism(s) 
seen at early stages of AD progression. Therefore, using dihydropyridines at a later stage 
in the disease, where progressive levels of neurodegeneration is observed may render 
them ineffective. In support, a cohort study conducted on individuals with hypertension 
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and PD revealed that although Cav1 blockers may have promising effects against PD risk 
at early stages of the disease, taken at later disease stages, CCBs were unable to prevent 
disease progression and to limit neurodegeneration (Marras et al., 2012). A similar trend 
in effectiveness of CCBs, dependent on disease stage, may also be true for AD. This 
suggests that use of compounds that modulate VGCCs would be most effective when 
given to patients at risk of developing AD or patients displaying MCI rather than at 
progressed (moderate or severe) AD stages where significant neuronal loss and brain 


















Figure 6.1.1: Progression of Alzheimer’s disease and CO as a therapeutic. Trend for Alzheimer’s disease progression 
can be seen in the graph. Age is known as a major risk factor for Alzheimer’s development and progression. As AD 
progresses, more brain atrophy is seen. Although HO-1 has been shown to be neuroprotective, and its expression is 
upregulated in Alzheimer’s disease, its activity is impaired, consequently rendering it ineffective. Use of CO, or 
activating CO- dependent mechanisms during early stages of the disease, where neuronal dysfunction is evident, but  
limited degree of brain atrophy is seen, might be an effective treatment against Alzheimer’s disease. 
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The current study has also revealed a reduction in Cav2.2 Ca2+ influx with 
protofibrillar Ab1-42 treatment. In contrast to Cav1 channels, Cav2 channels are found 
predominately at presynaptic sites with specialised functions such as in 
neurotransmission. As late stages of AD are characterised by pathological processes 
such as neurotransmitter depletion, reduction in spine density and overall number 
which aid synaptic decline (Miller et al., 2008; Yassa et al., 2010; Putcha et al., 2011; 
Busche et al., 2012; Busche and Konnerth, 2015; Arbel-Ornath et al., 2017), it is 
suggested that the inhibitory effect noted by protofibrillar Ab1-42 on Cav2.2 currents in 
the current study may represent a pathological mechanism seen at a later stage in 
disease progression where significant degree of synaptic dysfunction and neuronal loss 
is already evident. 
In AD, particularly in regions where amyloid plaques and neurofibrillary tangles 
are present, HO-1 expression has been shown to be upregulated as a defence 
mechanism against oxidative stress and free radicals (Pappolla et al., 1998; Schipper, 
2000, 2004). In transgenic animals that suffered an ischemic stroke, neuronal 
overexpression of HO-1 has been shown to minimize neuronal cell damage and maintain 
cell viability by reducing release of ROS as well as upregulating expression of anti-
apoptotic proteins (Panahian, Yoshiura and Maines, 1999; Schipper, 2004). While 
upregulation of HO-1 expression can be neuroprotective and could be beneficial in 
fighting Ab-dependent pathology, impaired HO-1 activity can drive AD pathology 
(Schipper, 2000; Takahashi et al., 2000). Therefore, there has been considerable interest 
in investigating whether CO, a HO-1 by-product can also act as a neuroprotectant. In the 
current study CORM2, similarly to protofibrillar Ab1-42, was shown to reduce Cav2.2 
currents. Although the manner by which protofibrillar Ab1-42 modulates Cav2 channels 
was not further investigated here, findings from the literature suggest changes at 
transcript level and direct interaction with specific subunits such as the accessory b 
subunit, consequently changing the number of functional VGCCs found at the cell 
membrane (Coon et al., 1999; Green and Peers, 2002; Chiou, 2006; Kim and Rhim, 
2011).  In contrast to protofibrillar Ab1-42, the current study was able to prove that 
CORM2, at least partly to CO release, can inhibit Cav2.2 channels through post-
translation modifications, specifically via redox modulation. This may potentially occur 
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through modulation of specific cysteine residues (Scragg et al., 2008; Boycott et al., 
2013; Kapetanaki et al., 2018).  The current study suggests that activating CO-dependent 
mechanisms at an early-stage in disease progression, prior to significant brain atrophy 
is seen (Fig. 6.1.1), where initially Ca2+ influx is elevated, may prevent some of the 
cytotoxic pathways associated with VGCC-dependent calcium dysregulation seen in AD, 
through redox modulation of these channels. In contrast, activating CO-dependent 
mechanisms at a later stage of the disease, where significant reduction in VGCC activity 
is observed, may have deleterious effects, further impairing processes such as 
neurotransmission, dendritic spine morphology and stability, and subsequently adding 
to the synaptic decline and overall neuronal loss observed. In support, experiments in 
the current study revealed that co-incubation of neuroblastoma cells with Ab1-42 and 
CORM2, CO was unable to prevent reduction in neuronal viability. This suggests that CO 
may have been unable to suppress neurotoxicity, because cell apoptosis pathways have 
already been activated.  
Findings from the current study have significant clinical implications as they 
demonstrate that activating CO-dependent processes that can modulate VGCCs via a 
redox manner, at an early stage in disease progression, may be neuroprotective and 
may significantly reduce the progression of dementia.  Such interventions may not only 
provide symptomatic relief, but also target some of the cytotoxic mechanisms mediated 
by Ab. Such a therapeutic would not only delay the progression of the disease, but may 















6.2. Future work 
 
Although the work conducted in this study proves that CORM2 can modulate 
VGCCs, specifically Cav2.2 channels, through redox modulation, all work was conducted 
in cell lines. HEK293 cells, which can easily be manipulated through transfections can 
provide an ideal in vitro model for studying ion channels ‘in isolation’ using techniques 
such as whole cell patch clamp. SH-SY5Y cells as an immature neuronal cell line model 
that can easily be differentiated into neuronal-like cells more closely resembling primary 
neurons are also widely used within the neuroscience field (Biedler and Schachner, 
1978; Morton et al., 1992; Kovalevich and Langford, 2013; Sousa et al., 2013; de 
Medeiros et al., 2019). Although SH-SY5Y cells are capable of undergo differentiation 
into neuronal-like cells, the effects identified here by protofibrillar Ab1-42 and CORM2 on 
VGCCs, would also need to be validated in primary neurons. Use of transgenic animal 
models such as the mice overexpressing human APP751 (mutation London (V717I) and 
Swedish (K670M/N671L)) which are capable of displaying both Ab accumulation and 
aggregation into small oligomers and eventually plaques (Sturchler-Pierrat et al., 1997), 
may not only allow the validation of the effects of Ab and CO on VGCCs in primary 
neurons, but it would also provide an opportunity to investigate how CO not only 
modulates neuronal VGCCs, but how it can influence the whole brain network by looking 
at neuronal and glial interactions. 
Although a role for the CORM2 ruthenium structure cannot be excluded, the 
current study is the first study to prove that CORM2, at least partly due to CO release, 
can influence Cav2.2 channel kinetics through redox modulation. Future studies can 
validate the inhibitory effect of CO through the use of other CORM compounds that do 
not contain a ruthenium structure, or even through the use of CO gas. Although it was 
proven that CORM2 works similarly to an oxidant, the mechanism by which it can confer 
this inhibitory effect will require further investigation. A number of studies have 
suggested that CO may modulate ion channels through interaction with specific cysteine 
subunits within the a1 pore-forming subunit (Scragg et al., 2008; Boycott et al., 2013). 
Future studies using site-directed mutagenesis, where specific cysteine residues within 
the a1 pore-forming subunit can be substituted by other residues such as alanine, could 
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help in identifying whether CO can modulate VGCCs through changing the gating 
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